1 	|BT| (S (ADVP (RB Additionally)) (, ,) (NP (NP (NP (NN transcription) (NN factor) (JJ early) (NN growth) (NN response-1)) (PRN (-LRB- -LRB-) (NP (NN Egr-1)) (-RRB- -RRB-))) (NN gene) (ADJP (RB transcriptionally) (VBN activated)) (NN level) (NP (NP (JJ non-steroidal) (JJ anti-inflammatory) (NN drug)) (PRN (-LRB- -LRB-) (NP (NN NSAID)) (-RRB- -RRB-)))) (: -) (NP (NP (NP (VBN activated) (NN gene-1)) (PRN (-LRB- -LRB-) (NP (NN NAG-1)) (-RRB- -RRB-))) (NN protein)) (ADVP (RB also)) (VP (VBD elevated) (NP (JJ PTX-2-treated) (NN Hep3B) (NN cell)))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 41:A11 52:E02 580:D12.776.260.158.500 796:D27.505.696.663.850.014.040.500 1272:D03.438.759.758.824.651.700|ES| 2:1 4:1 5:1 9:1 10:1 14:1 19:1 94:1 102:1 163:1 185:1 191:1 249:1 487:1 756:1 1128:1 1662:1 1854:1 1859:1 2367:1 2795:1 4068:1 4497:1 4498:1 4499:1 4500:1 4501:1 4502:1
1 	|BT| (S (NP (NP (NP (JJ Epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN tyrosine) (NN kinase) (NN inhibitor) (NN erlotinib)) (VP (VBP show) (SBAR (S (NP (JJ potent) (NP (NP (NN antitumor) (NN activity) (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (NN cell) (NN line)) (VP (VBD approved) (NP (NNP Food) (NNP Drug) (NNP Administration) (JJ second) (JJ third) (NN line) (NN treatment) (NN NSCLC))))))) |ET| |BS|52:E02 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 113:C04.697.650 633:I01.409.418.750.600.650.760 634:D12.125.072.050.875|ES| 10:1 14:1 18:1 19:1 22:1 94:1 102:1 185:1 186:1 187:1 264:1 327:1 328:1 329:1 380:1 399:1 429:1 470:1 546:1 2244:1 2340:1 2341:1 2342:1 2343:1 2344:1 2345:1 2346:1 2347:1 2348:1
1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN ACR) (NN GW4064)) (ADVP (RB cooperatively)) (VP (VBP inhibit) (SBAR (S (NP (NN RXRalpha) (NN phosphorylation)) (, ,) (VP (VBP modulate) (NP (NP (NN expression) (JJ FXR-regulated) (NN gene)) (, ,) (S (ADVP (RB thus)) (VP (VBG resulting) (NP (NN induction) (NN apoptosis) (NN inhibition) (NN growth) (NN HCC) (NN cell))))))))))))))) |ET| |BS|39:G04.299.139.160 41:A11 43:F01.145.544 45:G07.700.320.249 104:C04.557.470.200.025.255 122:C14.280.383 142:I01.880.604 155:G05.355.310 972:G02.111.087.677|ES| 2:1 9:1 19:1 89:1 94:1 101:1 102:1 103:1 115:1 384:1 441:1 658:1 736:1 796:1 1334:1 1370:1 3426:1 4017:1 4503:1 4504:1 4505:1 4506:1 4507:1
1 	|BT| (S (NP (JJ Quantitative) (JJ real-time) (NN RT-PCR) (NN analysis)) (VP (VBD showed) (SBAR (S (NP (NN troglitazone)) (VP (VBD down-regulated) (NP (NN Skp2) (NN mRNA) (NN level))))))) |ET| |BS|111:D13.444.735.544 142:I01.880.604 257:E05.393.620.500.706 351:A17.360 507:D12.776.157.743|ES| 19:1 132:1 249:1 325:1 661:1 874:1 1148:1 1283:1 1785:1 3732:1 4508:1
1 	|BT| (S (NP (DT This) (NN research)) (VP (VBZ provides) (NP (NN evidence) (NN tea)) (, ,) (NP (ADVP (RB particularly)) (NP (VBN administered) (NN combination) (NN sulindac)) (, ,) (NP (PP (ADJP (RB highly) (JJ effective)) (S (VP (VBG inhibiting) (NP (NP (NP (JJ intestinal) (NN neoplasia) (NN male) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN min)) (-RRB- -RRB-))) (NN mouse)) (PP (IN via) (NP (JJ direct) (JJ indirect) (NN effect) (NN beta-catenin/APC) (NN pathway)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 102:C04.588.274.476.411 122:C14.280.383 251:D02.455.426.559.847.486.875 644:H01.770.644 645:H01.770.644|ES| 2:1 10:1 14:1 19:1 38:1 52:1 75:1 109:1 280:1 383:1 530:1 596:1 626:1 640:1 807:1 815:1 869:1 880:1 1402:1 1639:1 1891:1 2336:1 2378:1 2379:1 2380:1 2381:1 2382:1 2383:1
1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NP (VBN isolated) (NN colon) (NNS CSCs)) (PRN (-LRB- -LRB-) (NP (NP (JJ positive) (NN CD44)) (, ,) (NP (NN CD133) (NN ALDH1b1) (NN marker))) (-RRB- -RRB-))) (VP (VBG functioning) (NP (NP (NN p53) (JJ shRNA-attenuated) (NN p53)) (VBN treated) (NN PA) (CD 5.0) (NN mug/ml)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 46:A03.556.124.526.356 52:E02 158:D23.101 556:C11.768.175 1127:Z01.107.757.656 1273:D13.150.650.700|ES| 2:1 10:1 12:1 14:1 19:1 113:1 233:1 534:1 652:1 1099:1 1581:1 1629:1 1653:1 1691:1 1966:1 3943:1 4509:1 4510:1 4511:1 4512:1
1 	|BT| (S (NP (NNP UNLABELLED) (: :)) (S (VP (TO To) (VP (VB evaluate) (NP (NN possibility) (JJ radionuclide) (NN gene) (NN therapy) (NN imaging) (JJ hepatocellular) (NN carcinoma) (NN cancer))))) (, ,) (VP (VBD investigated) (NP (NP (NP (NN iodine) (NN accumulation) (JJ human) (JJ hepatocellular) (NN carcinoma) (NN cell) (NN line)) (, ,) (NP (NN SK-Hep1))) (, ,) (NP (NP (NN transfer) (JJ human) (NN sodium) (NN iodide) (NN symporter)) (PRN (-LRB- -LRB-) (NP (NN hNIS)) (-RRB- -RRB-))) (NP (NN gene))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 38:Z01.058.290.120.180 40:Z01.542.248.700 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 104:C04.557.470.200.025.255 225:E05.337 265:C04.557.470.200 967:D01.248.497.158.490 1017:E01.370.350 1274:D01.268.380.400 1275:D01.496.749|ES| 2:1 9:1 10:1 14:1 18:1 19:1 36:1 94:1 104:1 130:1 264:1 303:1 304:1 343:1 403:1 407:1 828:1 890:1 1644:1 2120:1 2266:1 3561:1 4513:1 4514:1 4515:1 4516:1 4517:1 4518:1
1 	|BT| (SINV (SBAR (IN Whether) (S (NP (NP (JJ single) (NN cell)) (NP (NP (ADJP (RB immunohistochemically) (JJ positive)) (NN glutathione) (NN S-transferase) (NN P1-1)) (PRN (-LRB- -LRB-) (NP (NN GSTP1-1)) (-RRB- -RRB-)))) (VP (VBD induced) (NP (JJ female) (NN mouse) (NN liver) (NN DEN))))) (PRN (-LRB- -LRB-) (NP (NP (NNP Hatayama) (FW et) (FW al.)) (, ,) (NP (NN Carcinogenesis)) (, ,) (CD 14) (, ,) (CD 537-538) (, ,) (NP (CD 1993))) (-RRB- -RRB-)) (NP (NP (NN precursor) (VBD initiated) (NN cell) (JJ preneoplastic) (NN focus)) (, ,) (NP (NN importance) (NN chemical) (NN hepatocarcinogenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 242:A03.620 642:M01.975 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 897:Z01.252.245.500.375 962:A11.148.378 1276:D08.811.913.225.500.500|ES| 2:1 10:1 14:1 19:1 52:1 94:1 233:1 412:1 836:1 900:1 1404:1 1431:1 1438:1 1440:1 1660:1 1875:1 1900:1 2124:1 2744:1 2745:1 2846:1 3167:1 4519:1 4520:1 4521:1 4522:1 4523:1 4524:1 4525:1 4526:1 4527:1 4528:1
1 	|BT| (S (NP (CD 1,25) (NN D)) (VP (VBD inhibited) (SBAR (S (NP (NN MYC) (NN gene) (NN expression)) (VP (VBD accelerated) (NP (NN protein) (NN turnover))))))) |ET| |BS|7:D12.776 122:C14.280.383 155:G05.355.310 185:G05.360.340.024.340.375.500.791.420 186:G05.360.340.024.340.375.500.791.420 665:N04.452.677.680|ES| 4:1 9:1 19:1 115:1 365:1 472:1 1391:1 2424:1 4529:1
1 	|BT| (S (S (NP (CD 1,25) (NN D)) (VP (VBD inhibited) (SBAR (S (NP (NP (NN transcription) (JJ c-MYC-regulated) (NN gene) (NN vitro)) (, ,) (NP (JJ topical) (CD 1,25) (NN D))) (VP (VBD suppressed) (NP (NN expression) (NN c-MYC) (NN target) (CD setd8) (NN mouse) (NN skin)))))) (, ,)) (IN whereas) (S (NP (NN MXD1) (NN level)) (VP (VBD increased)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 122:C14.280.383 142:I01.880.604 185:G05.360.340.024.340.375.500.791.420 209:G02.111.087.847 785:A17.815|ES| 2:1 9:1 19:1 47:1 52:1 115:1 160:1 216:1 249:1 307:1 365:1 372:1 487:1 625:1 2319:1 4529:1 4530:1 4531:1 4532:1 4533:1
1 	|BT| (S (NP (DT A) (NN benzimidazole) (JJ derivative) (VBG exhibiting) (NN antitumor) (NN activity) (NN block) (NN EGFR) (NN HER2) (NN activity)) (VP (VBZ upregulates) (NP (NN DR5) (NN breast) (NN cancer) (NN cell)))) |ET| |BS|41:A11 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 122:C14.280.383 175:J01.897.280.500.269 798:D03.438.103|ES| 18:1 19:1 23:1 69:1 94:1 187:1 188:1 399:1 742:1 2153:1 2244:1 2812:1 2813:1 3755:1 3793:1
1 	|BT| (FRAG (NP (NP (DT A) (JJ critical) (NN threshold) (NN beta-catenin) (NN level) (JJ TCF-regulated) (NN transcription) (JJ uncovered) (NN Apc)) (JJ mutation-induced) (NN effect) (NN colon) (NN epithelium)) (, ,) (PP (IN along) (NP (NN evidence) (JJ feed-forward) (NN role) (NN beta-catenin) (NN Ctnnb1) (NN gene) (NN expression) (NN CTNNB1) (NN transcription)))) |ET| |BS|3:C04.557.470.035.215.100 15:F01.829.316.616 18:G05.365.590 23:D12.776.091.249 46:A03.556.124.526.356 62:A10.272 142:I01.880.604 155:G05.355.310 209:G02.111.087.847 1277:N03.219.442|ES| 2:1 9:1 19:1 31:1 38:1 60:1 69:1 75:1 113:1 115:1 173:1 249:1 280:1 487:1 825:1 1019:1 2666:1 3344:1 4032:1 4350:1 4534:1 4535:1 4536:1
1 	|BT| (S (NP (DT A) (VBN decreased) (NN protein) (NN level) (NN DAX-1) (NN APAP) (NN treatment)) (ADVP (RB also)) (VP (VBD enhanced) (SBAR (S (NP (NN miR-561)) (VP (VBP mimic) (NP (NN transfection) (NN HepG2) (NN cell) (JJ primary) (JJ human) (NNS hepatocytes))))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 112:D12.776.097.820 217:E05.393.350.810 262:A11.436.348 661:D02.065.199.092.040 1015:A11.251.860.180.432|ES| 4:1 5:1 19:1 36:1 69:1 94:1 202:1 249:1 344:1 385:1 546:1 567:1 746:1 894:1 3481:1 4193:1 4537:1 4538:1
1 	|BT| (S (NP (NN Activation) (NN RXRalpha) (JJ retinoic) (NN acid)) (VP (VBD increased) (NP (NP (NN cyclin) (NN E1) (NN promoter) (NN activity)) (VP (VBG indicating) (NP (ADJP (JJ retinoic) (JJ acid-mediated)) (NN signaling)))) (S (ADVP (RB positively)) (VP (VBP control) (NP (NN cyclin) (NN E1) (NN gene) (NN expression)))))) |ET| |BS|69:G02.111.087.800 155:G05.355.310 711:D02.455.326.271.665.202.495 770:D02.455.326.271.665.202.495.818.500|ES| 9:1 19:1 47:1 83:1 87:1 115:1 195:1 289:1 399:1 743:1 1275:1 1580:1 2236:1 2704:1 3848:1 4017:1 4539:1
1 	|BT| (S (S (NP (JJ Acute) (NN treatment) (NN B6C3F1) (NN mouse) (NN phenobarbital)) (VP (VBD resulted) (SBAR (S (NP (VBN increased) (NN level) (NN bcl-2)) (VP (VBD decreased) (NP (NN level) (NN bax) (NN protein))))))) (, ,) (NP (JJ acute) (NN treatment) (NN WY-14,643)) (VP (VBD resulted) (NP (VBN increased) (NN bcl-2) (NN BAG-1) (NN protein) (NN liver)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 54:G05.360.340.024.340.375.500.791.150 242:A03.620 342:D12.644.360.075.718.400 756:D03.383.742.698.253.650|ES| 2:1 4:1 19:1 47:1 52:1 90:1 151:1 202:1 249:1 546:1 594:1 836:1 1136:1 1893:1 2685:1 3986:1 4540:1 4541:1
1 	|BT| (S (ADVP (RB Additionally)) (, ,) (NP (NN DNA) (NN microarray) (NNS data)) (VP (VBD indicated) (SBAR (S (NP (NN cell) (JJ cycle-related) (NN gene) (NNS cyclins) (NN CCNB1) (NN CCNA2) (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN CDKN3)) (ADVP (RB also)) (VP (VBD down-regulated) (NP (NP (NN treatment)) (NP (CC either) (NP (NN PB) (NN CF) (CD 13) (NN week))))))))) |ET| |BS|52:E02 142:I01.880.604 325:Z01.058.290.100.140 351:A17.360 979:D12.644.360.262.120.100 996:G05.360.340.024.340.220 1278:D12.644.360.262.100.200 1279:D12.644.360.225 1280:D12.644.360.262|ES| 2:1 5:1 9:1 19:1 39:1 94:1 380:1 470:1 546:1 666:1 783:1 793:1 913:1 1100:1 1283:1 1532:1 1541:1 3496:1 4068:1 4542:1 4543:1 4544:1 4545:1 4546:1 4547:1
1 	|BT| (S (NP (NN AIMS/METHODS)) (: :) (NP (PRP We)) (VP (VBD evaluated) (NP (NP (FW vivo) (NN effect) (JJ intraperitoneal) (NN injection) (NN Ras) (NN inhibitor) (NN S-trans)) (, ,) (NP (NP (NP (JJ trans-farnesylthiosalicyclic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FTS)) (-RRB- -RRB-))) (S (NP (NN Ras) (NN activation) (NN development) (JJ preneoplastic) (NN liver) (NN lesion) (NN rat)) (VP (VBG receiving) (NP (NP (NP (JJ weekly) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN injection) (NNS 16weeks)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 168:E05.581 225:E05.337 226:E02.319.267.530 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 917:E02.319.267.530.490 1062:D01.029|ES| 2:1 10:1 14:1 19:1 35:1 75:1 104:1 225:1 378:1 380:1 548:1 780:1 785:1 836:1 843:1 849:1 1131:1 1275:1 1438:1 1775:1 1875:1 1952:1 3230:1 4076:1 4548:1 4549:1 4550:1 4551:1 4552:1
1 	|BT| (NP (NP (NNS AIMS)) (: :) (S (NP (DT The) (NN aim) (NN study)) (VP (VBP examine) (NP (NN effect) (NNS NSAIDs) (NP (NN mRNA) (NN expression) (NN tumour) (NN suppressor) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene)) (NN rat) (NN colon) (NN mucosa))))) |ET| |BS|3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 111:D13.444.735.544 155:G05.355.310 206:G05.360.340.024.340.375.249 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 302:A10.615.550 796:D27.505.696.663.850.014.040.500|ES| 9:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 75:1 104:1 113:1 115:1 131:1 325:1 579:1 691:1 700:1 849:1 960:1 1011:1 1567:1 1778:1 2966:1
1 	|BT| (S (NP (DT All) (NN result)) (VP (VBD revealed) (NP (NP (NN pterostilbene) (JJ effective) (NN antitumor) (NN agent)) (NP (RB well) (NP (JJ inhibitory) (NN effect) (NN down-regulation) (JJ inflammatory) (NN iNOS) (NN COX-2) (NN gene)) (NN expression) (NN up-regulation) (NN apoptosis) (NN mouse) (NN colon))) (, ,) (S (VP (VBG suggesting) (NP (NP (NP (NN pterostilbene)) (JJ novel) (JJ functional) (NN agent)) (ADJP (JJ capable) (S (VP (VBG preventing) (NP (JJ inflammation-associated) (NN colon) (NN tumorigenesis)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 46:A03.556.124.526.356 53:C06.405.205.265 85:G02.111.087.225 155:G05.355.310 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880 660:D27.505.954.248|ES| 2:1 9:1 19:1 52:1 67:1 75:1 76:1 78:1 89:1 101:1 113:1 115:1 257:1 275:1 415:1 728:1 787:1 891:1 896:1 965:1 1009:1 1639:1 1849:1 1937:1 2244:1 2428:1 2429:1 2430:1 2431:1
1 	|BT| (S (S (PP (IN Along) (NP (NN Nrf2) (NN inhibition))) (, ,) (NP (NN trig)) (VP (VBD blocked) (NP (NP (JJ Nrf2-dependent) (NN expression) (JJ proteasomal) (NN gene)) (PRN (-LRB- -LRB-) (NP (NP (NN example)) (, ,) (NP (NN s5a/psmd4) (NN alpha5/psma5))) (-RRB- -RRB-)))) (VP (VBD reduced) (NP (NP (NN proteasome) (NN activity) (NN cell) (NN line)) (VP (VBN tested)))))) |ET| |BS|43:F01.145.544 94:A11.251.210 122:C14.280.383 155:G05.355.310 799:D12.776.260.615.249 1281:D05.500.562.500|ES| 2:1 9:1 10:1 14:1 19:1 94:1 103:1 115:1 264:1 399:1 452:1 2777:1 2988:1 3490:1 4355:1 4553:1 4554:1 4555:1 4556:1 4557:1 4558:1 4559:1
1 	|BT| (S (SBAR (IN Although) (S (NP (NN study)) (VP (VBD needed) (VP (VB prove) (SBAR (S (NP (VBN increased) (NN expression) (NN Egr-1) (NN PTX-2)) (VP (ADVP (RB directly)) (VBP lead) (NP (NP (NN NAG-1) (NN induction) (NN apoptosis) (NN induction)) (NP (JJ p53-deficient) (NN Hep3B) (NN cell)))))))))) (, ,) (VP (VBP result) (SBAR (S (NP (NN study)) (VP (VBP suggest) (SBAR (S (NP (NN PTX-2)) (VP (MD may) (NP (JJ good) (NN candidate) (NN development) (JJ potential) (JJ anti-tumorigenic) (NN agent) (JJ p53-deficient) (NN tumor)))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 41:A11 86:D01.268.556.435 284:N03.349.380.420 1272:D03.438.759.758.824.651.700|ES| 2:1 7:1 19:1 35:1 47:1 89:1 94:1 101:1 107:1 115:1 131:1 254:1 491:1 621:1 728:1 736:1 796:1 827:1 981:1 1243:1 1318:1 1662:1 2669:1 4498:1 4502:1 4560:1 4561:1 4562:1
1 	|BT| (S (SBAR (IN Although) (S (NP (NP (NP (NN Mlh1)) (PRN (-LRB- -LRB-) (NP (NN G67R)) (-RRB- -RRB-))) (NN mutation)) (VP (VBD resulted) (NP (NN DNA) (NN repair) (NN deficiency) (JJ homozygous) (JJ mutant) (NN mouse))))) (, ,) (VP (VBP affect) (SBAR (S (NP (NP (JJ MMR-mediated) (JJ cellular) (NN response) (NN DNA) (NN damage)) (, ,) (PP (VBG including) (NP (NP (JJ apoptotic) (NN response) (JJ epithelial) (NN cell) (JJ intestinal) (NN mucosa) (NN cisplatin)) (, ,) (NP (NP (JJ defective) (NN Mlh1)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NN mouse))))) (VP (VBD remained) (NP (NP (NP (JJ normal) (NN Mlh1)) (PRN (-LRB- -LRB-) (NP (NN G67R/G67R)) (-RRB- -RRB-))) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 39:G04.299.139.160 41:A11 191:A03.556.124.369 433:F01.470.047 498:D01.210.375 526:G05.355.180 1282:C18.452.284 1283:G05.380.554|ES| 2:1 10:1 14:1 19:1 34:1 45:1 52:1 94:1 107:1 109:1 118:1 127:1 253:1 494:1 513:1 561:1 579:1 586:1 594:1 666:1 811:1 1486:1 1761:1 1848:1 1861:1 2223:1 3074:1 4563:1 4564:1 4565:1 4566:1 4567:1
1 	|BT| (NP (NP (PP (IN Among) (NP (JJ different) (NNS chemotherapeutics))) (, ,) (NP (NN induction) (NN WT1) (NN transcription) (JJ restricted) (NN topoisomerase) (CD 2) (NN inhibitor)))) |ET| |BS|209:G02.111.087.847 382:C04.557.435.595 1284:D27.505.519.389.892.750|ES| 2:1 19:1 148:1 380:1 414:1 487:1 736:1 1000:1 1292:1 4568:1 4569:1 4570:1
1 	|BT| (S (NP (DT An) (JJ apoptosis-related) (NN gene) (NN expression) (NN profiling) (NN analysis)) (VP (VBD provided) (SBAR (S (NP (NP (NP (NN clue) (JJ death-associated) (NN protein) (NN kinase) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN dapk1)) (-RRB- -RRB-))) (NN gene)) (VP (VBN upregulated) (NP (ADJP (JJS least) (JJ twofold)) (NN response) (NN grifolin) (NN treatment) (JJ nasopharyngeal) (NN carcinoma) (NN cell) (NN CNE1))))))) |ET| |BS|6:G05.360.340.024.340 39:G04.299.139.160 41:A11 52:E02 718:E05.588.570 1285:D08.811.913.696.620.682.700.125.387 1286:E05.393.332|ES| 4:1 9:1 10:1 14:1 19:1 94:1 98:1 115:1 125:1 304:1 470:1 494:1 546:1 661:1 1015:1 1142:1 1155:1 1178:1 1331:1 2148:1 4571:1 4572:1 4573:1 4574:1 4575:1 4576:1
1 	|BT| (VP (NP (NP (NP (NN Androgen)) (PRN (-LRB- -LRB-) (NP (NP (NN R1881)) (, ,) (NP (NN dihydrotestosterone))) (-RRB- -RRB-))) (NN treatment) (NP (NP (NN SVHUC) (VBN immortalized) (JJ normal) (JJ urothelial) (NN cell)) (ADVP (RB stably)) (VP (VBG expressing) (NP (NP (NN AR)) (PRN (-LRB- -LRB-) (NP (NN SVHUC-AR)) (-RRB- -RRB-)))))) (VP (VBD decreased) (NP (NN GATA3) (NN expression) (NN mRNA) (NN protein) (NN level))) (, ,) (VP (VBD abolished) (NP (NNS anti-androgens)))) |ET| |BS|7:D12.776 41:A11 52:E02 111:D13.444.735.544 321:A10.272.850 892:D27.505.696.399.472.161 1287:D04.808.054.040.248 1288:D06.347.065 1289:D04.808.365.415.550|ES| 2:1 4:1 10:1 14:1 19:1 94:1 115:1 118:1 202:1 249:1 325:1 478:1 546:1 810:1 1078:1 1357:1 1852:1 2152:1 4577:1 4578:1 4579:1 4580:1 4581:1 4582:1 4583:1
1 	|BT| (S (NP (NP (JJ Antisense) (NNS oligodeoxynucleotides) (JJ human) (NN superoxide) (NN dismutase) (CD 2)) (CC and/or) (NP (JJ ectopic) (NN bcl-2) (NN overexpression))) (VP (VBD avoided) (NP (NP (NNS polyphenols)) (SBAR (S (NP (JJ chemoradiotherapy-induced) (JJ colorectal) (NN cancer) (NN elimination)) (VP (VBD showed) (NP (NP (JJ mangano-type) (NN superoxide) (NN dismutase) (NN Bcl-2) (JJ key) (NN target) (JJ molecular) (NN mechanism)) (VP (VBN activated) (NP (JJ combined) (NN application) (NN t-PTER) (NNP QUER)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 57:D13.695.578.424.450 58:D08.811.682.881 59:E02.186.079|ES| 17:1 18:1 19:1 36:1 132:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1
1 	|BT| (S (NP (JJ Arsenic)) (VP (ADVP (RB also)) (NP (NP (ADVP (RB markedly)) (NP (VBN reduced) (NN methylation)) (PP (IN within) (NP (NN ER-alpha) (NN gene) (NN promoter) (NN region)))) (, ,) (NP (VBN assessed) (JJ methylation-specific) (NN PCR)) (, ,) (NP (NP (NN reduction)) (ADVP (RB statistically)) (NP (JJ significant) (CD 8) (CD 13) (NN CpG) (NN site))) (PP (IN within) (NP (NN promoter) (NN region)))))) |ET| |BS|6:G05.360.340.024.340 36:G02.111.087.029.538 196:G02.111.570.080.689.675 448:E05.393.620.500 1110:D12.776.826.750.350.174 1158:D01.268.513.249|ES| 2:1 5:1 9:1 19:1 81:1 83:1 135:1 370:1 452:1 662:1 667:1 781:1 875:1 1003:1 1532:1 2122:1 2396:1 3823:1 3887:1 4086:1 4584:1 4585:1
1 	|BT| (S (NP (JJ AST-induced) (NN NAG-1) (NN activation)) (VP (VBD intensified) (NP (NN PI3K) (NN inhibitor) (NN LY294002) (NN Akt) (NN inhibitor) (JJ co-treated) (JJ reversed) (NN NAG-1) (NN siRNA) (NN transfection)))) |ET| |BS|52:E02 117:D13.150.650.700 217:E05.393.350.810 378:D08.811.913.696.620.682.700.755 1042:Z01.107.757.284 1290:D08.811.913.696.620.500|ES| 19:1 225:1 351:1 380:1 746:1 1289:1 1662:1 3400:1 4352:1 4586:1 4587:1 4588:1 4589:1
1 	|BT| (S (PP (IN At) (NP (JJ molecular) (NN level))) (, ,) (NP (NN silibinin)) (VP (VBD increased) (NP (NP (NN IGFBP-3)) (, ,) (NP (NN Cip1/p21)) (, ,) (NP (NN Kip1/p27) (NN level) (NN ERK1/2) (NN activation))) (VP (VBD decreased) (NP (NN Bcl-2))) (, ,) (NP (JJ survivin) (NN VEGF) (NN level) (NN tumor)))) |ET| |BS|8:C04 54:G05.360.340.024.340.375.500.791.150 116:D08.811.913.696.620.682.700.567.249.750 1291:D12.776.157.420.270|ES| 2:1 7:1 19:1 47:1 158:1 161:1 202:1 225:1 249:1 2066:1 2229:1 2635:1 4590:1 4591:1 4592:1 4593:1 4594:1
1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (NP (NP (DT The) (ADJP (RB ubiquitously) (VBN expressed)) (NP (JJ basic) (JJ helix-loop-helix) (NN transcription) (NN factor) (NN ITF-2B) (JJ important) (NN role)) (NN differentiation) (NN process)) (, ,) (S (NP (NN transcription)) (VP (VBD regulated) (NP (NN beta-catenin)))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 23:D12.776.091.249 74:G04.299.151 142:I01.880.604 166:D12.776.930 209:G02.111.087.847 1292:G02.111.570.820.709.600.040.360.360|ES| 2:1 6:1 19:1 31:1 60:1 104:1 185:1 215:1 487:1 638:1 691:1 902:1 1046:1 1664:1 1777:1 1778:1 2041:1 3733:1 4595:1 4596:1
1 	|BT| (NP (NP (NP (VBN Based) (NN finding)) (, ,) (VBP conclude) (NN matrilysin) (NN suppressor) (NN Min) (NN phenotype)) (, ,) (VP (ADVP (RB possibly)) (VBG functioning) (NP (NN capacity) (JJ independent) (NN matrix) (NN degradation)))) |ET| |BS|80:G05.695 333:D01.045 557:D02.241.081.069.600.150 937:D08.811.277.656.300.480.525.700.250 1293:G03.495|ES| 2:1 19:1 236:1 597:1 650:1 700:1 883:1 927:1 1548:1 1629:1 1968:1 3289:1 3491:1 4597:1 4598:1
1 	|BT| (S (SBAR (IN Because) (S (NP (NN Notch) (NN signaling) (VBN implicated) (NN colon) (NN cancer) (NN tumorigenesis)) (VP (VBZ protects) (NP (NP (NN cell) (NN apoptosis)) (VP (VBG inducing) (NP (JJ prosurvival) (NN target))))))) (, ,) (VP (VBD hypothesized) (SBAR (S (NP (NP (NN inhibition) (NN Notch) (NN signaling) (NN gamma-secretase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN GSI)) (-RRB- -RRB-))) (VP (MD may) (NP (VB enhance) (NP (NN chemosensitivity) (NN colon) (NN cancer) (NN cell)))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 43:F01.145.544 69:G02.111.087.800 125:D08.811.277.656.300.032|ES| 2:1 10:1 14:1 18:1 19:1 78:1 89:1 94:1 103:1 113:1 160:1 195:1 256:1 380:1 386:1 491:1 977:1 1690:1 1750:1 1862:1 1863:1 1864:1 1865:1 1866:1 1867:1
1 	|BT| (S (NP (NNP Betaine) (NN supplementation)) (VP (VBD attenuated) (SBAR (S (NP (NN down-regulation) (NN p16)) (VP (VBD inhibited) (SBAR (S (NP (NN up-regulation) (NN c-myc)) (VP (VBD induced) (NP (NNP DEN) (JJ dose-dependent) (NN manner)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-)))))))))) |ET| |BS|85:G02.111.087.225 122:C14.280.383 142:I01.880.604 203:G05.360.340.024.340.375.249.375 743:D02.092.877.883.077|ES| 10:1 14:1 19:1 257:1 311:1 312:1 315:1 365:1 412:1 455:1 808:1 896:1 1313:1 1668:1 1875:1 2567:1 2824:1 4599:1
1 	|BT| (S (NP (JJ Biochemical) (NN analysis) (NN liver) (NN tissue)) (VP (VBD revealed) (NP (NN induction) (NN p66) (NN protein) (NN ethanol)) (, ,) (SBAR (IN whereas) (S (NP (JJ p66-deficient) (NN liver)) (VP (VBD responded) (NP (NP (NN alcohol) (JJ significant) (NN upregulation)) (NP (JJ mitochondrial) (JJ antioxidant) (NN enzyme) (NN MnSOD)))))) (, ,) (NP (ADJP (RB nearly) (JJ absent)) (NN control) (NN mouse)))) |ET| |BS|7:D12.776 11:B01.050.150.900.649.865.635.505.500 98:A10 242:A03.620 249:G05.355.315.800 339:G02.111.087.880 700:D27.505.519.217 730:D08.811 751:D02.033.375 822:D02.033|ES| 2:1 4:1 19:1 52:1 135:1 272:1 275:1 289:1 372:1 374:1 661:1 736:1 836:1 1126:1 2004:1 2388:1 2521:1 3440:1 3710:1 4600:1 4601:1 4602:1 4603:1 4604:1 4605:1
1 	|BT| (S (VP (VBG Blocking) (NP (NP (NN activation) (NN Notch) (NN signaling) (NN GSI34)) (VP (VBN sensitized) (NP (NP (NN cell) (NN chemotherapy) (JJ synergistic) (NN oxaliplatin)) (, ,) (NP (NN 5-FU)) (, ,) (NP (NN SN-38))))))) |ET| |BS|41:A11 69:G02.111.087.800 122:C14.280.383 151:E02.319 560:D03.383.742.698.875.404|ES| 2:1 19:1 94:1 195:1 225:1 256:1 495:1 598:1 2012:1 2308:1 2543:1 4606:1 4607:1 4608:1
1 	|BT| (NP (NP (NP (NN BTG3) (NN tumor) (NN suppressor) (NN gene) (NN promoter) (NN demethylation)) (, ,) (NP (NN histone) (NN modification) (NN cell) (NN cycle) (NN arrest)) (NP (NN genistein) (JJ renal) (NN cancer)))) |ET| |BS|206:G05.360.340.024.340.375.249 399:D12.776.660.470 773:G04.299.134.109 944:D03.383.663.283.266.450.400.375|ES| 2:1 7:1 9:1 18:1 19:1 83:1 94:1 503:1 601:1 602:1 700:1 922:1 2374:1 3312:1 3313:1 3314:1
1 	|BT| (NP (NP (PP (IN By) (NP (NN contrast))) (, ,) (NP (NP (NP (NN Ha-ras) (NN mutation) (JJ undetectable) (NN tumor) (NN mouse)) (VP (VBN treated) (NP (NP (NN DEN/PB)) (PRN (-LRB- -LRB-) (NP (CD 0/32)) (-RRB- -RRB-))))) (, ,) (NP (NP (QP (RB approximately) (CD 80)) (NN %)) (-LRB- -LRB-) (CD 37/46) (-RRB- -RRB-) (NN tumor) (NN group)) (NP (VBD showed) (NN beta-catenin) (NN mutation))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 52:E02 216:Z01.107.084.900.425 491:D27.505.259.500 829:M01.686|ES| 2:1 7:1 10:1 14:1 19:1 34:1 52:1 60:1 132:1 369:1 573:1 747:1 1099:1 1392:1 1843:1 1868:1 2300:1 4183:1 4609:1 4610:1 4611:1
1 	|BT| (NP (NP (NN Calcium) (NN chloride)) (, ,) (NP (NN DFMO) (NN piroxicam)) (NP (NP (VBD increased) (NN protein) (NN mRNA) (NN level) (NN p16)) (PP (IN along) (NP (NN sulindac)))) (NP (VBD increased) (NN protein) (NN level) (NN p27)) (, ,) (NP (NN mRNA))) |ET| |BS|7:D12.776 111:D13.444.735.544 203:G05.360.340.024.340.375.249.375 251:D02.455.426.559.847.486.875 1294:D01.146.300 1295:D12.125.068.665.340 1296:D02.886.665.500|ES| 2:1 4:1 19:1 47:1 249:1 325:1 869:1 1124:1 1313:1 2666:1 2788:1 4612:1 4613:1 4614:1
1 	|BT| (NP (NP (NP (NN Calcium) (NN chloride)) (, ,) (NP (NN DFMO)) (, ,) (NP (NP (NN piroxicam) (NN sulindac)) (VP (VBN administered) (NP (CD 7) (NN day)))) (VP (VBD decreased) (SBAR (S (NP (JJ mitotic) (NN index)) (VP (VBD reduced) (NP (NN protein) (NN mRNA) (NN level) (NN c-myc) (NN colon) (NN tumor)))))))) |ET| |BS|7:D12.776 51:C04.588.274.476.411.307.180 111:D13.444.735.544 212:E01.370.225.500.385.500 251:D02.455.426.559.847.486.875 1294:D01.146.300 1295:D12.125.068.665.340 1296:D02.886.665.500|ES| 2:1 4:1 7:1 19:1 113:1 202:1 249:1 325:1 452:1 455:1 720:1 721:1 869:1 988:1 2336:1 2788:1 4078:1 4612:1 4613:1 4614:1
1 	|BT| (S (NP (NN Cdh1) (NN knockdown) (NN siRNA)) (VP (VP (VBD reversed) (NP (JJ salinomycin-induced) (NN Skp2) (NN downregulation) (NN p27Kip1) (NN upregulation)) (, ,) (S (VP (VBG indicating) (NP (NN salinomycin)))) (VP (VBZ activates) (NP (NP (NN APC)) (PRN (-LRB- -LRB-) (NP (NN Cdh1)) (-RRB- -RRB-))))) (: -) (NP (NN Skp2-p27Kip1) (NN pathway)))) |ET| |BS|3:C04.557.470.035.215.100 85:G02.111.087.225 117:D13.150.650.700 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 507:D12.776.157.743|ES| 2:1 10:1 11:1 14:1 19:1 301:1 351:1 383:1 464:1 524:1 595:1 1126:1 1785:1 2236:1 4352:1 4615:1 4616:1 4617:1 4618:1
1 	|BT| (S (S (NP (NNP Celecoxib)) (VP (VBP induce) (NP (JJ significant) (NN autophagy) (NN U87MG-PFT)))) (, ,) (NP (NP (NN U87MG-E6) (NN U373MG) (NN cell)) (, ,) (S (VP (VBP lack) (NP (JJ functional) (NN p53)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 390:G04.299.139.399 684:D02.065.884.247|ES| 2:1 12:1 19:1 94:1 135:1 243:1 415:1 1317:1 2475:1 3937:1 4619:1 4620:1 4621:1
1 	|BT| (S (NP (NN Celecoxib)) (VP (VBD induced) (NP (NP (NN G1-phase) (NN cell) (NN cycle) (NN arrest)) (, ,) (NP (VBN accompanied) (NP (NN p21) (NN activation) (NN U87MG) (NN cell)))))) |ET| |BS|41:A11 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 2:1 19:1 94:1 225:1 412:1 601:1 602:1 1135:1 2475:1 2801:1 4622:1 4623:1
1 	|BT| (S (NP (NN Celecoxib)) (VP (VBZ inhibits) (NP (NN glioblastoma) (NN cell) (NN viability) (NN induction) (NN DNA) (NN damage)) (, ,) (S (VP (VBG leading) (NP (NP (JJ p53-dependent) (NN G1) (NN cell) (NN cycle) (NN arrest)) (JJ p53-dependent) (NP (NN autophagy)) (, ,) (NP (NN apoptosis))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 86:D01.268.556.435 108:G04.299.316 122:C14.280.383 390:G04.299.139.399 526:G05.355.180 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 2:1 19:1 88:1 89:1 94:1 309:1 601:1 602:1 615:1 639:1 666:1 670:1 736:1 1317:1 1848:1 2186:1 2475:1
1 	|BT| (S (NP (NN Cell) (NN cycle) (NN analysis)) (VP (VBD showed) (SBAR (S (NP (NN MK-801)) (VP (VBD induced) (NP (NP (NN G1) (NN cell) (NN cycle) (NN arrest)) (S (NP (JJ down-regulating) (NN cyclin) (NN D1)) (VP (VBG up-regulating) (NP (NN p27)))))))))) |ET| |BS|150:Z01.542.248.960 206:G05.360.340.024.340.375.249 209:G02.111.087.847 215:D12.644.360.262.150.100 351:A17.360 353:G04.299.134 463:C23.550.210.870 1076:G04.299.134.109.249 1297:D02.455.426.559.847.181.384.380|ES| 2:1 7:1 9:1 19:1 94:1 132:1 412:1 487:1 601:1 602:1 661:1 670:1 700:1 715:1 743:1 744:1 1124:1 1256:1 1334:1 1618:1 1876:1 3097:1 3264:1 4094:1 4624:1 4625:1 4626:1 4627:1
1 	|BT| (S (NP (NN Cell) (NN proliferation)) (ADVP (RB significantly)) (VP (VBD inhibited) (, ,) (SBAR (S (NP (NN apoptosis)) (VP (VBD induced) (NP (NP (NN area) (NN GST-P) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NN focus) (NNP Valerian) (NN group)) (VP (VBN associated) (NP (NN suppression) (NN c-myc)))) (, ,) (NP (NP (NN Mafb)) (, ,) (NP (NP (NN cyclin) (NN D1) (NN induction) (NN p21)) (PRN (-LRB- -LRB-) (NP (NN Waf1/Cip1)) (-RRB- -RRB-))) (, ,) (NP (NN p53) (NN Bax) (NN mRNA) (NN expression)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 111:D13.444.735.544 122:C14.280.383 183:G04.299.233.750 215:D12.644.360.262.150.100 292:Z01 342:D12.644.360.075.718.400 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 1298:D12.776.260.108.500.061.500 1299:D12.644.360.225.500 1300:E05.318.308.112|ES| 2:1 10:1 12:1 14:1 19:1 89:1 115:1 124:1 169:1 299:1 325:1 365:1 412:1 455:1 736:1 743:1 744:1 1135:1 1431:1 2300:1 2453:1 3057:1 3058:1 3059:1 4080:1 4094:1 4628:1 4629:1 4630:1
1 	|BT| (NP (NP (JJ Chemopreventive) (NN agent)) (VP (VBD reported) (S (NP (NN mechanism) (VBG targeting) (NN epigenome)) (VBP include) (NP (NN micronutrient)) (-LRB- -LRB-) (NP (NP (NP (NN folate)) (, ,) (NP (NP (NN selenium)) (, ,) (NP (JJ retinoic) (NN acid))) (, ,) (NP (NN Vit))))))) |ET| |BS|224:D03.438.733.631.400 770:D02.455.326.271.665.202.495.818.500 833:D27.505.696.706.018 835:D27.505.696.377.605 935:D01.268.185.850|ES| 2:1 10:1 19:1 162:1 616:1 728:1 778:1 993:1 1275:1 2704:1 2973:1 3284:1 3972:1 4631:1 4632:1 4633:1
1 	|BT| (NP (NP (JJ Chemopreventive) (NN agent)) (VP (VBD reported) (S (NP (NN mechanism) (VBG targeting) (NN epigenome)) (VBP include) (NP (NN micronutrient)) (-LRB- -LRB-) (NP (NP (NP (NN folate)) (, ,) (NP (NP (NN selenium)) (, ,) (NP (JJ retinoic) (NN acid))) (, ,) (NP (NN Vit))))))) |ET| |BS|36:G02.111.087.029.538 56:D02.455.426.559.389.657.715 224:D03.438.733.631.400 399:D12.776.660.470 433:F01.470.047 595:G07.203.650.240 652:D20.215.784.249 674:B01.650.510.956 684:D02.065.884.247 692:D02.455.326.146.485.222.222 737:D04.808.105.225.272.962 741:D03.383.663.283.909 770:D02.455.326.271.665.202.495.818.500 833:D27.505.696.706.018 835:D27.505.696.377.605 935:D01.268.185.850 944:D03.383.663.283.266.450.400.375 1001:B01.650.940.800.575.100.401.750 1032:D03.383.663.283.266.450.400 1059:H01.158.703 1295:D12.125.068.665.340 1301:B01.650.940.800.575.100.842.500.444 1302:D02.455.426.559.389.140.450.582 1303:D02.455.426.559.847.562.050.650 1304:B01.650.940.800.575.100.610.100 1305:D27.505.954.122.085.255.135 1306:D27.505.954.122.085 1307:D02.241.081.114.750 1308:D10.212.302.380.410 1309:D02.241.081.114 1310:D02.033.623 1311:D12.125.068.555 1312:D02.886.489 1313:D02.092.782 1314:D08.811.913 1315:D01.875|ES| 2:1 10:1 14:1 19:1 69:1 81:1 154:1 162:1 380:1 399:1 503:1 616:1 728:1 778:1 993:1 1275:1 1380:1 1712:1 2070:1 2085:1 2379:1 2386:1 2433:1 2458:1 2498:1 2530:1 2566:1 2594:1 2630:1 2704:1 2807:1 2973:1 3219:1 3284:1 3314:1 3371:1 3598:1 3707:1 3758:1 3916:1 3924:1 3972:1 4229:1 4245:1 4613:1 4631:1 4632:1 4633:1 4634:1 4635:1 4636:1 4637:1 4638:1 4639:1 4640:1 4641:1 4642:1 4643:1 4644:1 4645:1 4646:1 4647:1 4648:1 4649:1 4650:1 4651:1 4652:1 4653:1 4654:1 4655:1 4656:1 4657:1 4658:1 4659:1 4660:1 4661:1 4662:1 4663:1 4664:1 4665:1 4666:1 4667:1 4668:1 4669:1 4670:1 4671:1 4672:1 4673:1 4674:1
1 	|BT| (S (NP (JJ Colonic) (NN adenocarcinoma)) (ADVP (RB rapidly)) (VP (VBD induced) (NP (NP (JJ combined) (NP (NN treatment) (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine) (NN dextran) (NN sodium) (NN sulfate) (JJ male) (NN ICR) (NN mouse) (NN posse) (NN beta-catenin) (NN gene) (NN mutation)) (NN increase) (NN immunoreactivity) (NN beta-catenin)) (, ,) (NP (NN cyclooxygenase-2) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase))))) |ET| |BS|18:G05.365.590 22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 46:A03.556.124.526.356 84:C04.557.470.200.025 131:D09.698.365.272.300 618:E02.186 744:D03.383.725 1316:B01.050.050.199.520.520.510|ES| 2:1 9:1 19:1 34:1 40:1 52:1 60:1 61:1 63:1 64:1 65:1 66:1 164:1 255:1 406:1 407:1 412:1 546:1 1373:1 1378:1 1402:1 2638:1 2639:1 2640:1 3048:1 3300:1 3424:1 4675:1 4676:1 4677:1
1 	|BT| (NP (NP (NN CONCLUSION) (: :)) (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN curcumin)) (VP (VBZ potentiates) (NP (NP (JJ antitumor) (NN effect) (NN radiation) (NN therapy)) (JJ colorectal) (NN cancer) (VBG suppressing) (NP (NN NF-kappaB) (JJ NF-kappaB-regulated) (NN gene) (NN product))) (, ,) (NP (VBG leading) (NN inhibition) (NN proliferation) (NN angiogenesis))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 43:F01.145.544 52:E02 86:D01.268.556.435 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 693:G01.750.745|ES| 2:1 9:1 17:1 18:1 19:1 75:1 101:1 103:1 104:1 130:1 299:1 639:1 675:1 714:1 796:1 1872:1 1882:1 2244:1 2250:1 2498:1 2499:1 2500:1 2501:1 2502:1
1 	|BT| (S (NP (NN CONCLUSION) (: :)) (NP (PRP$ Our) (NN finding)) (VP (VBP reveal) (NP (NN p53) (NN increase) (JJ human) (NN glioblastoma) (NN sensitivity) (NN celecoxib)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 55:B01.050.150.900.649.801.400.112.400.400 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247|ES| 12:1 19:1 36:1 40:1 104:1 607:1 658:1 927:1 1670:1 1882:1 2186:1 2807:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT Both) (NP (NN sulindac) (NN etodolac))) (VP (VBD reduced) (NP (NN occurrence) (NN ACF) (VBD induced) (NN increase) (NN APC) (NN mRNA) (NN rat) (NN colon) (NN mucosa))))) |ET| |BS|3:C04.557.470.035.215.100 12:Z01.542.049 46:A03.556.124.526.356 111:D13.444.735.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 251:D02.455.426.559.847.486.875 302:A10.615.550 842:N02.278.035 1317:D03.066.288.200|ES| 11:1 19:1 40:1 104:1 113:1 239:1 325:1 412:1 452:1 579:1 849:1 869:1 2282:1 2914:1 4678:1 4679:1
1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN FTS)) (VP (VBZ inhibits) (NP (NP (NN Ras)) (NN activation)))) (VP (VBZ prevents) (NP (NP (JJ preneoplastic) (NN liver) (NN nodule) (NN development)) (VP (VBG inducing) (NP (NP (NN apoptosis)) (VP (VBN transformed) (NP (NNS hepatocytes) (NN activation) (NN Fas/Fas) (NN ligand) (NN system)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 39:G04.299.139.160 122:C14.280.383 242:A03.620 262:A11.436.348 1318:D12.644.276.374.750.249|ES| 19:1 35:1 89:1 104:1 225:1 239:1 593:1 615:1 836:1 894:1 1438:1 1775:1 1835:1 1864:1 2718:1 4551:1 4680:1 4681:1 4682:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NP (DT The) (JJ novel) (NN effect) (NN ROS)) (VP (VBG modulating) (NP (NP (NP (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NN expression) (NN splice) (NN variant)))) (VP (MD could) (VP (VB play) (NP (JJ relevant) (NN role) (NN liver) (NN injury) (NN TNFalpha) (NN regulation)))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 142:I01.880.604 242:A03.620 259:D12.776.395.240.150.500 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 10:1 14:1 19:1 31:1 75:1 104:1 115:1 238:1 239:1 438:1 691:1 836:1 865:1 891:1 908:1 990:1 2356:1 2416:1 2435:1 4116:1 4683:1 4684:1 4685:1
1 	|BT| (S (ADVP (RB Consistently)) (, ,) (NP (NP (NN expression) (JJ oxidative-stress-inducible) (NN gene) (NN heme) (NN oxygenase-1)) (PRN (-LRB- -LRB-) (NP (NN HO-1)) (-RRB- -RRB-))) (VP (VBD upregulated) (NP (NN liver) (JJ arsenic) (NN group)))) |ET| |BS|155:G05.355.310 716:G03.495.710 1158:D01.268.513.249 1226:E01.370.372.460 1319:D08.811.682.690.708.410.500|ES| 2:1 9:1 10:1 14:1 19:1 115:1 125:1 836:1 2300:1 4106:1 4686:1 4687:1 4688:1 4689:1 4690:1
1 	|BT| (S (ADVP (RB Consistently)) (, ,) (VP (VBD found) (SBAR (S (NP (NN simvastatin)) (ADVP (RB also)) (VP (VBD increased) (NP (NP (NN p21) (NN p27) (NN expression) (NN tumor) (NN section)) (VP (VBG reducing) (NP (NP (NN Skp2) (NN expression)) (VP (VBG inducing) (NP (NN AMPK) (NN activation) (NN STAT3) (NN suppression) (NN tumor) (NN tissue))))))))))) |ET| |BS|8:C04 82:D12.644.360.024.342.300 98:A10 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900|ES| 2:1 5:1 7:1 19:1 37:1 47:1 115:1 225:1 251:1 272:1 1124:1 1135:1 1785:1 1864:1 2453:1 2679:1 3331:1 4686:1 4691:1 4692:1
1 	|BT| (S (ADVP (RB Conversely)) (, ,) (NP (NN IEX-1) (NN overexpression) (NN Colo320mut) (NN cell)) (VP (VBD caused) (SBAR (S (NP (NP (NN increase) (JJ basal) (NN TNFalpha)) (: -) (NP (JJ 5-FU-induced) (NN apoptosis)) (, ,) (NP (NN effect))) (VP (VBD triggered) (NP (NN G17) (NN treatment))))))) |ET| |BS|12:Z01.542.049 39:G04.299.139.160 41:A11 52:E02 560:D03.383.742.698.875.404 573:N05.715.350.200.650 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 19:1 40:1 75:1 89:1 94:1 152:1 546:1 760:1 2506:1 3398:1 3404:1 4184:1 4693:1 4694:1 4695:1 4696:1
1 	|BT| (S (ADVP (RB Conversely)) (, ,) (NP (NP (NN MBO-asGCS) (NN treatment)) (VP (VBD decreased) (NP (NP (NP (NN globo) (NN series) (NNS GSLs)) (PRN (-LRB- -LRB-) (NP (NP (NN Gb3)) (, ,) (NP (NN Gb4))) (-RRB- -RRB-))) (, ,) (NP (NN cSrc) (NN kinase) (JJ nuclear) (NN beta-catenin)) (, ,)))) (VP (VBD suppressed) (NP (NN MDR-1) (NN expression) (JJ dose-dependent) (NN pattern)))) |ET| |BS|23:D12.776.091.249 52:E02 469:D08.811.913.696|ES| 2:1 10:1 14:1 19:1 60:1 115:1 202:1 260:1 307:1 470:1 546:1 1256:1 1807:1 2824:1 3404:1 4697:1 4698:1 4699:1 4700:1 4701:1 4702:1 4703:1
1 	|BT| (NP (NP (ADJP (NN Correction) (JJ malignant)) (NN behavior) (ADJP (NN tumor) (NN cell) (JJ traditional)) (JJ Chinese) (NN herb) (NN medicine) (NN restoration) (NN p53))) |ET| |BS|2:G05.360.340.024.340.375.249.385 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 788:H01.158.273.118.598.500 876:F01.145 1320:E02.190.488.585.520|ES| 7:1 12:1 19:1 94:1 802:1 2326:1 2327:1 2763:1 2764:1 4704:1 4705:1 4706:1
1 	|BT| (S (NP (NP (NN Cr)) (PRN (-LRB- -LRB-) (NP (NNP VI)) (-RRB- -RRB-))) (VP (VBD caused) (NP (NP (JJ significant) (NN increase) (NN miR-21) (NN expression)) (VBN associated) (NN inhibition) (NN PDCD4) (NN expression)))) |ET| |BS|43:F01.145.544 1321:Z01.107.084.900.182|ES| 10:1 14:1 19:1 40:1 103:1 115:1 135:1 169:1 2177:1 2506:1 4707:1 4708:1 4709:1
1 	|BT| (S (NP (NP (JJ CRC-associated) (NN symptom) (NN patient)) (PP (VBG including) (NP (JJ intestinal) (NN bleeding) (NN anaemia)))) (ADVP (RB faithfully)) (VP (VBD mimicked) (NP (NP (NP (JJ AOM-treated) (NN MybER) (JJ transgenic) (NN mouse)) (VBN implicated) (NN hypoxia) (NN vessel) (NN leakage)) (VP (VBG identifying) (NP (ADJP (ADJP (JJ additional)) (ADJP (JJ pathogenic))) (NN role) (NN Myb)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 15:F01.829.316.616 47:A03.556.124 50:M01.643 52:E02 99:B01.050.050.136.500 132:D02.172.080 327:G06.930 371:A07.231 1011:C23.888.852.079 1322:C15.378.071 1323:C23.550.414|ES| 19:1 31:1 52:1 109:1 120:1 285:1 561:1 977:1 980:1 1698:1 2474:1 4710:1 4711:1 4712:1 4713:1 4714:1 4715:1 4716:1 4717:1 4718:1 4719:1 4720:1 4721:1
1 	|BT| (S (NP (NN Ctnnb1) (JJ hemizygous) (NN dose)) (VP (VP (ADVP (RB markedly)) (VBD inhibited) (NP (NN increase) (NN beta-catenin) (NN level) (NN cytoplasm) (NN nucleus)) (PP (VBG following) (NP (NN Apc) (NN inactivation) (NN colon) (NN epithelium)))) (, ,) (VP (VBD attenuated) (NP (NN expression) (JJ key) (JJ beta-catenin/TCF-regulated) (NN target) (NN gene)) (, ,) (PP (VBG including) (S (VP (VBG encoding) (NP (NP (NP (NN EphB2/B3) (NN receptor)) (, ,) (NP (NN stem) (NN cell) (NN marker) (NN Lgr5)) (, ,) (NP (NN Myc)) (, ,) (NP (VBG leading) (NN maintenance) (NN crypt) (NN compartmentalization) (NN restriction) (NN stem))) (VP (VBG proliferating) (NP (NN cell) (NN crypt) (NN base)))))))))) |ET| |BS|3:C04.557.470.035.215.100 23:D12.776.091.249 41:A11 46:A03.556.124.526.356 62:A10.272 86:D01.268.556.435 122:C14.280.383 142:I01.880.604 155:G05.355.310 158:D23.101 188:N02.628 308:A11.872 309:A18.024.937 333:D01.045 1098:A11.284.430.214 1104:A11.284.430.106 1324:D08.811.913.696.620.682.725.400.850.650|ES| 2:1 9:1 19:1 40:1 60:1 94:1 113:1 115:1 159:1 160:1 173:1 186:1 249:1 280:1 365:1 534:1 561:1 639:1 808:1 1063:1 1106:1 1314:1 1786:1 2301:1 2396:1 2865:1 2913:1 3510:1 3873:1 4032:1 4722:1 4723:1 4724:1 4725:1 4726:1 4727:1 4728:1 4729:1 4730:1
1 	|BT| (S (NP (NN Curcumin)) (VP (VBD suppressed) (NP (NP (NP (NN expression) (NN protein) (JJ related) (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (NN bcl-2) (NN bcl-xL)) (-RRB- -RRB-))) (, ,) (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN cyclin) (NN D1) (NN c-myc)) (-RRB- -RRB-))) (, ,) (NP (NP (NN tumor) (NN invasion)) (NP (NP (-LRB- -LRB-) (NN MMP-9) (NN ICAM-1) (-RRB- -RRB-) (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-)))) (, ,) (NP (NN microvessel) (NN density))))) |ET| |BS|7:D12.776 8:C04 54:G05.360.340.024.340.375.500.791.150 108:G04.299.316 215:D12.644.360.262.150.100 586:D08.811.277.656.300.480.205.360 692:D02.455.326.146.485.222.222 1325:D12.776.395.550.200.450 1326:A07.231.461|ES| 2:1 4:1 7:1 10:1 14:1 19:1 94:1 115:1 151:1 274:1 299:1 307:1 419:1 455:1 620:1 743:1 744:1 2066:1 2158:1 2502:1 3429:1 4731:1 4732:1 4733:1 4734:1
1 	|BT| (S (NP (NP (NN Cyp2b20)) (, ,) (NP (NN growth) (NN arrest)) (: -) (NP (NP (JJ damage-inducible) (NN gene) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN Gadd45beta)) (-RRB- -RRB-))) (, ,) (NP (NP (ADJP (NN tumor) (NN necrosis) (NN factor) (JJ alpha-induced)) (NN protein) (CD 2) (JJ insulin-like) (NN growth) (NN factor) (NN binding) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN Igfbp5)) (-RRB- -RRB-))) (NP (NN gene) (NN protein))) (VP (VP (VBD upregulated) (NP (NN oxazepam) (, ,) (NN Cyp2b20) (, ,) (NN Cyclin) (NN D1)) (, ,) (S (VP (VBG proliferating) (NP (NP (NP (NN cell) (JJ nuclear) (NN antigen)) (, ,) (NP (NN Igfbp5)) (, ,)) (NP (NP (NN Gadd45beta) (NN cell) (JJ death-inducing) (NN DNA) (NN fragmentation) (NN factor) (NN alpha) (JJ subunit-like) (NN effector)) (DT A)))))) (VP (VBD exhibited) (NP (JJR higher) (NN expression) (NN Wy-14,643) (NN treatment))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 45:G07.700.320.249 52:E02 134:G04.299.139 175:J01.897.280.500.269 198:D13.444.308 215:D12.644.360.262.150.100 583:D12.776.813 768:D12.776.660.740 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1327:D12.776.157.420.250 1328:D06.472.699.322.326.562 1329:D03.438.079.080.070.663 1330:G05.355.180.230|ES| 2:1 4:1 7:1 9:1 10:1 14:1 19:1 69:1 94:1 98:1 102:1 115:1 125:1 148:1 170:1 185:1 546:1 570:1 609:1 666:1 744:1 1030:1 1256:1 1487:1 1836:1 1972:1 2093:1 2865:1 4173:1 4257:1 4735:1 4736:1 4737:1 4738:1 4739:1 4740:1 4741:1 4742:1 4743:1 4744:1 4745:1
1 	|BT| (S (NP (NP (NNP DCA)) (, ,) (NP (NNP TCA) (JJR lesser) (NN extent)) (NN chloroform)) (VP (VBD decreased) (SBAR (S (NP (NN methylation)) (VP (VBD increased) (NP (NN mRNA) (NN expression) (NN c-myc) (NN gene))))))) |ET| |BS|36:G02.111.087.029.538 111:D13.444.735.544 155:G05.355.310 1196:D02.455.526.439.224 1331:C06.198.439 1332:Z01.107.084.900|ES| 2:1 9:1 19:1 47:1 81:1 115:1 202:1 325:1 455:1 2805:1 4179:1 4180:1 4486:1 4746:1
1 	|BT| (S (NP (JJ DHMEQ-treated) (NN cell)) (VP (VP (VBD exhibited) (NP (NN DNA) (NN damage))) (, ,) (VP (VBD evaluated) (NP (NN accumulation) (JJ nuclear) (NN focus) (NN phospho-H2AX))) (, ,) (S (ADVP (RB completely)) (VP (VBD reversed) (NP (NN NAC)))))) |ET| |BS|41:A11 52:E02 94:A11.251.210 155:G05.355.310 175:J01.897.280.500.269 225:E05.337 526:G05.355.180 1071:G04.434 1333:G02.111.087.750.700|ES| 2:1 9:1 10:1 14:1 19:1 94:1 115:1 264:1 325:1 346:1 412:1 494:1 609:1 622:1 666:1 774:1 780:1 1256:1 1431:1 1848:1 1912:1 2120:1 2522:1 2824:1 3223:1 3745:1 3746:1 4271:1 4352:1 4441:1 4747:1 4748:1 4749:1 4750:1 4751:1 4752:1 4753:1 4754:1
1 	|BT| (S (NP (NP (JJ Dietary) (NN intake) (NN pterostilbene)) (, ,) (NP (NN constituent) (NN blueberry)) (, ,)) (VP (VBZ inhibits) (NP (NN beta-catenin/p65) (JJ downstream) (NN signaling) (NN pathway) (NN colon) (NN carcinogenesis) (NN rat)))) |ET| |BS|23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 710:B01.650.940.800.575.100.343.774.249|ES| 2:1 19:1 113:1 195:1 207:1 383:1 560:1 615:1 849:1 2428:1 2457:1 2562:1 2563:1 2564:1 2565:1
1 	|BT| (S (NP (JJ Differential) (NN expression)) (VBN selected) (NP (NP (JJ beta-catenin/TCF-regulated) (NN gene)) (, ,) (NP (NN Myc)) (, ,)) (ADVP (JJ likely)) (VP (VBZ underlies) (NP (JJ context-dependent) (NN effect) (NN Ctnnb1) (NN gene) (NN dosage) (NN tumorigenesis)))) |ET| |BS|23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 142:I01.880.604 155:G05.355.310 280:G05.380.350|ES| 2:1 9:1 19:1 75:1 78:1 115:1 1328:1 1786:1 1905:1 2586:1 4032:1 4724:1 4755:1 4756:1 4757:1
1 	|BT| (S (NP (NN Down-regulation) (NN Notch) (NN signaling)) (ADVP (RB also)) (VP (VBD prevented) (NP (NP (NP (NN induction)) (JJ prosurvival) (NN pathway)) (, ,) (NP (NP (ADJP (RB notably) (JJ phosphoinositide)) (NN kinase-3)) (: /) (NP (NNP Akt))) (, ,) (NP (NN oxaliplatin))))) |ET| |BS|69:G02.111.087.800 85:G02.111.087.225 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550|ES| 2:1 5:1 19:1 195:1 256:1 383:1 736:1 1865:1 1944:1 2080:1 2543:1 3458:1 4758:1 4759:1
1 	|BT| (S (NP (NP (NN Doxorubicin) (NN treatment)) (VP (VBD induced) (NP (NP (NP (NNS GCS)) (NP (NN MDR1) (NN expression) (NN tumor))) (, ,) (NP (NN MBO-asGCS) (NN treatment))))) (VP (VBD eliminated) (NP (NP (`` ``) (JJ in-vivo) ('' '') (NN growth) (JJ drug-resistant) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NN NCI/ADR-RES)) (-RRB- -RRB-))))) |ET| |BS|8:C04 45:G07.700.320.249 52:E02 67:D26 120:I01.409.418.750.600.480.150 136:D02.455.426.559.847.562.050.200.175|ES| 2:1 7:1 10:1 14:1 19:1 102:1 115:1 412:1 453:1 546:1 3247:1 3268:1 3269:1 4697:1 4760:1 4761:1 4762:1 4763:1 4764:1
1 	|BT| (NP (NP (NP (NN Effect) (JJ antisense) (NN oligodeoxy) (NN nucleotide) (NN c-Myc) (NN E2F1)) (NP (VBN studied) (NP (JJ human) (NN HCC) (NN cell) (NN line))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 104:C04.557.470.200.025.255 1334:D09.408.620|ES| 19:1 36:1 94:1 264:1 401:1 441:1 824:1 1961:1 3661:1 4765:1 4766:1 4767:1
1 	|BT| (NP (NP (NN Effect) (NN chloroform) (JJ dichloroacetic) (NN acid) (JJ trichloroacetic) (JJ acid-induced) (NN hypomethylation) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN kidney) (NN tumor) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 155:G05.355.310 242:A03.620 274:C04.588.945.947.535 1196:D02.455.526.439.224 1219:D02.241.081.018.214.500 1335:D02.241.081.018.214.750|ES| 7:1 9:1 19:1 52:1 115:1 455:1 836:1 1275:1 1717:1 2337:1 2599:1 3661:1 4107:1 4179:1 4273:1 4768:1
1 	|BT| (NP (NP (NP (VBN Enhanced) (NN sensitivity) (NN celecoxib) (JJ human) (NN glioblastoma) (NN cell)) (: :) (NP (NP (NN Induction) (NN DNA) (NN damage)) (VP (VBG leading) (NP (JJ p53-dependent) (NN G1) (NN cell) (NN cycle) (NN arrest) (NN autophagy)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 390:G04.299.139.399 526:G05.355.180 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 19:1 36:1 88:1 94:1 104:1 601:1 602:1 607:1 639:1 666:1 670:1 1317:1 1848:1 2020:1 2186:1 2807:1 3466:1
1 	|BT| (S (NP (NN Erlotinib)) (VP (VBZ induces) (NP (NP (JJ mitochondrial-mediated) (NN apoptosis)) (NP (NP (JJ human) (NN H3255) (JJ non-small-cell) (NN lung) (ADJP (NN cancer) (NN cell) (JJ epidermal)) (NN growth) (NN factor) (NN receptorL858R) (NN mutation)) (NP (JJ mitochondrial) (JJ oxidative) (JJ phosphorylation-dependent) (NN activation) (NN BAX) (NN BAK)))))) |ET| |BS|18:G05.365.590 39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 110:C04.588.894.797.520.109.220.249 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 923:D06.472.317.350 1336:G02.111.087.677.550|ES| 18:1 19:1 34:1 36:1 89:1 94:1 102:1 184:1 185:1 214:1 225:1 327:1 328:1 2004:1 2583:1 2596:1 4769:1 4770:1 4771:1 4772:1 4773:1 4774:1
1 	|BT| (S (NP (NN Expression) (NN profiling) (NN CC531) (NN colon) (NN carcinoma) (NN cell)) (VP (VBZ reveals) (NP (JJ similar) (NN regulation) (NN beta-catenin) (NN target) (NN gene) (NN butyrate) (NN aspirin)))) |ET| |BS|23:D12.776.091.249 41:A11 46:A03.556.124.526.356 140:G05.355.315 265:C04.557.470.200 670:D02.455.426.559.389.657.410.595.176 1307:D02.241.081.114.750 1309:D02.241.081.114|ES| 9:1 19:1 60:1 94:1 113:1 160:1 304:1 316:1 332:1 438:1 2148:1 2253:1 2487:1 3758:1 4775:1
1 	|BT| (S (S (NP (NN Flavokawain) (NN B)) (ADVP (RB also)) (VP (VBP down-regulate) (NP (ADJP (NN Bcl-2) (JJ concomitant)) (NN increase) (NN Bax) (NN level)))) (, ,) (VP (VBD resulted) (NP (NN release) (NN cytochrome) (NN c)))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 342:D12.644.360.075.718.400 351:A17.360 589:E02.204.125 1337:D08.244.286.100 1338:D08.244.286.150|ES| 2:1 5:1 19:1 40:1 158:1 249:1 594:1 763:1 1159:1 1681:1 2165:1 3788:1 4630:1 4776:1 4777:1
1 	|BT| (S (SBAR (IN For) (S (NP (NN therapy)) (VP (VBD advanced) (NP (NNP MTC))))) (, ,) (NP (NNP Food) (NNP Drug) (NNP Administration)) (ADVP (RB recently)) (VP (VBD approved) (NP (NP (NP (NN vandetanib) (NN cabozantinib) (, ,) (NN tyrosine) (NN kinase) (NN inhibitor)) (VP (VBG targeting) (NP (NNP RET)))) (, ,) (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor) (NN receptor)) (, ,) (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (CC and/or) (NP (NN c-MET))))))) |ET| |BS|52:E02 64:D08.811.913.696.620.682.725.400.009.300 633:I01.409.418.750.600.650.760 1339:D08.811.913.696.620.682.725.400.950 1340:D08.811.913.696.620.682.725|ES| 2:1 19:1 102:1 130:1 149:1 184:1 185:1 186:1 380:1 470:1 616:1 772:1 956:1 997:1 1251:1 2341:1 2343:1 2344:1 2345:1 2346:1 3092:1 3489:1 4778:1 4779:1 4780:1 4781:1
1 	|BT| (NP (NP (JJ Formalin-fixed) (, ,) (NP (NP (NP (NN paraffin) (JJ wax-embedded) (JJ pre-operative) (NN biopsy)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 14)))) (-RRB- -RRB-))) (NP (NP (NP (JJ surgical) (NN resection) (NN specimen)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 40)))) (-RRB- -RRB-))) (NP (S (NP (NP (NN patient) (JJ rectal) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (JJ clinical) (NN UICC) (NN stage) (NN II/III)) (-RRB- -RRB-))) (VP (VBG receiving) (NP (NP (JJ neo-adjuvant) (JJ 5-FU-based) (NN chemoradiotherapy)) (VP (VBN studied) (S (NP (NN TS) (: -))))))) (, ,) (NP (ADJP (NN TP) (: -) (, ,) (ADJP (JJ DPD-gene))) (NN expression) (JJ quantitative) (NNP TaqMan) (JJ real-time) (NN PCR) (NN laser) (NN microdissection))))))) |ET| |BS|6:G05.360.340.024.340 50:M01.643 115:E04 154:Z01.058.266.887 257:E05.393.620.500.706 333:D01.045 346:E05.393.620.500.706 347:D02.047.407 559:E01.370.225.500.384.100 560:D03.383.742.698.875.404 561:E02.186.079.500 1341:E01.370.225.998.221.580.500 1342:Z01.639.040 1343:D02.455.612|ES| 2:1 10:1 14:1 19:1 84:1 115:1 120:1 128:1 304:1 341:1 401:1 548:1 580:1 581:1 582:1 817:1 874:1 875:1 1129:1 1154:1 1440:1 1550:1 1984:1 1986:1 1987:1 1988:1 1989:1 3543:1 4046:1 4782:1 4783:1 4784:1 4785:1 4786:1 4787:1 4788:1 4789:1 4790:1
1 	|BT| (S (NP (NN FoxM1) (NN expression) (NN activity) (NN cancer) (NN cell)) (VP (VBN targeted) (S (VP (VBG using) (NP (NN PPARgamma) (NN agonist) (JJ anti-neoplastic) (JJ antibiotic) (NN mithramycin)))))) |ET| |BS|8:C04 41:A11 719:D12.776.826.239.588 1303:D02.455.426.559.847.562.050.650 1306:D27.505.954.122.085|ES| 16:1 18:1 19:1 94:1 115:1 350:1 399:1 2588:1 3228:1 4658:1 4659:1 4791:1 4792:1
1 	|BT| (S (S (S (NP (NN FTS)) (VP (VBZ abrogates) (NP (JJ DEN-induced) (NN Ras) (NN membrane) (NN activity)))) (, ,) (NP (NN increase) (NP (NP (NNP Tunel) (JJ positive) (NN cell)) (VP (VBN transformed)) (, ,) (NP (JJ GSTp-expressing) (NNS hepatocytes)) (, ,))) (VP (VBZ up-regulates) (NP (NN caspase) (CD 3) (CD 8) (NN activity)))) (, ,) (VP (VBZ induces) (SBAR (S (NP (NP (NN Fas)) (, ,) (NP (NN Fas) (NN ligand) (NN JNK) (NN phosphorylation))) (VP (VBZ occurs) (NP (RB independently) (NN TNFalpha) (NN Trail))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 41:A11 144:E05.393.475 150:Z01.542.248.960 262:A11.436.348 789:D12.644.276.374.500.800 790:D12.644.276.374.750 906:D08.811.277.656.262.500.126.350.300 972:G02.111.087.677 1318:D12.644.276.374.750.249 1344:A10.615|ES| 2:1 19:1 40:1 94:1 214:1 233:1 399:1 657:1 781:1 862:1 894:1 1775:1 1835:1 2149:1 2580:1 2735:1 3426:1 3622:1 4276:1 4551:1 4681:1 4685:1 4793:1 4794:1 4795:1 4796:1 4797:1 4798:1
1 	|BT| (S (NP (JJ Further) (NN study)) (VP (VBD revealed) (SBAR (S (NP (ADJP (NN TFSC) (VBD induced)) (NN HCC) (NN cell) (NN apoptosis)) (VP (VBD inhibited) (NP (NP (JJ expressional) (NN level) (NN NF-kappaB) (JJ responsive) (NN gene)) (VP (VBN transplanted) (NP (NN tumor) (NN tissue))))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 39:G04.299.139.160 41:A11 104:C04.557.470.200.025.255 122:C14.280.383 210:D12.776.260.600 1345:A01.941 1346:A01.941|ES| 7:1 9:1 19:1 89:1 94:1 131:1 249:1 272:1 275:1 330:1 365:1 412:1 441:1 714:1 4799:1 4800:1 4801:1 4802:1
1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN calcitriol)) (PRN (-LRB- -LRB-) (NP (JJ active) (NN form) (NN vitamin) (NN D)) (-RRB- -RRB-))) (VP (VBD suppressed) (NP (NN CYP3A4) (NN expression) (VBG activating) (NN miR-627)))) |ET| |BS|189:V02.460 720:D04.808.247.222.474 721:D04.808.812.768 1347:D04.808.247.222.159.478.387.300 1348:D08.244.453.400|ES| 2:1 10:1 14:1 19:1 115:1 197:1 307:1 334:1 630:1 1958:1 2591:1 2592:1 4803:1 4804:1 4805:1
1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN PSI) (NN treatment)) (VP (VBD increased) (NP (NN level) (NN Bax)) (, ,) (SBAR (S (NP (NP (NN cytochrome) (NN c)) (, ,) (NP (VBN activated) (NN caspase-3)) (, ,) (NP (JJ active) (NN caspase-9)) (, ,) (NP (NP (VBN cleaved) (NN poly)) (PRN (-LRB- -LRB-) (NP (NN ADP-ribose)) (-RRB- -RRB-))) (NP (NN polymerase))) (VP (VBD decreased) (NP (NP (NN Bcl-2) (NN expression) (NN level)) (NP (JJ extracellular) (JJ signal-regulated) (NN kinase-1) (: /) (CD 2) (NN activity)))))))) |ET| |BS|52:E02 54:G05.360.340.024.340.375.500.791.150 116:D08.811.913.696.620.682.700.567.249.750 342:D12.644.360.075.718.400 906:D08.811.277.656.262.500.126.350.300 1248:D08.811.913.400.725.115.690 1337:D08.244.286.100 1338:D08.244.286.150 1349:D08.811.277.656.262.500.126.550.900|ES| 2:1 10:1 14:1 19:1 47:1 115:1 158:1 163:1 197:1 202:1 249:1 334:1 394:1 399:1 546:1 1707:1 3788:1 4630:1 4777:1 4806:1 4807:1 4808:1 4809:1 4810:1 4811:1 4812:1 4813:1
1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN cancer) (NN cell)) (VP (VBD showed) (SBAR (S (NP (VBN increased) (NN level) (VBN activated) (NN caspase-3)) (VP (VBD increased) (NP (NN Bax) (NN Bcl-2) (NN Bax) (NN Bcl-xL) (NN ratio)) (, ,) (S (VP (VBG suggesting) (NP (NP (NN cell)) (VP (VBG undergoing) (NP (NN apoptosis))))))))))) |ET| |BS|39:G04.299.139.160 41:A11 54:G05.360.340.024.340.375.500.791.150 342:D12.644.360.075.718.400 906:D08.811.277.656.262.500.126.350.300|ES| 2:1 18:1 19:1 47:1 89:1 94:1 132:1 158:1 163:1 249:1 334:1 1009:1 2940:1 4630:1 4807:1 4814:1 4815:1
1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN Cr)) (PRN (-LRB- -LRB-) (NP (NNP VI)) (-RRB- -RRB-))) (VP (VP (VBD induced) (SBAR (S (NP (NN inhibition) (NN PDCD4)) (VP (VBD suppressed) (NP (JJ downstream) (NN E-cadherin) (NN protein) (NN expression)))))) (, ,) (VP (VBD promoted) (NP (JJ beta-catenin/TCF-dependent) (NN transcription) (NN uPAR) (NN c-Myc))))) |ET| |BS|7:D12.776 23:D12.776.091.249 43:F01.145.544 209:G02.111.087.847 613:D12.776.395.550.200.200 1321:Z01.107.084.900.182|ES| 2:1 4:1 10:1 14:1 19:1 103:1 115:1 307:1 334:1 412:1 487:1 560:1 824:1 1912:1 2267:1 4707:1 4708:1 4709:1 4816:1 4817:1
1 	|BT| (S (NP (NN gamma-Secretase) (NN inhibitor)) (VP (VBP abrogate) (NP (NP (JJ oxaliplatin-induced) (NN activation) (NN Notch-1) (NN signaling) (NN pathway) (NN colon) (NN cancer) (NN cell)) (VP (VBG resulting) (NP (VBN enhanced) (NN chemosensitivity)))))) |ET| |BS|41:A11 69:G02.111.087.800 125:D08.811.277.656.300.032 126:G02.111.087.800|ES| 18:1 19:1 20:1 94:1 113:1 195:1 225:1 379:1 380:1 381:1 382:1 383:1 384:1 385:1 386:1
1 	|BT| (S (NP (JJ Gefitinib) (NN treatment)) (VP (VBD diminished) (NP (NP (ADJP (NP (NN phosphorylation) (NN ErbB-3)) (JJR >)) (NN EGFR)) (JJR >) (NN HER2/neu) (NN signal) (NN transducer) (NN activator) (NN transcription) (JJ dose-dependent) (NN fashion)))) |ET| |BS|52:E02 63:G05.360.340.024.340.375.500.791.295.305 209:G02.111.087.847 250:E07.305.812 972:G02.111.087.677 1350:G05.360.340.024.340.375.500.791.295|ES| 19:1 187:1 487:1 546:1 859:1 860:1 861:1 901:1 1466:1 2824:1 3024:1 3426:1 4156:1 4754:1 4818:1
1 	|BT| (NP (NP (NP (S (NP (NP (NN Gene) (NN expression) (NN analysis) (NN Bcl-2) (NN family) (NN gene)) (NP (JJ antioxidant) (NN enzyme))) (VP (VBD revealed) (NP (NP (NN t-PTER)) (CC +) (NP (NN QUER)) (NP (NN treatment))) (SBAR (S (ADVP (RB preferentially)) (VP (VBZ promotes)))))) (, ,) (NP (NN HT-29) (NN cell)) (ADVP (VBG growing) (FW vivo)) (, ,) (-LRB- -LRB-) (NP (NP (NP (-RRB- -RRB-) (NN superoxide) (NN dismutase) (CD 2) (NN overexpression)) (PRN (-LRB- -LRB-) (NP (ADJP (ADJP (RB approximately) (JJ 5.7-fold)) (, ,) (ADJP (IN via) (NN specificity))) (NN protein) (JJ 1-dependent) (NN transcription) (NN regulation)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN b)) (-RRB- -RRB-))) (NP (NP (NN down-regulation) (NN bcl-2) (NN expression)) (PRN (-LRB- -LRB-) (ADVP (RB approximately) (RB 3.3-fold)) (, ,)))) (PP (IN via) (NP (NN inhibition) (JJ nuclear) (NN factor-kappaB) (NN activation)))) (ADJP (-RRB- -RRB-))) |ET| |BS|43:F01.145.544 44:F01.829.263 52:E02 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 142:I01.880.604 155:G05.355.310 209:G02.111.087.847 210:D12.776.260.600 700:D27.505.519.217 730:D08.811 792:A11.251.210.190.475 1050:D12.776.157.125.050.060 1052:D12.776.641.750 1224:E05.318.740.872|ES| 2:1 4:1 9:1 10:1 14:1 19:1 94:1 97:1 103:1 115:1 146:1 147:1 148:1 151:1 152:1 158:1 166:1 167:1 225:1 257:1 275:1 298:1 378:1 438:1 487:1 546:1 596:1 661:1 1233:1 1256:1 1843:1 2388:1 2521:1 2702:1 2782:1 3059:1 3532:1 4819:1 4820:1 4821:1 4822:1 4823:1 4824:1
1 	|BT| (S (NP (NP (NNS Genes)) (VP (VBG encoding) (NP (NP (NN DNA) (JJ damage-inducible) (CD 45) (-LRB- -LRB-) (NN GADD45) (-RRB- -RRB-) (NN family) (NN protein)) (, ,) (NP (NP (JJ particular) (NN GADD45g)) (PRN (-LRB- -LRB-) (NP (NN GADD45) (NN gamma)) (-RRB- -RRB-)))))) (VP (VBD down-regulated) (NP (NP (NN treatment)) (NP (CC either) (NP (NN PB) (NN CF) (CD 4) (CD 13) (NN week)))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 44:F01.829.263 52:E02 142:I01.880.604 325:Z01.058.290.100.140 351:A17.360 526:G05.355.180|ES| 2:1 4:1 10:1 14:1 19:1 39:1 97:1 319:1 485:1 546:1 666:1 783:1 1100:1 1283:1 1532:1 2389:1 3495:1 3496:1 4177:1 4725:1 4737:1 4825:1 4826:1
1 	|BT| (S (NP (NN Genistein) (NN 5Aza-C) (NN treatment)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NN promoter) (NN methylation)) (, ,) (S (VP (VBG reactivating) (NP (NN BTG3) (NN expression)))))) |ET| |BS|36:G02.111.087.029.538 52:E02 944:D03.383.663.283.266.450.400.375|ES| 2:1 19:1 81:1 83:1 115:1 124:1 202:1 546:1 3312:1 4827:1 4828:1 4829:1
1 	|BT| (S (NP (NP (JJ Global) (NN gene) (NN expression) (NN analysis)) (NP (JJ subsequent) (JJ quantitative) (JJ real-time) (JJ reverse) (NN transcription-polymerase) (NN chain) (NN reaction))) (VP (VBD revealed) (NP (NN BNF) (VBD induced) (`` `) (NP (NN AhR) (NN gene) (NN battery'Cyp) (NN 1a1)) (, ,) (NP (NN Cyp1a2)) (, ,) (NP (NN Cyp1b1)) (, ,) (NP (NN Nqo1)) (, ,) (NP (NN Aldh3a1) (NN Ugt1a6)) (RB also) (NP (NP (NN transcription) (NN factor) (JJ NF-E2-related) (NN factor) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN Nrf2)) (-RRB- -RRB-))) (PRN (: -) (NP (NP (VBN regulated) (NN gene) (NN Gstm1) (, ,) (NN Gpx2) (, ,) (NP (NP (NN Akr7a3) (NN Yc2)) (PRN (-LRB- -LRB-) (ADVP (RB also)) (NP (NN Nqo1)) (-RRB- -RRB-))) (, ,)) (NP (RB presumably) (JJ due) (JJ adaptive) (NN response) (JJ BNF-triggered) (JJ oxidative) (NN stress) (NN response))))))) |ET| |BS|6:G05.360.340.024.340 142:I01.880.604 155:G05.355.310 197:A01.456.505.420 257:E05.393.620.500.706 346:E05.393.620.500.706 573:N05.715.350.200.650 591:G02.111.087.847.500 705:D08.244.453.040.443 716:G03.495.710 799:D12.776.260.615.249 1351:D08.244.453.040.500 1352:D08.244.453.040.332 1353:D12.776.260.262.500.750|ES| 2:1 5:1 9:1 10:1 14:1 19:1 115:1 148:1 185:1 275:1 412:1 487:1 494:1 661:1 768:1 817:1 874:1 939:1 941:1 1319:1 2522:1 2583:1 2851:1 4037:1 4355:1 4830:1 4831:1 4832:1 4833:1 4834:1 4835:1 4836:1 4837:1 4838:1 4839:1 4840:1 4841:1 4842:1 4843:1 4844:1 4845:1 4846:1 4847:1
1 	|BT| (S (NP (NN Glucosylceramide) (NN synthase)) (VP (VBZ upregulates) (NP (NN MDR1) (NN expression) (NN regulation) (NN cancer) (NN drug) (NN resistance) (NN cSrc) (NN beta-catenin) (NN signaling)))) |ET| |BS|23:D12.776.091.249 69:G02.111.087.800 142:I01.880.604 1354:G07.690.773.984.395|ES| 18:1 19:1 60:1 66:1 115:1 191:1 195:1 438:1 453:1 1094:1 2153:1 4702:1 4848:1
1 	|BT| (NP (NP (NP (NNP Grifolin)) (, ,) (NP (JJ potent) (NN antitumour) (JJ natural) (NN product)) (VP (VBZ upregulates) (NP (NP (JJ death-associated) (NN protein) (NN kinase) (CD 1) (NN DAPK1)) (PP (IN via) (NP (NN p53) (JJ nasopharyngeal) (NN carcinoma) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 793:D20.215 1285:D08.811.913.696.620.682.700.125.387|ES| 2:1 4:1 12:1 19:1 22:1 94:1 98:1 304:1 470:1 596:1 675:1 1178:1 2153:1 2333:1 4572:1 4849:1 4850:1 4851:1
1 	|BT| (S (NP (NP (NNS GSLs)) (, ,) (NP (JJ particular) (NN globo) (NN series) (NNS GSLs))) (VP (VBP mediate) (NP (NN gene) (NN expression) (NN MDR1) (NN cSrc) (NN beta-catenin) (NN signaling) (NN pathway)))) |ET| |BS|23:D12.776.091.249 69:G02.111.087.800 126:G02.111.087.800 155:G05.355.310|ES| 2:1 9:1 19:1 60:1 115:1 195:1 383:1 453:1 485:1 1601:1 1807:1 4698:1 4699:1 4702:1
1 	|BT| (S (NP (NN GST-P) (NN gene) (NN expression) (VBN linked) (NN reporter) (NN gene)) (ADVP (RB specifically)) (VP (VBD suppressed) (NP (NP (NN cotransfection) (NN PPAR) (NN alpha) (NN expression) (NN plasmid) (NN presence) (NN peroxisome) (NN proliferator)) (, ,) (NP (NN clofibrate))))) |ET| |BS|155:G05.355.310 457:G05.360.600 536:D12.776.826.239.500 910:D02.241.081.114.968.500.500.195 912:D27.888.569.100.675 1355:G05.360.340.024.340.435|ES| 2:1 9:1 19:1 115:1 288:1 307:1 346:1 1279:1 1363:1 1597:1 1836:1 1887:1 1888:1 3058:1 3200:1 3227:1 4852:1
1 	|BT| (FRAG (NP (NP (NP (NN H)) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (NP (NN O) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-))) (RRC (ADVP (RB also)) (NP (VBN stimulated) (NP (NN expression) (NN Gadd45b) (VBN cultured) (NN cell)))))) |ET| |BS|94:A11.251.210 1356:D01.268.406.500 1357:A11.251|ES| 5:1 10:1 14:1 19:1 94:1 115:1 148:1 612:1 1232:1 4853:1 4854:1 4855:1
1 	|BT| (S (ADVP (RB Hence)) (, ,) (NP (NN chloroform)) (VP (VBD prevented) (SBAR (S (NP (NN hypomethylation)) (VP (VBD increased) (NP (NP (NN mRNA)) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN tumor) (NN DCA)) (, ,) (S (VP (VBG enhancing) (NP (JJ DCA-promotion) (NN kidney) (NN tumor))))))))) |ET| |BS|111:D13.444.735.544 155:G05.355.310 274:C04.588.945.947.535 515:C04.588.274.623 1196:D02.455.526.439.224|ES| 2:1 7:1 9:1 19:1 47:1 115:1 325:1 455:1 836:1 1717:1 1943:1 1944:1 2337:1 2527:1 4107:1 4179:1 4180:1 4181:1
1 	|BT| (S (VP (VP (ADVP (RB Here)) (VP (VBP show)) (S (NP (NN Sp1)) (VP (VBP bind) (NP (NP (NN FoxM1) (NN promoter) (NN region)) (ADVP (RB positively))))) (VP (VBZ regulates) (NP (NP (NN FoxM1) (NN transcription)) (, ,) (NP (NN mithramycin)) (, ,) (NP (NN chemotherapy) (NN drug)) (S (ADVP (RB specifically)) (VP (VBP bind) (SBAR (S (NP (NP (NN GC)) (JJ rich) (NN sequence) (NN DNA)) (VP (VBZ inhibits) (NP (NN activity) (NN Sp1)))))))))) (, ,) (VP (VBZ inhibits) (NP (NN expression) (NN FoxM1))))) |ET| |BS|67:D26 122:C14.280.383 151:E02.319 196:G02.111.570.080.689.675 209:G02.111.087.847 1303:D02.455.426.559.847.562.050.650 1358:G02.111.570.080.380|ES| 2:1 19:1 83:1 115:1 191:1 293:1 399:1 400:1 429:1 487:1 495:1 554:1 603:1 615:1 666:1 667:1 1279:1 3848:1 4659:1 4791:1 4856:1 4857:1 4858:1
1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBP describe) (NP (JJ functional) (NN characterization) (JJ novel) (NN rat) (JJ mutant) (NN model) (NN MMR) (NN gene) (NN Msh6)) (SBAR (S (ADVP (RB genetically)) (VP (VBD inactivated) (NP (JJ N-ethyl-N-nitrosourea-driven) (JJ target-selected) (NN mutagenesis))))))) |ET| |BS|6:G05.360.340.024.340 66:F01.658.293 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 259:D12.776.395.240.150.500 1359:G05.355.600 1360:D02.654.692|ES| 2:1 9:1 19:1 72:1 400:1 415:1 811:1 849:1 891:1 898:1 1735:1 2134:1 4859:1 4860:1 4861:1 4862:1 4863:1 4864:1
1 	|BT| (FRAG (ADVP (RB Here)) (, ,) (NP (VBD investigated) (NP (NP (NN effect) (JJ erlotinib) (JJ apoptotic) (NN signal) (NN pathway) (NN H3255) (NN cell) (NN EGFR)) (PRN (-LRB- -LRB-) (NP (NN L858R)) (-RRB- -RRB-))) (NN mutation))) |ET| |BS|18:G05.365.590 39:G04.299.139.160 41:A11 761:G02.111.087.800|ES| 2:1 10:1 14:1 19:1 34:1 75:1 94:1 187:1 383:1 400:1 403:1 859:1 2223:1 2342:1 4770:1 4865:1
1 	|BT| (S (ADVP (RB Here)) (, ,) (NP (NN report) (NN NaB)) (ADVP (RB specifically)) (VP (VBZ represses) (NP (NP (NP (NP (NN expression) (NN MUC2) (NN gene)) (, ,) (NP (NN differentiation) (NN marker) (JJ secretory) (NN goblet) (NN cell) (NN lineage)) (, ,) (NP (NN forskolin)) (: -)) (NP (NN 12-O-tetradecanoylphorbol) (JJ 13-acetate-induced) (NN HT29) (NN cell))) (, ,) (NP (NN Cl) (CD .16) (NN E) (NN cell)) (, ,) (NP (JJ clonal) (JJ derivative) (NN HT29) (NN cell))) (VP (ADVP (RB spontaneously)) (VBZ differentiates) (NP (JJ goblet) (NN cell))))) |ET| |BS|41:A11 74:G04.299.151 155:G05.355.310 158:D23.101 301:A11.251.353 792:A11.251.210.190.475 1361:D02.455.849.291.500.510.850 1362:A03.556.124.369.320 1363:D02.455.849.291.300|ES| 2:1 9:1 19:1 94:1 115:1 212:1 215:1 347:1 400:1 417:1 534:1 643:1 1069:1 1262:1 1279:1 1506:1 2473:1 2813:1 3017:1 3759:1 4866:1 4867:1 4868:1 4869:1 4870:1
1 	|BT| (S (NP (NN Hes1) (NN induction)) (VP (VBD mediated) (SBAR (S (NP (NN beta-catenin)) (VP (VBD resulted) (NP (NN induction) (NN Notch) (NN ligand/receptor) (JJ Notch-independent) (NN control) (NN Hes1) (NN promoter) (NN beta-catenin))))))) |ET| |BS|23:D12.776.091.249 170:D27.720.470.480|ES| 19:1 60:1 83:1 256:1 258:1 289:1 437:1 594:1 736:1 4871:1 4872:1
1 	|BT| (S (NP (JJ Hexavalent) (NN chromium)) (VP (VBZ induces) (NP (JJ malignant) (NN transformation) (JJ human) (NN lung) (JJ bronchial) (JJ epithelial) (NN cell)) (PP (IN via) (NP (JJ ROS-dependent) (NN activation) (NN miR-21-PDCD4) (NN signaling))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 75:A11.436 231:C04.557.465.625.600.380.590 1364:C08.127.509|ES| 19:1 36:1 94:1 127:1 195:1 214:1 225:1 328:1 596:1 802:1 1384:1 4873:1 4874:1 4875:1 4876:1 4877:1
1 	|BT| (S (NP (NN Histone) (NN deacetylase) (NN inhibitor)) (VP (VBP suppress) (SBAR (S (NP (NN thymidylate) (NN synthase) (NN gene) (NN expression)) (VP (VBP synergize) (NP (NNS fluoropyrimidines) (NP (NN colon) (NN cancer) (NN cell)))))))) |ET| |BS|41:A11 153:D27.505.519.389.360 155:G05.355.310 713:D08.811.913.555.500.862|ES| 9:1 18:1 19:1 66:1 94:1 113:1 115:1 380:1 504:1 2441:1 2578:1 3528:1 4878:1 4879:1
1 	|BT| (S (NP (NN HO-3867)) (VP (VBD induced) (NP (NN G) (S (-LRB- -LRB-) (NP (NP (CD 2) (-RRB- -RRB-) (: -)) (NP (NP (NN M) (NN cell) (NN cycle) (NN arrest) (NN A2780) (NN cell) (NN modulating) (NN cell) (NN cycle) (JJ regulatory) (NN molecule) (NN p53)) (, ,) (NP (NN p21)) (, ,) (NP (NN p27)) (, ,) (NP (JJ cyclin-dependent) (NN kinase) (CD 2)) (, ,) (NP (NN cyclin)) (, ,))) (VP (VBD promoted) (NP (NN apoptosis) (NN caspase-8) (NN caspase-3) (NN activation))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 353:G04.299.134 768:D12.776.660.740 773:G04.299.134.109 906:D08.811.277.656.262.500.126.350.300 1034:D08.811.277.656.262.500.126.550.800 1280:D12.644.360.262 1365:D08.811.913.696.620.682.700.646.500.750|ES| 2:1 10:1 12:1 14:1 19:1 89:1 94:1 148:1 180:1 225:1 412:1 470:1 601:1 602:1 743:1 1124:1 1135:1 1817:1 1912:1 2435:1 3016:1 3612:1 4546:1 4807:1 4880:1 4881:1 4882:1
1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NP (NNS pretreatments) (NP (NP (JJ selective) (JJ mitogen-activated) (NN protein) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN MAPK)) (-RRB- -RRB-))) (NN inhibitor)) (, ,) (NP (NP (NP (NP (NN SB203580)) (PRN (-LRB- -LRB-) (NP (NN p38) (NN inhibitor)) (-RRB- -RRB-))) (NN PD0325901)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2) (NN inhibitor)) (-RRB- -RRB-))) (, ,)) (ADVP (RB significantly)) (VP (VBD suppressed) (NP (NN activation) (NN EGCG) (NN BTG2) (NN expression)))) |ET| |BS|116:D08.811.913.696.620.682.700.567.249.750 478:D08.811.913.696.620.682.700.567|ES| 2:1 4:1 10:1 14:1 19:1 115:1 124:1 225:1 307:1 380:1 433:1 470:1 809:1 1666:1 1749:1 2525:1 3295:1 4594:1 4883:1 4884:1 4885:1 4886:1
1 	|BT| (S (ADVP (RB Importantly)) (, ,) (NP (NN cotreatment) (JJ low) (NNS dos) (NP (NP (NNS oligoamines) (NN DNA) (NN methyltransferase) (NN inhibitor)) (ADVP (RB highly)))) (VP (VBZ induces) (SBAR (S (NP (NN reexpression)) (ADVP (RB aberrantly)) (VP (VBD silenced) (SBAR (S (NP (NN SFRP2) (NN gene)) (VP (VBP result) (NP (NP (JJ significant) (NN inhibition) (NN growth)) (VBN established) (NN tumor) (JJ human) (NN colon) (NN tumor) (NN model)) (FW vivo))))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 43:F01.145.544 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 618:E02.186 746:D08.811.150.240|ES| 2:1 7:1 9:1 19:1 36:1 72:1 101:1 102:1 103:1 113:1 135:1 214:1 378:1 380:1 531:1 626:1 666:1 2651:1 2652:1 2653:1 2654:1 2655:1 2656:1 2657:1 2658:1 2659:1 2660:1
1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN reporter) (NN assay)) (VP (VBD indicated) (SBAR (S (NP (NN FXRE) (NN promoter) (NN activity)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (NN treatment) (NN ACR)) (CC plus) (NP (NN GW4064)))))))) |ET| |BS|52:E02 106:E05.091|ES| 2:1 19:1 47:1 83:1 124:1 244:1 288:1 310:1 399:1 468:1 546:1 1541:1 4503:1 4504:1 4887:1 4888:1
1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN PIM) (NN kinase)) (VP (VBP activate) (S (NP (NN MYC) (NN signaling) (NN mRNA) (NN translation) (NN prostate) (NN cancer)) (VP (VBP cooperate) (S (NP (NN MYC)) (VP (VB accelerate) (NP (NN tumorigenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 69:G02.111.087.800 145:G02.111.087.675.871|ES| 2:1 18:1 19:1 77:1 78:1 195:1 244:1 325:1 468:1 469:1 470:1 471:1 472:1 473:1 474:1 475:1
1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN treatment) (JJ nude) (NN mouse) (NN isochaihulactone)) (NP (VBD increased) (FW vivo) (NN NAG-1) (NN expression)) (VP (VBD examined) (NP (NN immunohistochemistry) (NN tumor) (NN biopsy)))) |ET| |BS|8:C04 52:E02 88:B01.050.150.900.649.865.635.505.500.550.500 143:E01.370.225.500.607.512 559:E01.370.225.500.384.100|ES| 2:1 7:1 19:1 47:1 52:1 115:1 244:1 266:1 324:1 378:1 468:1 546:1 833:1 1662:1 1984:1 4889:1
1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ ursolic) (NN acid)) (VP (VBD suppressed) (NP (ADJP (NP (NP (NN EGF) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (VBD induced)) (NN p53) (NN p21) (NN expression)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 64:D08.811.913.696.620.682.725.400.009.300|ES| 2:1 10:1 12:1 14:1 19:1 115:1 186:1 187:1 244:1 307:1 412:1 468:1 1135:1 1275:1 4890:1 4891:1
1 	|BT| (S (PP (IN In) (NP (JJ AR-positive) (NN bladder) (NN cancer) (NN cell) (NN line))) (, ,) (NP (NN dihydrotestosterone) (NN treatment)) (VP (VP (VBD increased) (NP (NP (NP (NN ELK1)) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (NN mRNA)) (, ,) (NP (NN protein))) (-RRB- -RRB-))) (S (VP (JJ nuclear) (NP (NP (NN translocation)) (, ,) (NP (NN ELK1) (JJ transcriptional) (NN activity)) (, ,) (NP (NN c-fos)) (NP (NN expression)) (, ,))))) (VP (VBD restored) (NP (JJ anti-androgen) (NN hydroxyflutamide))))) |ET| |BS|7:D12.776 52:E02 94:A11.251.210 111:D13.444.735.544 165:G05.360.340.024.340.375.500.791.330 209:G02.111.087.847 463:C23.550.210.870 1287:D04.808.054.040.248 1288:D06.347.065 1366:D12.776.260.108.765|ES| 2:1 4:1 10:1 14:1 18:1 19:1 47:1 94:1 115:1 244:1 264:1 325:1 399:1 546:1 558:1 559:1 562:1 564:1 1256:1 1618:1 4578:1 4892:1 4893:1 4894:1 4895:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN study)) (VP (VBP show) (SBAR (S (NP (NN TS) (NN gene) (NN expression) (NN pretreatment) (NN biopsy)) (VP (VBZ predicts) (NP (NN response) (JJ local) (JJ rectal) (NN cancer) (JJ neo-adjuvant) (JJ 5-FU-based) (NN chemoradiotherapy) (JJ high) (NN percentage))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 154:Z01.058.266.887 155:G05.355.310 333:D01.045 559:E01.370.225.500.384.100 560:D03.383.742.698.875.404 561:E02.186.079.500|ES| 2:1 9:1 18:1 19:1 115:1 131:1 178:1 244:1 429:1 494:1 509:1 1284:1 1751:1 1983:1 1984:1 1985:1 1986:1 1987:1 1988:1 1989:1 1990:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN troglitazone)) (VP (VBD attenuated) (NP (NN Skp2) (NN expression)) (, ,) (S (VP (ADVP (RB thereby)) (NP (VBG promoting) (NP (NN p27) (-LRB- -LRB-) (NN Kip1) (-RRB- -RRB-) (NN accumulation) (JJ human) (NN hepatoma) (NN cell))))))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 338:D12.644.360.225.600 507:D12.776.157.743 515:C04.588.274.623|ES| 2:1 10:1 14:1 19:1 36:1 94:1 115:1 244:1 808:1 881:1 1124:1 1125:1 1284:1 1785:1 2120:1 3896:1 4508:1 4896:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (VP (VBD found) (NP (NP (NN U0126) (JJ atypical) (NN PXR) (NN ligand)) (PP (IN via) (NP (NP (NP (NP (JJ direct)) (PRN (-LRB- -LRB-) (NP (NN binding) (NN activation) (NN PXR)) (-RRB- -RRB-))) (ADJP (ADJP (JJ indirect)) (PRN (-LRB- -LRB-) (NP (NN SHP) (NN dowregulation)) (-RRB- -RRB-)))) (NN mechanism)))) (PP (ADVP (RB selectively)) (VBZ restores) (NP (NN CYP3A) (NN gene) (NN HepG2) (NN cell))))) |ET| |BS|6:G05.360.340.024.340 170:D27.720.470.480 1015:A11.251.860.180.432|ES| 2:1 9:1 10:1 14:1 19:1 37:1 94:1 162:1 225:1 244:1 596:1 1284:1 1487:1 1835:1 1891:1 2382:1 3481:1 3523:1 4897:1 4898:1 4899:1 4900:1 4901:1 4902:1 4903:1
1 	|BT| (FRAG (PP (IN In) (NP (NN LNCaP) (NN cell))) (, ,) (NP (NP (JJ caspase-mediated) (NN apoptosis) (NN induction) (NN PGG)) (SBAR (S (NP (VBN associated) (JJ mediated) (JJ major) (NN part) (NN activation) (NN p53)) (VP (VBD established) (NP (JJ small) (VBG interfering) (NN RNA) (NN knockdown) (JJ dominant-negative) (JJ mutant) (NN approach))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11 117:D13.150.650.700 133:D01.248.497.158.685.750.744.600 1367:D08.811.277.656.262.500.126|ES| 2:1 12:1 19:1 89:1 94:1 169:1 225:1 244:1 413:1 437:1 451:1 462:1 464:1 515:1 736:1 750:1 811:1 911:1 2115:1 2660:1 3019:1 4904:1 4905:1
1 	|BT| (S (PP (IN In) (NP (NP (NP (NN mouse) (JJ ovarian) (JJ endometrioid) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NNS OEAs)) (-RRB- -RRB-))) (VP (VBG arising) (NP (NN Apc))))) (: -) (NP (NP (NN Pten-inactivation)) (, ,) (NP (NN Ctnnb1) (JJ hemizygous) (NN dose))) (VP (VBD affected) (NP (NP (NN beta-catenin) (NN level) (NN beta-catenin/TCF) (NN target) (NN gene)) (, ,) (NP (NN Myc) (NN induction))) (VP (VBD retained) (SBAR (S (NP (NNS OEAs)) (VP (VBD arose) (NP (NP (NN fashion) (JJ akin)) (VBN seen) (JJ intact) (NN Ctnnb1) (NN gene) (NN dose)))))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 213:F02.830.816.964 433:F01.470.047 1368:C04.557.470.200.025.240 1369:A05.360.319.114.630|ES| 2:1 9:1 10:1 14:1 19:1 52:1 60:1 160:1 244:1 249:1 255:1 724:1 736:1 1577:1 1763:1 1786:1 2301:1 4032:1 4422:1 4722:1 4754:1 4906:1 4907:1 4908:1 4909:1 4910:1 4911:1 4912:1 4913:1 4914:1
1 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NN SAHA)) (VP (VP (VBD inhibited) (S (NP (NN growth) (JJ human) (JJ pancreatic) (NN cancer) (NN cell)) (VP (VBG inducing) (NP (NN apoptosis))))) (, ,) (NP (NP (NN differentiation) (NN cell) (NN cycle) (NN arrest)) (, ,) (ADVP (RB well)) (NP (NN increase) (NN expression) (JJ several) (NN tumor) (NN suppressor) (NN gene))))) |ET| |BS|39:G04.299.139.160 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 122:C14.280.383 206:G05.360.340.024.340.375.249 773:G04.299.134.109|ES| 2:1 7:1 9:1 18:1 19:1 36:1 40:1 89:1 94:1 102:1 115:1 215:1 244:1 262:1 365:1 467:1 490:1 601:1 602:1 700:1 787:1 1864:1 4915:1
1 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (JJ small) (NN molecule) (NN inhibitor) (NN imatinib)) (VP (VP (VBZ attenuates) (NP (JJ stromal) (NN cell) (NN proliferation) (JJ PDGF-C-induced) (NN HCC))) (, ,) (VP (VBZ coincides) (NP (NP (VBN decreased) (NN expression) (NN CD34) (NN PDGFRalpha)) (, ,) (NP (VBN activated) (NN Akt)))))) |ET| |BS|104:C04.557.470.200.025.255 183:G04.299.233.750 378:D08.811.913.696.620.682.700.755 1370:D08.811.913.696.620.682.725.400.900.500|ES| 2:1 19:1 94:1 115:1 163:1 180:1 202:1 244:1 299:1 380:1 441:1 490:1 750:1 1289:1 2423:1 4916:1 4917:1 4918:1 4919:1 4920:1 4921:1
1 	|BT| (S (PP (IN In) (NP (NN H1373) (NN xenograft) (NN model))) (, ,) (NP (NN treatment) (NN JQ1)) (ADVP (RB significantly)) (VP (VBD reduced) (SBAR (S (NP (NN tumor) (NN growth)) (VP (VBD downregulated) (NP (NN expression) (NN c-Myc))))))) |ET| |BS|8:C04 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875|ES| 2:1 7:1 19:1 72:1 102:1 115:1 124:1 244:1 265:1 426:1 452:1 546:1 824:1 4922:1 4923:1
1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (NP (NN report) (NN vitro) (NN treatment) (JJ primary) (NN hepatoma)) (, ,) (NP (NP (NN HepG2)) (PRN (-LRB- -LRB-) (NP (JJ wild-type) (NN p53)) (-RRB- -RRB-))) (, ,) (NP (NP (NN PLC/PRF/5)) (PRN (-LRB- -LRB-) (NP (NN p53-mutant)) (-RRB- -RRB-))) (, ,) (NP (NP (NN Hep3B)) (PRN (-LRB- -LRB-) (ADJP (JJ p53-deleted)) (-RRB- -RRB-))) (NP (NP (NN cell) (NN 2-chloroethyl-3-sarcosinamide-1-nitrosourea)) (PRN (-LRB- -LRB-) (NP (NN SarCNU)) (-RRB- -RRB-)))) (VP (VBD resulted) (NP (NP (NN upregulation) (NN p53) (, ,) (NN p21) (-LRB- -LRB-) (NN Cip1/Waf1) (-RRB- -RRB-)) (, ,) (NP (NP (VBN phosphorylated) (NN cdc-2) (NN Tyr15) (JJ wild-type) (NN p53) (NN cell) (NN phosphorylation) (NN cdc-2) (NN Tyr15)) (NP (JJ p53-mutant) (NP (JJ p53-deleted) (NN hepatoma) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 52:E02 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880 515:C04.588.274.623 972:G02.111.087.677 1371:I01.409.418.750.600.650.225|ES| 2:1 8:1 10:1 12:1 14:1 19:1 94:1 131:1 216:1 244:1 344:1 417:1 546:1 594:1 1126:1 1135:1 1307:1 3426:1 3481:1 3896:1 4502:1 4924:1 4925:1 4926:1 4927:1 4928:1 4929:1 4930:1 4931:1 4932:1
1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBP demonstrate) (S (NP (NP (NP (NN histone) (NN deacetylase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN HDACi)) (-RRB- -RRB-))) (NN vorinostat) (NN LBH589)) (VP (ADVP (RB significantly)) (VBP downregulate) (NP (NN TS) (NN gene) (NN expression) (NN panel) (NN colon) (NN cancer) (NN cell) (NN line)))))) |ET| |BS|94:A11.251.210 153:D27.505.519.389.360 154:Z01.058.266.887 155:G05.355.310|ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 113:1 115:1 124:1 131:1 244:1 264:1 380:1 502:1 503:1 504:1 505:1 506:1 507:1 508:1 509:1 510:1
1 	|BT| (NP (NP (PP (IN In) (NP (NP (NN tumor) (NN mouse) (VBN treated) (NN DEN)) (ADVP (RB alone)))) (, ,) (NP (NP (NP (NN prevalence) (NN Ha-ras) (NN mutation)) (NP (ADJP (QP (RB approximately) (CD 30)) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 6/20)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN beta-catenin) (NN mutation)) (PRN (-LRB- -LRB-) (NP (CD 0/13)) (-RRB- -RRB-))) (NP (JJ detectable) (NN tumor) (NN treatment) (NN group))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 52:E02 60:E05.318.308.985.525.750 216:Z01.107.084.900.425 829:M01.686|ES| 2:1 7:1 10:1 14:1 19:1 34:1 52:1 60:1 179:1 241:1 244:1 369:1 546:1 747:1 1099:1 1520:1 1843:1 1875:1 2300:1 4933:1 4934:1 4935:1
1 	|BT| (S (NP (ADJP (FW In) (FW vivo)) (NN treatment) (NN imatinib)) (ADVP (RB also)) (VP (VBP block) (NP (NN expression) (NN CD34) (NN PDGF-C) (NN Tg) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 122:C14.280.383|ES| 5:1 19:1 52:1 115:1 244:1 378:1 546:1 742:1 4916:1 4920:1 4936:1 4937:1
1 	|BT| (NP (NP (NP (NN Incubation) (NNS pro-oxidants) (JJ arachidonic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN AA)) (-RRB- -RRB-))) (, ,) (NP (NN beta-naphtoflavone)) (, ,) (NP (NN H) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (S (NP (NN O) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (VP (VBD enhanced) (NP (NP (NP (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NN splice) (NN variant)))))) |ET| |BS|636:D01.339.431 1014:D10.251.355.255.100.100 1356:D01.268.406.500|ES| 2:1 10:1 14:1 19:1 148:1 385:1 517:1 612:1 990:1 1275:1 3553:1 4116:1 4683:1 4684:1 4853:1 4938:1 4939:1 4940:1
1 	|BT| (S (NP (NN Inhibition) (NN FoxM1) (NN expression) (NNS TZDs)) (VP (VBZ provides) (SBAR (S (NP (JJ new) (NN mechanism) (NN TZD)) (VP (VBD mediated) (NP (JJ negative) (NN regulation) (NN cancer) (NN cell) (NN growth))))))) |ET| |BS|41:A11 43:F01.145.544 45:G07.700.320.249 142:I01.880.604|ES| 18:1 19:1 94:1 102:1 115:1 162:1 437:1 438:1 449:1 712:1 815:1 2703:1 3119:1 4791:1 4941:1
1 	|BT| (S (NP (NN Inhibition) (JJ functional) (NN p53) (NN glioblastoma) (NN cell)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (JJ anti-proliferative) (NN effect) (NN celecoxib)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 43:F01.145.544 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247|ES| 12:1 19:1 75:1 94:1 124:1 415:1 452:1 2186:1 2703:1 2807:1 3695:1
1 	|BT| (S (NP (NP (NN Inhibition) (JJ isochaihulactone-induced) (NN NAG-1) (NN expression) (NN EGR-1)) (ADJP (JJ small) (S (VP (VBG interfering) (NP (NN RNA)))))) (VP (VBD blocked) (NP (JJ isochaihulactone-induced) (NN apoptosis) (NN A549) (NN cell)) (, ,) (S (VP (VBG suggesting) (NP (NN induction) (NN EGR-1) (NN expression) (NN decrease) (NN survival) (NN A549) (NN cell)))))) |ET| |BS|39:G04.299.139.160 41:A11 43:F01.145.544 108:G04.299.316 117:D13.150.650.700 122:C14.280.383 580:D12.776.260.158.500|ES| 2:1 19:1 89:1 94:1 115:1 274:1 295:1 364:1 515:1 736:1 750:1 1009:1 1662:1 2703:1 2777:1 3019:1 3874:1 4942:1
1 	|BT| (S (NP (NN Inhibition) (NN JNK) (NN chemical) (JJ genetic) (NN method)) (VP (VBD attenuated) (NP (JJ NaBT-induced) (NN PTEN) (NN expression)))) |ET| |BS|43:F01.145.544 1372:E05.393|ES| 19:1 115:1 808:1 864:1 1599:1 1936:1 2124:1 2703:1 4276:1 4943:1
1 	|BT| (FRAG (ADVP (RB Interestingly)) (, ,) (NP (NP (JJ DEN-induced) (NN Pol) (CD III) (NN gene) (NN transcription) (NN H3S10ph) (NN tumor) (NN cell) (NN liver)) (NP (ADJP (RB significantly) (JJR higher)) (NP (JJ non-tumor) (NN cell))))) |ET| |BS|8:C04 41:A11 209:G02.111.087.847 515:C04.588.274.623 614:G05.360.340.024.340.364.875.667 1373:Z01.542.248.679|ES| 2:1 7:1 9:1 19:1 94:1 124:1 170:1 487:1 518:1 836:1 2280:1 2281:1 2735:1 4944:1 4945:1
1 	|BT| (S (NP (JJ Intracellular) (NN beta-catenin) (NN level)) (ADVP (RB slightly)) (VP (VBD reduced) (SBAR (S (NP (JJ NDRG2-transfected) (NN SW620) (NN cell) (NN regulation) (NN beta-catenin) (NN stability) (NN TCF/LEF) (NN activity)) (VP (VBD mediated) (NP (NP (NN modulation) (NN glycogen) (NN synthase) (NN kinase-3beta)) (NN activity) (NN NDRG2) (NN function))))))) |ET| |BS|23:D12.776.091.249 41:A11 142:I01.880.604 924:A11.284.430.214|ES| 19:1 33:1 60:1 66:1 92:1 93:1 94:1 249:1 399:1 437:1 438:1 452:1 1945:1 4946:1 4947:1 4948:1 4949:1 4950:1 4951:1 4952:1
1 	|BT| (NP (NP (NP (NP (JJ Intratumoral) (NN injection) (JJ anti-Wnt-1) (NN antibody)) (NP (VBD suppressed) (FW vivo) (NN tumor) (NN growth) (NN Huh7) (NN xenograft) (NN model))) (, ,) (NP (NP (ADVP (RB also)) (VBN associated) (NN apoptosis)) (VP (VBD reduced) (NP (NP (NN c-Myc)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (NN survivin) (NN expression))))))) |ET| |BS|8:C04 39:G04.299.139.160 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 215:D12.644.360.262.150.100 1374:E02.095.465.425.400.330|ES| 2:1 5:1 7:1 19:1 72:1 89:1 102:1 115:1 169:1 265:1 307:1 378:1 452:1 743:1 744:1 785:1 824:1 2229:1 2611:1 3482:1 4953:1 4954:1
1 	|BT| (S (NP (NN IR-5) (NN bear) (JJ novel) (NN point) (NN mutation) (NN HER2/neu)) (VP (VP (VBZ corresponds) (SBAR (S (NP (NN L726I) (JJ ATP-binding) (NN pocket)) (VP (VBP correlate) (NP (NN log) (NN decrease) (NN sensitivity) (NN gefitinib)))))) (, ,) (NP (NP (VBD increased) (NN heterodimerization) (NN EGFR) (NN HER3)) (, ,) (NP (JJ impaired) (NN down-regulation))))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 85:G02.111.087.225 259:D12.776.395.240.150.500 438:G05.365.590.675 455:B01.050.150.900.649.147.890 1064:Z01.252.245.500.350 1065:D01.268.556.401|ES| 2:1 19:1 34:1 47:1 187:1 257:1 295:1 607:1 891:1 901:1 1740:1 2003:1 2121:1 3310:1 3505:1 4281:1 4955:1 4956:1 4957:1 4958:1 4959:1 4960:1 4961:1
1 	|BT| (S (NP (NN Isochaihulactone)) (VP (VBD increased) (NP (NN EGR-1) (NN NAG-1) (NN mRNA) (NN protein) (NN expression)))) |ET| |BS|7:D12.776 111:D13.444.735.544 580:D12.776.260.158.500|ES| 4:1 19:1 47:1 115:1 325:1 1662:1 3874:1 4962:1
1 	|BT| (S (NP (NN Isochaihulactone) (NN treatment)) (VP (VBD increased) (NP (NP (NN luciferase)) (NP (NN activity) (NN NAG-1) (NN A549) (NN cell)) (NP (VBN transfected) (NN NAG-1) (NN promoter) (NN construct))))) |ET| |BS|41:A11 52:E02 1375:D08.811.682.517|ES| 19:1 47:1 83:1 94:1 364:1 399:1 479:1 546:1 1662:1 4962:1 4963:1 4964:1
1 	|BT| (S (NP (JJ Isochaihulactone-induced) (NN increase) (NN EGR-1) (NN NAG-1) (NN expression)) (VP (VBD reduced) (SBAR (S (NP (NP (NP (JJ mitogen-activated) (NN protein) (NN kinase) (NN kinase)) (CD 1/2) (NN inhibitor) (CD 2) ('' ')) (: -) (NP (NP (NN amino-3)) ('' ') (: -) (NP (NN methoxyflavone) (-LRB- -LRB-) (NN PD98059) (-RRB- -RRB-))) (, ,) (NP (NN effect))) (VP (VBD blocked) (NP (NP (NP (NP (NP (NN phosphatidylinositol) (JJ 3-kinase/protein) (NN kinase) (NN B) (NN pathway) (NN inhibitor) (CD 2)) (: -) (PRN (-LRB- -LRB-) (NP (NN 4-morpholinyl)) (-RRB- -RRB-))) (NN -8-phenyl-1)) (PRN (-LRB- -LRB-) (NP (NN 4H)) (-RRB- -RRB-))) (: -) (NP (NP (NN benzopyran-4-one) (NN hydrochloride)) (PRN (-LRB- -LRB-) (NP (NN LY294002)) (-RRB- -RRB-))))))))) |ET| |BS|122:C14.280.383 378:D08.811.913.696.620.682.700.755 580:D12.776.260.158.500 1376:D08.811.913.696.620.682.700.565.300 1377:D08.811.913.696.620.500.100|ES| 2:1 4:1 10:1 14:1 19:1 40:1 75:1 115:1 380:1 383:1 452:1 470:1 763:1 1662:1 2777:1 3295:1 3874:1 4588:1 4965:1 4966:1 4967:1 4968:1 4969:1 4970:1 4971:1 4972:1 4973:1 4974:1 4975:1 4976:1
1 	|BT| (S (NP (JJ Isochaihulactone-inducible) (NN gene)) (VP (VBD included) (S (NP (NP (JJ early) (NN growth) (NN response) (NN gene-1)) (PRN (-LRB- -LRB-) (NP (NN EGR-1)) (-RRB- -RRB-))) (NP (NP (JJ nonsteroidal) (JJ anti-inflammatory) (JJ drug-activated) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN NAG-1)) (-RRB- -RRB-)))))) |ET| |BS|6:G05.360.340.024.340 45:G07.700.320.249 796:D27.505.696.663.850.014.040.500|ES| 9:1 10:1 14:1 19:1 102:1 494:1 1128:1 1528:1 1662:1 1859:1 2795:1 3046:1 3874:1 4977:1 4978:1
1 	|BT| (S (NP (PRP It)) (VP (VBD augmented) (SBAR (S (NP (NN caspase-3) (NN activity)) (VP (VBD downregulated) (NP (NP (NN expression) (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (NN cIAP1) (NN cFLIP)))))))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 906:D08.811.277.656.262.500.126.350.300|ES| 2:1 19:1 115:1 158:1 399:1 426:1 1327:1 4807:1 4814:1 4979:1 4980:1 4981:1
1 	|BT| (NP (NP (NP (NN KLF4)) (NP (ADVP (RB therefore)) (NP (JJ potential) (NN mediator) (NN antitumor) (NN effect) (NN Notch) (NN inhibitor) (NN dibenzazepine))))) |ET| |BS||ES| 19:1 75:1 218:1 256:1 380:1 827:1 1892:1 2244:1 3018:1 3351:1
1 	|BT| (FRAG (NN Ku70) (: -) (: /) (: -) (FRAG (S (NP (NNS HCCs)) (VP (VBD showed) (SBAR (S (NP (JJ high) (JJ proliferative) (NN activity)) (VP (VBD increased) (S (NP (NN cyclin) (NN D1)) (VP (VBG proliferating) (NP (NN cell) (JJ nuclear) (NN antigen) (NN expression))))))))) (, ,) (NP (NP (NNP Aurora) (NNP A) (NN kinase) (NN activity)) (, ,) (VP (VP (VBD enhanced) (NP (NP (NN ataxia) (NN telangiectasia)) (NP (VBN mutated) (NN kinase) (NN ubiquitination)))) (, ,) (NP (NP (NN loss) (NN p53)) (PP (IN via) (NP (NP (JJ proteasomal) (NN degradation)) (, ,) (S (NP (NN feature)) (ADVP (RB closely)) (VP (VBP resemble) (NP (JJ human) (NN HCC))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 215:D12.644.360.262.150.100 469:D08.811.913.696 520:C10.228.140.252.190.530.060 768:D12.776.660.740 1281:D05.500.562.500 1293:G03.495 1378:D08.811.913.696.620.682.700.103.500 1379:G02.111.087.675.871.790.600.925|ES| 2:1 12:1 19:1 32:1 36:1 47:1 69:1 94:1 115:1 132:1 178:1 229:1 385:1 399:1 441:1 470:1 596:1 597:1 743:1 744:1 855:1 1030:1 1132:1 1250:1 1256:1 2865:1 4117:1 4556:1 4982:1 4983:1 4984:1 4985:1 4986:1 4987:1
1 	|BT| (S (NP (NNS Levels) (NN PGE2)) (VP (VBD correlated) (NP (NN YAP) (NN level) (JJ human) (JJ sporadic) (JJ colorectal) (NN tumor) (JJ colitis-associated) (NN tumor)))) |ET| |BS|8:C04 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 1031:C04.588.274.476.411.307 1118:D10.251.355.255.550.250.200|ES| 7:1 17:1 19:1 36:1 249:1 410:1 446:1 725:1 4988:1 4989:1 4990:1
1 	|BT| (FRAG (S (NP (NN LRAT) (NN deficiency)) (VP (VBD decreased) (SBAR (S (NP (JJ diethylnitrosamine-induced) (NN injury) (NN tumour) (NN load)) (VP (VBD increased) (NP (NN expression) (JJ retinoic) (NN acid) (JJ responsive) (NN gene) (NN Cyp26a1))))))) (, ,) (NP (NP (NN RARb) (NN p21)) (, ,) (VP (VBG suggesting) (S (NP (JJR lower) (NN tumour) (NN load) (JJ LRAT-deficient) (NN mouse) (NN result)) (VP (VBD increased) (NP (NN retinoid) (NN signalling) (JJ subsequent) (JJ p21-mediated) (NN inhibition) (NN proliferation))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 87:C18.654.521 155:G05.355.310 554:D02.654.442.200 711:D02.455.326.271.665.202.495 770:D02.455.326.271.665.202.495.818.500 1380:E05.041.124.892|ES| 2:1 9:1 19:1 47:1 52:1 101:1 103:1 115:1 117:1 202:1 253:1 299:1 1009:1 1011:1 1135:1 1275:1 1319:1 2416:1 2437:1 2573:1 2704:1 2732:1 4140:1 4801:1 4991:1 4992:1 4993:1 4994:1 4995:1
1 	|BT| (S (NP (NN MBO-asGCS)) (VP (VBD suppressed) (NP (NP (NN expression) (NN MDR1) (NNS GCS)) (NP (VBN sensitized) (NN NCI/ADR-RES) (NN tumor) (NN doxorubicin))))) |ET| |BS|8:C04 120:I01.409.418.750.600.480.150 136:D02.455.426.559.847.562.050.200.175|ES| 7:1 19:1 115:1 307:1 453:1 598:1 599:1 4697:1 4761:1 4764:1
1 	|BT| (S (S (NP (NNP Mebendazole) (JJ single) (NN agent)) (VP (VBD decreased) (NP (NN COX2) (NN expression)))) (, ,) (NP (NP (NN blood) (NN vessel) (NN formation)) (, ,) (NP (NN VEGFR2) (NN phosphorylation)) (, ,)) (VP (VBD worked) (ADVP (RB synergistically)) (S (NP (NN sulindac)) (VP (VB reduce) (NP (NP (NN overexpression) (NN MYC)) (, ,) (NP (NN BCL2)) (, ,) (NP (JJ various) (JJ pro-inflammatory) (NN cytokine))))))) |ET| |BS|20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 54:G05.360.340.024.340.375.500.791.150 251:D02.455.426.559.847.486.875 371:A07.231 445:I03.946 752:D12.644.276.374 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 972:G02.111.087.677 1185:D12.125.072.401.623 1381:D08.811.913.696.620.682.725.400.950.200 1382:D02.241.081.251.415|ES| 2:1 19:1 43:1 115:1 152:1 202:1 472:1 728:1 869:1 1096:1 1559:1 2361:1 2676:1 2846:1 3349:1 3426:1 3685:1 4118:1 4718:1 4996:1 4997:1 4998:1 4999:1
1 	|BT| (S (VP (ADVP (RB Mechanistically)) (, ,) (VP (VBD demonstrated) (SBAR (S (NP (NN EPLE)) (VP (VBD exerted) (NP (NN function) (VBG suppressing) (NN Wnt) (NN signaling) (NN pathway)))))) (, ,) (VP (VBN evidenced) (NP (NP (JJ EPLE-mediated) (NN downregulation) (NN Wnt) (NN target) (NN gene) (NN c-Myc)) (, ,) (NP (NN Axin2) (NN Survivin)))))) |ET| |BS|6:G05.360.340.024.340 85:G02.111.087.225 147:G02.149.115.800.925|ES| 2:1 9:1 19:1 33:1 160:1 195:1 308:1 383:1 595:1 824:1 877:1 1175:1 2102:1 2250:1 2489:1 3779:1 5000:1 5001:1 5002:1
1 	|BT| (S (NP (NN Meloxicam) (NN therapy)) (VP (VBD inhibited) (NP (NN cell) (NN proliferation)) (, ,) (VP (VBD induced) (NP (NP (NN cell) (NN apoptosis)) (, ,) (NP (NP (VBN reduced) (NN expression)) (VP (VBG proliferating) (NP (NN cell) (JJ nuclear) (NN antigen)))) (, ,))) (NP (NP (VBD increased) (NP (NN activation) (NN caspase-3))) (, ,) (NP (VBN upregulated) (NN Bax))))) |ET| |BS|8:C04 39:G04.299.139.160 41:A11 52:E02 122:C14.280.383 183:G04.299.233.750 342:D12.644.360.075.718.400 371:A07.231 768:D12.776.660.740 906:D08.811.277.656.262.500.126.350.300 1067:D12.644.276.624.120 1130:D12.644.276.390 1383:D27.505.696.377.077.077|ES| 2:1 5:1 7:1 19:1 47:1 75:1 89:1 94:1 102:1 115:1 125:1 130:1 185:1 225:1 299:1 365:1 412:1 452:1 1030:1 1251:1 1256:1 2213:1 2502:1 2865:1 3092:1 3733:1 4630:1 4807:1 4947:1 5003:1
1 	|BT| (NP (NP (NP (NNS METHODS)) (CC AND) (NP (NNS RESULTS)) (: :)) (S (NP (JJ Endogenous) (NN ROS) (NN production) (JJ CYP2E1-expressing) (NN HepG2) (NN cell)) (VP (VBD induced) (NP (NP (NP (NN mRNA) (NN protein) (NN expression) (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NN splice) (NN variant)) (S (VP (VBN compared) (NP (NN control) (NN cell))))))) |ET| |BS|7:D12.776 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 111:D13.444.735.544 168:E05.581 1015:A11.251.860.180.432 1218:D08.244.453.300|ES| 4:1 10:1 14:1 19:1 50:1 94:1 104:1 115:1 289:1 325:1 412:1 565:1 688:1 710:1 990:1 2356:1 2677:1 3481:1 4116:1 4683:1 4684:1 5004:1 5005:1
1 	|BT| (S (NP (NP (NNS Mice)) (VP (VBG receiving) (NP (NN NaTC)))) (VP (VBD manifested) (NP (NP (VBN increased) (JJ intestinal) (NN expression) (JJ FXR-regulated) (NN gene)) (, ,) (NP (NP (NNP Shp)) (, ,) (NP (NNP FGF15) (NNP IBABP)) (, ,) (NP (JJ concomitant) (NN decrease) (NN cyclin) (NN D1) (NN message)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 47:A03.556.124 142:I01.880.604 155:G05.355.310 215:D12.644.360.262.150.100|ES| 2:1 9:1 19:1 47:1 109:1 115:1 295:1 548:1 583:1 743:1 744:1 1681:1 1928:1 4507:1 5006:1 5007:1 5008:1 5009:1 5010:1
1 	|BT| (S (NP (NN Microarray) (NN analysis) (NN liver) (NN sample)) (VP (VBD showed) (SBAR (S (NP (NN arsenic)) (VP (VBD induced) (NP (NP (JJ aberrant) (NN gene) (NN expression)) (PP (VBG including) (NP (NP (JJ steroid-related) (NN gene)) (, ,) (NP (NN cytokine)) (, ,) (NP (JJ apoptosis-related) (NN gene) (NN cell) (JJ cycle-related) (NN gene)))))))))) |ET| |BS|6:G05.360.340.024.340 39:G04.299.139.160 155:G05.355.310 242:A03.620 718:E05.588.570 752:D12.644.276.374 996:G05.360.340.024.340.220 1158:D01.268.513.249 1384:D04.808|ES| 2:1 9:1 19:1 94:1 115:1 132:1 412:1 561:1 661:1 835:1 836:1 1725:1 2676:1 3738:1 4106:1 4542:1 4571:1 5011:1
1 	|BT| (S (NP (NN MK-801)) (VP (VBN dephosphorylated) (S (NP (NN Thr24) (NN FOXO1)) (VP (VBD induced) (NP (JJ nuclear) (NN translocation)) (, ,) (ADVP (RB thus)) (VP (VP (VBG increasing) (NP (NN transcription) (NN TXNIP))) (, ,) (NP (NN tumor) (NN suppressor) (NN gene))))))) |ET| |BS|206:G05.360.340.024.340.375.249 209:G02.111.087.847 463:C23.550.210.870 1297:D02.455.426.559.847.181.384.380|ES| 2:1 7:1 9:1 19:1 412:1 487:1 700:1 715:1 1256:1 1334:1 1618:1 3264:1 4624:1 4625:1 4626:1 4627:1
1 	|BT| (S (S (NP (NP (NN MLN8237)) (, ,) (NP (JJ investigational) (JJ small-molecule) (JJ selective) (NN inhibitor) (NN AURKA)) (, ,)) (VP (VBD reduced) (S (NP (NP (JJ nuclear) (NN staining) (JJ nuclear) (NN factor-kappaB)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-))) (VP (NN p65) (NP (JJ human) (JJ gastric) (NN cancer) (NN sample) (NN mouse) (JJ epithelial) (NN cell)))))) (, ,) (VP (VBD suppressed) (SBAR (S (NP (NP (NN NF-kappaB) (NN reporter) (NN activity)) (, ,) (NP (VBN reduced) (NN expression) (NN NF-kappaB) (NN target) (NN gene))) (VP (VBP regulate) (NP (NN inflammation) (NN cell) (NN survival))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 55:B01.050.150.900.649.801.400.112.400.400 75:A11.436 108:G04.299.316 155:G05.355.310 210:D12.776.260.600 225:E05.337 525:C23.550.470 1378:D08.811.913.696.620.682.700.103.500|ES| 2:1 9:1 10:1 14:1 18:1 19:1 36:1 52:1 86:1 94:1 115:1 127:1 160:1 274:1 288:1 307:1 380:1 399:1 452:1 714:1 835:1 858:1 1256:1 1605:1 1749:1 2702:1 3064:1 5012:1 5013:1 5014:1 5015:1 5016:1
1 	|BT| (S (NP (NP (NP (NN Modulation) (NN dasatinib)) (PRN (-LRB- -LRB-) (NP (NN c-Src) (NN inhibitor)) (-RRB- -RRB-))) (NN cytotoxicity) (NN STAT3) (NN knockdown)) (VP (VBN measured) (NP (NP (NNP MTT)) (, ,) (NP (NN cell) (NN cycle)) (, ,) (NP (NN apoptosis) (NN assay))))) |ET| |BS|39:G04.299.139.160 82:D12.644.360.024.342.300 106:E05.091 228:E05.978 353:G04.299.134 946:D27.888.569.213 1385:G05.360.340.024.340.375.500.791.570 1386:D02.886.675.184|ES| 2:1 10:1 14:1 19:1 89:1 94:1 251:1 310:1 380:1 464:1 601:1 789:1 2760:1 3317:1 5017:1 5018:1 5019:1
1 	|BT| (S (ADVP (RBR More) (RB importantly)) (, ,) (NP (NN ATRA)) (VP (VBD downregulated) (NP (NN expression) (NNP CSC) (NN marker) (NN CD44) (NN ALDH)) (SBAR (S (NP (ADJP (RB well) (JJ stemness)) (NN gene) (NN Klf4) (NN Sox2)) (VP (VBD induced) (NP (NN differentiation) (NNS tumorspheres))))))) |ET| |BS|6:G05.360.340.024.340 74:G04.299.151 158:D23.101 556:C11.768.175 770:D02.455.326.271.665.202.495.818.500 1387:D12.776.260.719.100|ES| 2:1 9:1 19:1 115:1 215:1 412:1 426:1 534:1 787:1 1581:1 2767:1 2768:1 3577:1 5020:1 5021:1 5022:1 5023:1 5024:1 5025:1
1 	|BT| (FRAG (ADVP (RB Moreover)) (, ,) (SBAR (IN although) (NP (NP (NP (NP (JJ sulindac-mediated) (NN induction) (NN p21)) (PRN (-LRB- -LRB-) (NP (NN cip/waf1)) (-RRB- -RRB-))) (ADJP (CD 113) (NN %)) (JJ wild-type) (NN HT-29)) (, ,) (S (NP (NN induction)) (VP (VBD alleviated) (NP (NP (NNP Csk) (NN shRNA) (NNS transfectants)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 65) (NN %)) (NN induction)) (: ;) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01))))) (-RRB- -RRB-)))))))) |ET| |BS|251:D02.455.426.559.847.486.875 792:A11.251.210.190.475 1273:D13.150.650.700|ES| 2:1 8:1 10:1 14:1 19:1 217:1 311:1 312:1 315:1 369:1 622:1 736:1 1135:1 1592:1 2782:1 4230:1 4235:1 5026:1 5027:1 5028:1 5029:1 5030:1 5031:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (S (NP (NN curcumin)) (VP (VBD suppressed) (NP (NP (NN NF-kappaB) (NN activity) (NN expression) (JJ NF-kappaB-regulated) (NN gene) (NN product)) (PRN (-LRB- -LRB-) (NP (NP (NN cyclin) (NN D1)) (, ,) (NP (NN c-myc)) (, ,) (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (JJ cellular) (NN inhibitor) (NN apoptosis) (NN protein-1)) (, ,) (NP (NN cyclooxygenase-2)) (, ,) (NP (NN matrix) (NN metalloproteinase-9)) (, ,) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor))) (-RRB- -RRB-))))) (, ,) (NP (JJ many)) (VP (VBD induced) (SBAR (S (NP (NN radiation) (NN therapy)) (VP (VBP mediate) (NP (NN radioresistance))))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 41:A11 54:G05.360.340.024.340.375.500.791.150 142:I01.880.604 155:G05.355.310 210:D12.776.260.600 215:D12.644.360.262.150.100 281:E02.815 371:A07.231 586:D08.811.277.656.300.480.205.360 692:D02.455.326.146.485.222.222 1130:D12.644.276.390|ES| 2:1 9:1 10:1 14:1 19:1 61:1 89:1 102:1 115:1 130:1 158:1 185:1 307:1 380:1 399:1 412:1 455:1 622:1 675:1 714:1 743:1 744:1 1040:1 1251:1 1601:1 2157:1 2498:1 2500:1 2501:1 3074:1 3092:1 3491:1 4814:1 5032:1 5033:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (VP (NP (NN DENA)) (VP (VBD decreased) (NP (NP (NN gene) (NN expression) (NN GSHPx)) (, ,) (NP (NN GST) (NN CAT)))) (VP (VBD caused) (NP (JJ severe) (JJ histopathological) (NN lesion) (NN liver) (NN tissue))))) |ET| |BS|98:A10 155:G05.355.310 242:A03.620 554:D02.654.442.200 1388:B01.050.150.900.649.147.354.250.125 1389:B01.050.150.900.649.147.354.250|ES| 2:1 9:1 19:1 115:1 202:1 272:1 622:1 836:1 1131:1 2506:1 3527:1 4413:1 5034:1 5035:1 5036:1 5037:1
1 	|BT| (S (VP (ADVP (RB Moreover)) (, ,) (NP (NN inhibition) (NN EIF5A) (JJ small) (S (VP (VBG interfering) (NP (NP (NP (NN RNA) (-LRB- -LRB-) (NN siRNA) (-RRB- -RRB-) (NN deoxyhypusine) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN DHPS)) (-RRB- -RRB-))) (NP (NN inhibitor) (NN GC7)))))) (, ,) (VP (VBZ inhibits) (NP (NN EIF5A2) (NN maturation))) (, ,) (VP (MD could) (ADVP (RB effectively)) (VP (VB decrease) (NP (NN cell) (NN motility)))))) |ET| |BS|43:F01.145.544 117:D13.150.650.700 122:C14.280.383|ES| 2:1 10:1 14:1 19:1 66:1 94:1 103:1 295:1 351:1 380:1 515:1 615:1 622:1 750:1 908:1 1177:1 1311:1 2977:1 3019:1 5038:1 5039:1 5040:1 5041:1 5042:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN MCC-555)) (VP (VBD increased) (NP (JJ transcriptional) (NN activity) (JJ human) (NN mouse) (NN MUC2) (NN promoter)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 209:G02.111.087.847 1390:I03|ES| 2:1 19:1 36:1 47:1 52:1 83:1 212:1 399:1 559:1 622:1 5043:1
1 	|BT| (FRAG (ADVP (RB Moreover)) (, ,) (NP (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNFalpha)) (-RRB- -RRB-))) (: -) (NP (NP (JJ 5-FU-induced) (NN apoptosis)) (VP (ADVP (RB greatly)) (VBD enhanced) (SBAR (S (NP (NN G17) (NN treatment) (NN Colo320wt) (NN cell)) (VP (VBD prevented) (SBAR (S (NP (NN IEX-1) (NN expression)) (VP (VBD repressed))))))))))) |ET| |BS|39:G04.299.139.160 41:A11 52:E02 560:D03.383.742.698.875.404 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 7:1 10:1 14:1 19:1 89:1 94:1 115:1 185:1 385:1 466:1 546:1 622:1 760:1 1836:1 1944:1 2691:1 3398:1 3984:1 4257:1 4685:1 4696:1 5044:1
1 	|BT| (NP (NP (JJ Negative) (NN regulation) (JJ oncogenic) (NN transcription) (NN factor) (NN FoxM1) (NNS thiazolidinediones) (NN mithramycin))) |ET| |BS|142:I01.880.604 166:D12.776.930 279:D27.888.569.100 862:D02.886.675.933 1303:D02.455.426.559.847.562.050.650|ES| 19:1 185:1 438:1 487:1 953:1 3118:1 4659:1 4791:1 5045:1
1 	|BT| (S (ADVP (RB Nevertheless)) (, ,) (NP (NN extent) (NN NAG-1) (NN induction)) (VP (MD could) (NP (VBN altered) (NN ERK) (NN inhibitor) (NN PD98059)))) |ET| |BS||ES| 2:1 19:1 380:1 693:1 736:1 908:1 1662:1 4486:1 4968:1 5046:1 5047:1
1 	|BT| (S (NP (NN Niclosamide)) (VP (VBD caused) (NP (NP (NN dose)) (: -) (NP (NP (NP (JJ time-dependent) (NN reduction) (NN beta-catenin) (JJ key) (NN component)) (PRN (-LRB- -LSB-) (PP (FW e.g.) (, ,) (NP (NP (NNS DVLs)) (, ,) (NP (NP (NN phospho-GSK3beta)) (PRN (-LRB- -LRB-) (NP (NN S9)) (-RRB- -RRB-))) (, ,) (NP (NN c-Myc) (NN Cyclin) (NN D1)))) (-RRB- -RSB-))) (JJ canonical) (NN Wnt/beta-catenin) (NN pathway))))) |ET| |BS|23:D12.776.091.249 105:G02.149.115.800.925 215:D12.644.360.262.150.100 322:G01.910 1391:D02.065.199.860.470|ES| 2:1 10:1 14:1 19:1 60:1 159:1 302:1 370:1 383:1 744:1 824:1 1021:1 1373:1 1378:1 1997:1 2506:1 3236:1 4742:1 5048:1 5049:1 5050:1 5051:1 5052:1 5053:1
1 	|BT| (NP (NP (JJ Nicotine-induced) (ADJP (NN survival) (NN signaling) (NN lung) (NN cancer) (NN cell) (JJ dependent)) (ADJP (NN p53) (NN status) (NN down-regulation) (NN curcumin) (JJ independent)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 69:G02.111.087.800 85:G02.111.087.225 96:I03.784 108:G04.299.316 692:D02.455.326.146.485.222.222 1392:D03.132.760.570|ES| 12:1 18:1 19:1 94:1 195:1 257:1 274:1 321:1 328:1 416:1 883:1 2498:1 5054:1
1 	|BT| (S (DT No) (NP (NP (NP (NP (NN PPARgamma/retinoid) (NN X) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN RXR)) (-RRB- -RRB-))) (NP (NN consensus) (NN DNA) (NN binding) (NN site))) (VP (VBD detected) (NP (NP (NN FoxM1) (NN promoter)) (VP (VBG extending) (NP (NP (CD -10) (NN kb)) (NP (RB upstream) (, ,) (JJ knockdown) (NN PPARgamma) (NN impact) (NN TZD))))))) (VP (VBD mediated) (NP (NN downregulation) (NN FoxM1) (NN expression)))) |ET| |BS|13:D01.339.387 85:G02.111.087.225 198:D13.444.308 719:D12.776.826.239.588 1393:D12.776.826.701.500 1394:F01.829.316.068 1395:G02.111.570.120|ES| 2:1 10:1 14:1 19:1 83:1 115:1 186:1 437:1 464:1 595:1 666:1 929:1 1003:1 1007:1 1487:1 1996:1 2588:1 3119:1 3541:1 3660:1 4791:1 5055:1 5056:1 5057:1 5058:1 5059:1 5060:1
1 	|BT| (S (NP (NN NO-ASA)) (VP (VBD reduced) (NP (NP (NN expression) (NN cyclin) (NN D1)) (, ,) (NP (NP (JJ downstream) (NN target) (NN gene) (NN play) (JJ important) (NN role)) (NN colon) (NN carcinogenesis))))) |ET| |BS|6:G05.360.340.024.340 12:Z01.542.049 15:F01.829.316.616 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 215:D12.644.360.262.150.100|ES| 2:1 9:1 19:1 31:1 113:1 115:1 160:1 207:1 238:1 452:1 560:1 743:1 744:1 902:1 3892:1
1 	|BT| (S (NP (JJ Novel) (NN oligoamine) (NN analogue)) (VP (VBP inhibit) (SBAR (S (NP (JJ lysine-specific) (NN demethylase) (CD 1)) (VP (VBP induce) (NP (NN reexpression)) (VP (ADVP (RB epigenetically)) (NP (VBN silenced) (NN gene)))))))) |ET| |BS|6:G05.360.340.024.340 122:C14.280.383 259:D12.776.395.240.150.500 1311:D12.125.068.555|ES| 9:1 19:1 98:1 243:1 1370:1 1380:1 2656:1 2658:1 5061:1 5062:1 5063:1 5064:1 5065:1
1 	|BT| (S (NP (NN Nrf2)) (VP (VBZ transactivates) (SBAR (S (NP (JJ wide) (NN variety)) (VP (VBP ARE) (PRN (-LRB- -LRB-) (NP (JJ anti-oxidant) (NN response) (NN element)) (-RRB- -RRB-)))))) (: -) (VP (VBN mediated) (NP (NN enzyme) (PP (VBG including) (NP (NN GSTP1-1)))))) |ET| |BS|730:D08.811 799:D12.776.260.615.249 1396:G02.111.570.080.689.675.700.040 1397:D08.811.913.225.500.500|ES| 10:1 14:1 19:1 494:1 561:1 952:1 2388:1 4048:1 4355:1 4522:1 5066:1 5067:1 5068:1 5069:1 5070:1
1 	|BT| (S (NP (JJ Oral) (NN administration) (NN gefitinib) (JJ able) (VBP prevent) (NP (NN outgrowth) (NN Bam1a) (NN tumor) (NN cell) (JJ palpable) (NN lesion))) (PRN (, ,) (S (VP (VB shrink) (NP (VBN established) (NN tumor)))) (, ,)) (VP (VB eliminate) (NP (NP (NN HER2) (NN HER3) (NN phosphorylation)) (, ,) (NP (NP (NN decrease) (NN MAPK) (NN Akt) (NN signaling)) (FW vivo))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 378:D08.811.913.696.620.682.700.755 385:F02.784.629.131 739:E02.319.267.100 972:G02.111.087.677|ES| 2:1 7:1 19:1 94:1 188:1 195:1 295:1 378:1 733:1 809:1 1131:1 1289:1 2575:1 2660:1 2832:1 3310:1 3426:1 4031:1 4961:1 5071:1 5072:1 5073:1 5074:1 5075:1
1 	|BT| (NP (NP (NP (NP (NNP Ornithine) (NN decarboxylase)) (PRN (-LRB- -LRB-) (NP (NN ODC)) (-RRB- -RRB-))) (, ,) (NP (JJ first) (NN enzyme) (NN polyamine) (NN synthesis)) (, ,) (NP (JJ transcriptional) (NN target) (NN c-myc) (NN modifier) (JJ APC-dependent) (NN tumorigenesis)))) |ET| |BS|3:C04.557.470.035.215.100 20:G03.495 32:C04.697.098.500 33:C04.697.098 209:G02.111.087.847 730:D08.811 1313:D02.092.782 1398:D08.811.520.224.125.425|ES| 2:1 10:1 14:1 19:1 78:1 160:1 455:1 559:1 816:1 2388:1 2697:1 3436:1 3819:1 4672:1 5076:1 5077:1 5078:1
1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBD revealed) (NP (NP (NN HBx)) (ADJP (JJ survivin-dependently) (S (VP (VBN down-regulated) (S (VP (NN miR-520b) (S (VP (VBG interacting) (NP (NN Sp1) (NN cell)))))))))))) |ET| |BS|41:A11 142:I01.880.604 351:A17.360|ES| 19:1 94:1 275:1 658:1 793:1 1283:1 2014:1 4856:1 5079:1 5080:1 5081:1
1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN TZD)) (VP (VBD mediated) (NP (NN suppression) (NN Sp1) (JJ responsible) (NN downregulation) (NN FoxM1) (NN gene) (NN expression))))))) |ET| |BS|85:G02.111.087.225 155:G05.355.310|ES| 9:1 19:1 115:1 437:1 595:1 658:1 793:1 796:1 2132:1 2453:1 3119:1 4791:1 4856:1
1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBP support) (NP (NP (NN PGG) (JJ multitargeting) (NN agent) (NN chemoprevention) (NN therapy) (NN prostate) (NN cancer)) (VP (VBG activating) (NP (NP (NN p53) (NN tumor) (NN suppressor) (NN pathway)) (VP (VBG inhibiting) (NP (NN STAT3) (JJ oncogenic) (NN signaling)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 52:E02 69:G02.111.087.800 82:D12.644.360.024.342.300 122:C14.280.383 133:D01.248.497.158.685.750.744.600 253:E02.319.162 279:D27.888.569.100 1399:D12.776.260.820|ES| 7:1 12:1 18:1 19:1 77:1 130:1 195:1 251:1 383:1 413:1 658:1 700:1 728:1 793:1 870:1 880:1 953:1 1364:1 1958:1 5082:1
1 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (SBAR (S (NP (NN NAG-1) (NN expression)) (VP (VBD up-regulated) (NP (NP (NN isochaihulactone) (JJ ERK-dependent) (NN pathway)) (VP (VBG involving) (NP (NN activation) (NN EGR-1))))))))) |ET| |BS|142:I01.880.604 150:Z01.542.248.960 580:D12.776.260.158.500 1400:G02.111.087.800.560|ES| 19:1 115:1 225:1 383:1 658:1 796:1 927:1 1301:1 1662:1 3874:1 4055:1 4889:1 5083:1
1 	|BT| (S (S (NP (PRP$ Our) (NN result)) (VP (VBD demonstrated) (SBAR (S (NP (NP (NN soy) (NN peptide)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (VP (ADVP (RB dramatically)) (VBZ inhibits) (NP (NN expression) (NN HSP90))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG suppressing) (NP (NN signaling) (NN pathway) (VBG leading) (NN NF-gammaB) (NN activation)))))) (: ;) (S (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (VP (VBZ induces) (NP (NP (NN expression) (NN p21)) (, ,) (NP (NP (NN p53)) (, ,) (NP (NN caspase-3) (NN protein))) (: ;) (S (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (VP (VBZ inhibits) (NP (NN expression) (NN VEGF)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 7:D12.776 69:G02.111.087.800 86:D01.268.556.435 122:C14.280.383 126:G02.111.087.800 906:D08.811.277.656.262.500.126.350.300 1001:B01.650.940.800.575.100.401.750 1113:D12.776.580.216.380 1401:D12.644|ES| 2:1 4:1 10:1 12:1 14:1 19:1 98:1 101:1 115:1 148:1 195:1 214:1 217:1 225:1 383:1 615:1 639:1 645:1 658:1 862:1 1135:1 1175:1 2066:1 2250:1 4636:1 4807:1 4896:1 5084:1 5085:1 5086:1
1 	|BT| (NP (NP (PRP$ Our) (VBP result) (VBP indicate) (NN EGCG) (S (VP (VBZ attenuates) (S (NP (NN cell) (NN proliferation) (NN OSCC) (NN cell)) (VP (VBG upregulating) (NP (NN BTG2) (NN expression)) (PP (IN via) (NP (NN p38) (NN ERK) (NN pathway))))))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 183:G04.299.233.750 1400:G02.111.087.800.560|ES| 19:1 94:1 101:1 115:1 299:1 383:1 596:1 658:1 1479:1 1666:1 2423:1 3140:1 4885:1 4886:1 5047:1 5087:1
1 	|BT| (S (NP (PRP$ Our) (NN result)) (VP (VBD showed) (SBAR (S (NP (NNP Protandim)) (VP (VBD suppressed) (NP (JJ mitochondrial) (NN translocation) (NN p53) (JJ mitochondrial) (JJ outer) (NN membrane) (NN protein) (NN Bax))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 342:D12.644.360.075.718.400 463:C23.550.210.870 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 1402:A11.284.149.450.349|ES| 4:1 12:1 19:1 101:1 132:1 307:1 658:1 1618:1 2004:1 3622:1 4630:1 5088:1 5089:1
1 	|BT| (NP (NN Overexpression) (S (NP (NP (NN c-Jun) (JJ N-terminal) (NN kinase) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN JNK1)) (-RRB- -RRB-))) (VP (VBD resulted) (NP (NN miR-122) (NN down-regulation) (NN induction) (NN PTP1B))))) |ET| |BS|85:G02.111.087.225 469:D08.811.913.696|ES| 10:1 14:1 19:1 98:1 257:1 470:1 594:1 668:1 736:1 1686:1 1789:1 2357:1 5090:1 5091:1
1 	|BT| (S (S (NP (NN Overexpression) (NN NF-kappaB) (NN superrepressor)) (VP (VBD increased) (NP (NN PTEN) (NN expression) (NN JNK) (NN activity)))) (, ,) (IN whereas) (S (NP (NN overexpression) (NN p65) (NN NF-kappaB) (NN subunit)) (VP (VBD reduced) (NP (JJ basal) (JJ NaBT-mediated) (NN JNK) (NN activation) (NN PTEN) (NN expression))))) |ET| |BS|210:D12.776.260.600 583:D12.776.813|ES| 2:1 19:1 47:1 115:1 152:1 225:1 372:1 399:1 452:1 668:1 714:1 1936:1 2110:1 4184:1 4276:1 5016:1 5092:1 5093:1
1 	|BT| (S (NP (NN p66) (NN overexpression)) (ADVP (RB also)) (VP (VBD prevented) (NP (NP (NN activation) (NN luciferase) (NN reporter) (NN gene)) (VP (VBN controlled) (NP (NN SOD2) (NN promoter)))) (, ,) (S (VP (VBG indicating) (S (NP (NN p66) (NN repression) (NN MnSOD)) (VP (VBZ operates) (NP (JJ transcriptional) (NN level)))))))) |ET| |BS|208:F01.393.821 209:G02.111.087.847 264:G05.355.315.800 1375:D08.811.682.517 1403:D08.811.682.881|ES| 2:1 5:1 9:1 19:1 83:1 152:1 225:1 249:1 288:1 559:1 706:1 1944:1 2236:1 4601:1 4604:1 4963:1 5094:1 5095:1 5096:1
1 	|BT| (S (NP (NN Penta-1,2,3,4,6-O-galloyl-beta-D-glucose)) (VP (VP (VBZ induces) (SBAR (S (NP (NN p53)) (VP (VBZ inhibits) (NP (NN STAT3) (NN prostate) (NN cancer) (NN cell) (NN vitro)))))) (VP (VBZ suppresses) (NP (NN prostate) (NN xenograft) (NN tumor) (NN growth)) (FW vivo)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 82:D12.644.360.024.342.300 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 202:C04.588.945.440.770|ES| 7:1 12:1 18:1 19:1 77:1 94:1 102:1 214:1 216:1 251:1 265:1 378:1 615:1 685:1 686:1
1 	|BT| (S (NP (NN Penta-O-galloyl-beta-D-glucose)) (VP (VBZ induces) (NP (NN G1) (NN arrest) (NN DNA) (JJ replicative) (NN S-phase) (NN arrest)) (NP (NP (ADJP (RB independently) (JJ cyclin-dependent)) (NN kinase) (NN inhibitor) (NN 1A)) (, ,) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN 1B) (NN P53) (JJ human) (NN breast) (NN cancer) (NN cell)) (NP (RB orally) (JJ active) (JJ triple) (JJ negative) (NN xenograft) (NN growth))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 198:D13.444.308 338:D12.644.360.225.600 1299:D12.644.360.225.500 1404:G02.111.087.222.880|ES| 2:1 18:1 19:1 23:1 36:1 94:1 102:1 197:1 214:1 265:1 380:1 449:1 470:1 602:1 666:1 670:1 1503:1 1916:1 2052:1 2149:1 4226:1 4546:1 5097:1 5098:1 5099:1 5100:1
1 	|BT| (S (NP (NN POX)) (ADVP (RB markedly)) (VP (VBD elevated) (SBAR (S (NP (JJ p53-induced) (NN apoptosis)) (VP (VBZ generates) (NP (JJ proline-dependent) (NP (NP (JJ reactive) (NN oxygen) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-))))))) (, ,) (NP (NP (ADVP (RB specifically)) (NP (NN superoxide) (NN radical))) (, ,) (NP (VBP induce) (NN apoptosis) (JJ mitochondrial) (NN death) (NN receptor) (NN pathway))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 135:C23.550.260 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 636:D01.339.431 1185:D12.125.072.401.623 1405:D01.248.497.158.685.750.850|ES| 2:1 10:1 14:1 19:1 89:1 146:1 186:1 243:1 383:1 411:1 480:1 756:1 1279:1 2004:1 2353:1 2354:1 2355:1 2356:1 2396:1 5101:1 5102:1 5103:1 5104:1
1 	|BT| (S (NP (VBN Presented) (NNS data)) (VP (VP (VBP reveal) (S (NP (NN pterostilbene)) (ADJP (JJ novel)))) (, ,) (NP (NP (ADJP (ADJP (JJ effective)) (, ,) (ADJP (JJ anti-metastatic))) (NN agent) (NN function)) (VP (VBG downregulating) (NP (NN MMP-9) (NN gene) (NN expression)))))) |ET| |BS|155:G05.355.310 259:D12.776.395.240.150.500 586:D08.811.277.656.300.480.205.360|ES| 2:1 9:1 19:1 33:1 115:1 728:1 793:1 891:1 1639:1 1670:1 2065:1 2158:1 2428:1 5105:1 5106:1
1 	|BT| (S (S (NP (NN Pretreatment) (NN p38) (NN kinase) (NN inhibitor)) (VP (VBD blocked) (NP (JJ VES-induced) (NN increase) (NN NAG-1) (NN protein) (NN mRNA) (NN level)))) (, ,) (IN whereas) (NP (NP (NN inhibition) (NN protein) (NN kinase) (NN C)) (, ,) (NP (NN Akt)) (, ,) (FRAG (NN c-Jun) (NNP NH) (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (: -) (NP (NP (JJ terminal) (NN kinase)) (, ,) (NP (NP (NN MEK) (NN activity) (NN effect)) (JJ VES-induced) (NN NAG-1) (NN level)))))) |ET| |BS|7:D12.776 12:Z01.542.049 13:D01.339.387 43:F01.145.544 111:D13.444.735.544 122:C14.280.383 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565 378:D08.811.913.696.620.682.700.755 469:D08.811.913.696 470:C02.782.160.927 992:D08.811.913.696.620.682.700.725 1406:D02.455.526.728.650.529|ES| 2:1 4:1 10:1 14:1 19:1 40:1 75:1 103:1 148:1 249:1 325:1 372:1 380:1 399:1 470:1 1289:1 1661:1 1662:1 1666:1 1686:1 1955:1 2777:1 5107:1 5108:1 5109:1 5110:1
1 	|BT| (S (NP (NP (NN Protein) (NN analysis)) (VP (VBN treated) (NP (NN tumor) (NN biopsy)))) (VP (VBD revealed) (NP (NP (NP (JJ elevated) (NN amount) (NN cell) (NN cycle) (NN regulator)) (NP (NN p21) (NN proapoptosis) (NN factor))) (, ,) (NP (NP (NN caspase) (CD 3)) (CD 7) (VBN cleaved) (NN poly) (-LRB- -LSB-) (NN ADP-ribose) (-RRB- -RSB-) (NN polymerase)) (, ,) (VP (VBN coupled) (VP (VBN decreased) (NP (NP (NN level) (JJ antiapoptotic) (NN factor) (NN Bcl-2) (NN Bcl-X)) (PRN (-LRB- -LRB-) (NP (NN L)) (-RRB- -RRB-)))))))) |ET| |BS|52:E02 54:G05.360.340.024.340.375.500.791.150 353:G04.299.134 418:D12.644.360.075.718.937 559:E01.370.225.500.384.100 906:D08.811.277.656.262.500.126.350.300 1248:D08.811.913.400.725.115.690 1407:D12.776.624|ES| 2:1 7:1 10:1 14:1 19:1 94:1 158:1 185:1 202:1 235:1 249:1 275:1 394:1 601:1 661:1 709:1 756:1 862:1 988:1 1099:1 1135:1 1373:1 1378:1 1436:1 1984:1 2911:1 4796:1 4809:1 4810:1 4811:1 5111:1 5112:1 5113:1 5114:1
1 	|BT| (S (NP (NN Rapamycin)) (VP (VBZ inhibits) (SBAR (S (NP (JJ multiple) (NN stage) (NN c-Neu/ErbB2)) (VP (VBD induced) (NP (NP (NN tumor) (NN progression) (JJ transgenic) (NN mouse) (NN model)) (NP (JJ HER2-positive) (NN breast) (NN cancer)))))))) |ET| |BS|8:C04 16:C23.550.291.656 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 99:B01.050.050.136.500 122:C14.280.383 827:D02.540.505.760 1002:C04.588.180|ES| 7:1 18:1 19:1 23:1 48:1 52:1 72:1 285:1 412:1 615:1 649:1 1129:1 2225:1 5115:1 5116:1
1 	|BT| (S (NP (NP (NNS Rats)) (VP (VBN fed) (NP (JJ high-dose) (NN CP-31398) (NN combination) (JJ low-dose) (NN CP-31398) (NN celecoxib)))) (VP (VBD showed) (NP (NP (NP (NP (NP (JJ considerable) (NN enhancement) (NN p53) (NN p21)) (PRN (-LRB- -LRB-) (NP (NN WAF1/CIP)) (-RRB- -RRB-))) (NN expression)) (, ,) (NP (NN apoptosis)) (, ,)) (VP (VBN reduced) (NP (NN tumor) (NN cell) (NN proliferation) (JJ colonic) (NN tumor)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 39:G04.299.139.160 51:C04.588.274.476.411.307.180 183:G04.299.233.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 663:C16.320.565.398.500.330.500 684:D02.065.884.247|ES| 2:1 7:1 10:1 12:1 14:1 19:1 89:1 94:1 115:1 132:1 299:1 452:1 530:1 677:1 1135:1 2278:1 2426:1 2807:1 3047:1 3049:1 3664:1 5117:1 5118:1 5119:1
1 	|BT| (NP (NP (RB Regardless) (NN p53) (NN status)) (, ,) (NP (NN celecoxib)) (VP (VBD caused) (NP (NP (JJ significant) (NN difference) (NN apoptosis) (NN level) (NN U87MG)) (, ,) (NP (NN U87MG-PFT)) (, ,) (NP (NN U87MG-E6) (NN U373MG) (NN cell))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 13:D01.339.387 39:G04.299.139.160 41:A11 684:D02.065.884.247|ES| 2:1 12:1 19:1 89:1 94:1 135:1 249:1 416:1 1674:1 2506:1 2807:1 4619:1 4620:1 4621:1 4623:1 5120:1
1 	|BT| (NP (NP (NP (NN Regulation) (NN PTEN) (NN expression) (JJ intestinal) (JJ epithelial) (NN cell) (NN c-Jun) (JJ NH2-terminal) (NN kinase) (NN activation)) (NP (JJ nuclear) (NN factor-kappaB) (NN inhibition)))) |ET| |BS|43:F01.145.544 47:A03.556.124 75:A11.436 142:I01.880.604 210:D12.776.260.600 771:D08.811.913.696.620.682.700.567.374|ES| 19:1 94:1 103:1 109:1 115:1 127:1 225:1 470:1 699:1 1256:1 1686:1 1936:1 2702:1 2708:1
1 	|BT| (NP (NP (NP (NN Relationship) (NN CYP1A) (NN induction) (NN indole-3-carbinol) (NN flutamide) (NN liver)) (JJ tumor-promoting) (JJ potential) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 1172:D02.065.199.420|ES| 19:1 736:1 827:1 836:1 849:1 3647:1 3776:1 4057:1 5121:1 5122:1
1 	|BT| (S (ADVP (RB Remarkably)) (, ,) (NP (NP (NN F-box) (NN protein) (NN FBW7)) (, ,) (NP (NN E3-ubiquitin) (NN ligase)) (, ,)) (VP (VBN controlled) (NP (NP (NN stability) (NN arm) (NN c-MYC/MXD1) (JJ push-pull) (NN network)) (, ,) (NP (NN FBW7) (NN ablation)))) (S (VP (VBD attenuated) (NP (CD 1,25) (NN D) (NN regulation) (NN c-MYC) (NN MXD1) (NN turnover))))) |ET| |BS|142:I01.880.604 588:I01.880.853.500.600 665:N04.452.677.680 1408:C04.557.450.590.550.660.665 1409:D08.811.464.938.750 1410:A01.378.800.075|ES| 2:1 4:1 19:1 91:1 438:1 625:1 808:1 2154:1 2424:1 4529:1 4533:1 4950:1 5094:1 5123:1 5124:1 5125:1 5126:1 5127:1 5128:1 5129:1 5130:1
1 	|BT| (NP (NP (NN Repression) (NN MUC2) (NN gene) (NN expression) (NN butyrate)) (, ,) (NP (JJ physiological) (NN regulator) (JJ intestinal) (NN cell) (NN maturation))) |ET| |BS|47:A03.556.124 155:G05.355.310 208:F01.393.821 230:G04 1307:D02.241.081.114.750 1309:D02.241.081.114|ES| 2:1 9:1 19:1 94:1 109:1 115:1 212:1 235:1 3758:1 3762:1 5042:1 5131:1
1 	|BT| (S (NP (NNS RESULTS) (: :)) (S (NP (NP (NN Depletion) (NN c-Src) (JJ small) (VBG interfering) (NN RNA)) (VP (VBD sustained) (NP (NN inhibition) (NN dasatinib)))) (VP (VBD increased) (NP (NN pSTAT3)))) (, ,) (VP (MD could) (VP (VBD blocked) (NP (NN inhibition) (NN JAK))))) |ET| |BS|43:F01.145.544 117:D13.150.650.700 122:C14.280.383 1386:D02.886.675.184|ES| 2:1 19:1 47:1 103:1 104:1 515:1 710:1 750:1 908:1 1847:1 2777:1 3019:1 5017:1 5018:1 5132:1 5133:1 5134:1
1 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (NP (NN MDR1) (NNS GCS)) (ADVP (RB coincidently)) (VP (VBN overexpressed) (NP (NP (JJ drug-resistant) (NN breast)) (, ,) (NP (NN ovary)) (, ,) (NP (JJ cervical) (NN colon) (NN cancer) (NN cell))))) (FRAG (: ;) (NP (NP (NN silencing) (NNS GCS)) (VP (VBG using) (NP (NP (NP (JJ novel) (NN mixed-backbone) (NN oligonucleotide)) (PRN (-LRB- -LRB-) (NP (NN MBO-asGCS)) (-RRB- -RRB-))) (VP (VBN sensitized) (NP (CD four) (JJ drug-resistant) (NN cell) (NN line) (NN doxorubicin)))))))) |ET| |BS|10:A01.236 41:A11 67:D26 94:A11.251.210 136:D02.455.426.559.847.562.050.200.175 259:D12.776.395.240.150.500 575:V02.050 1369:A05.360.319.114.630 1411:D13.695.578.424 1412:A02.835.232.834 1413:A01.598|ES| 2:1 10:1 14:1 18:1 19:1 23:1 25:1 94:1 100:1 104:1 113:1 217:1 264:1 350:1 453:1 598:1 599:1 710:1 891:1 3247:1 4188:1 4697:1 4761:1 5135:1 5136:1 5137:1 5138:1 5139:1
1 	|BT| (S (S (NP (NN Resveratrol)) (VP (VBD induced) (NP (NP (NN cell) (NN cycle) (NN arrest)) (VP (VBG up-regulating) (NP (NN expression) (NN p21/CIP1)))))) (, ,) (S (NP (NN p27/KIP1)) (VP (VBG inhibiting) (NP (NN expression) (NN cyclin) (NN D1))))) |ET| |BS|122:C14.280.383 150:Z01.542.248.960 215:D12.644.360.262.150.100 338:D12.644.360.225.600 773:G04.299.134.109|ES| 2:1 19:1 94:1 115:1 412:1 601:1 602:1 743:1 744:1 880:1 1876:1 2946:1 5140:1 5141:1
1 	|BT| (S (NP (NNP Resveratrol)) (VP (VBZ prevents) (S (NP (NN tumorigenesis) (NN mouse) (NN model)) (VP (NNP Kras) (VP (VBD activated) (S (NP (JJ sporadic) (JJ colorectal) (NN cancer)) (VP (VBG suppressing) (NP (JJ oncogenic) (NN Kras) (NN expression))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 279:D27.888.569.100 388:G05.360.340.024.340.375.500.791.550|ES| 17:1 18:1 19:1 52:1 72:1 78:1 115:1 163:1 725:1 953:1 2250:1 2718:1 2946:1 5142:1
1 	|BT| (S (NP (NN Retinol) (NN treatment)) (VP (VP (VBD decreased) (NP (NN transcription) (NN TOPFlash) (NN reporter) (NN construct) (NN mRNA) (NN level) (JJ endogenous) (NN beta-catenin) (NN target) (NN gene))) (, ,) (NP (NN cyclin) (NN D1) (NN c-myc)))) |ET| |BS|6:G05.360.340.024.340 23:D12.776.091.249 52:E02 111:D13.444.735.544 209:G02.111.087.847 215:D12.644.360.262.150.100 1414:D02.455.326.271.665.202.495.818 1415:D02.455.326.271.665.202.495.818|ES| 2:1 9:1 19:1 60:1 160:1 202:1 249:1 288:1 325:1 455:1 487:1 546:1 743:1 744:1 3870:1 4964:1 5143:1 5144:1
1 	|BT| (NP (NP (NP (NN Role)) (NP (VBN phosphorylated) (NN histone) (NN H3) (NN serine) (CD 10) (JJ DEN-induced) (NN deregulation) (NN Pol) (CD III) (NN gene) (NN cell) (NN proliferation) (NN transformation)))) |ET| |BS|15:F01.829.316.616 183:G04.299.233.750 614:G05.360.340.024.340.364.875.667 926:D12.125.154.800 1416:D12.776.660.470|ES| 9:1 19:1 94:1 299:1 402:1 503:1 1384:1 1519:1 2187:1 2280:1 2281:1 2735:1 4930:1 5145:1 5146:1
1 	|BT| (S (NP (NNS RWPs)) (VP (VBD reduced) (NP (SBAR (S (NP (NP (NN expression) (NN VEGF)) (, ,) (NP (NP (NP (NN matrix) (NN metalloproteinase)) (PRN (-LRB- -LRB-) (NP (NN MMP)) (-RRB- -RRB-))) (CD -2) (, ,) (NN MMP-9) (, ,) (NN cyclooxygenase-2))) (VP (VBD increased) (NP (NN expression) (NN tumor) (NN suppressor) (NN gene) (NN p16) (-LRB- -LRB-) (NN INK4A) (-RRB- -RRB-))))) (, ,) (NP (NN p53) (, ,) (NN p73) (NN tumor) (NN cell))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 24:D08.811.600.720.750 41:A11 155:G05.355.310 203:G05.360.340.024.340.375.249.375 206:G05.360.340.024.340.375.249 586:D08.811.277.656.300.480.205.360 1417:D08.811.277.656.300.480.205.352|ES| 2:1 7:1 9:1 10:1 12:1 14:1 19:1 47:1 61:1 94:1 115:1 452:1 700:1 1313:1 2066:1 2158:1 2892:1 3182:1 3491:1 5147:1 5148:1 5149:1 5150:1
1 	|BT| (S (S (NP (NN SAHA)) (VP (VBD decreased) (NP (NN cyclin) (NN B1) (NN expression)))) (: ;) (S (NP (NN cyclin)) (ADVP (RB normally)) (VP (VBZ promotes) (NP (NN progression) (NN G2) (NN cell) (NN cycle))))) |ET| |BS|16:C23.550.291.656 353:G04.299.134 768:D12.776.660.740 979:D12.644.360.262.120.100 1280:D12.644.360.262|ES| 19:1 48:1 94:1 115:1 202:1 217:1 298:1 601:1 743:1 3455:1 4915:1 5151:1 5152:1
1 	|BT| (S (NP (NN Salinomycin)) (VP (VBD induced) (NP (NN degradation) (NN Skp2)) (ADVP (RB thus)) (VP (VBN accumulated) (NP (NN p27Kip1))))) |ET| |BS|338:D12.644.360.225.600 507:D12.776.157.743 1293:G03.495|ES| 19:1 412:1 597:1 1334:1 1785:1 4616:1 5153:1 5154:1
1 	|BT| (S (NP (NN Salinomycin)) (VP (VBZ induces) (NP (NN cell) (NN death)) (PP (IN via) (NP (NN inactivation) (NN Stat3) (NN downregulation) (NN Skp2))))) |ET| |BS|82:D12.644.360.024.342.300 85:G02.111.087.225 134:G04.299.139 507:D12.776.157.743|ES| 19:1 94:1 214:1 411:1 595:1 596:1 1314:1 1785:1 2646:1 5153:1
1 	|BT| (S (NP (NN Selenium) (NN treatment) (NN tumor) (NN promotion)) (VP (VBD increased) (S (NP (JJ hepatic) (NN GPx4) (NN expression)) (VP (VBN reduced) (NP (NN expression) (NN VEGF) (NN AP-1) (NN component) (NN c-fos)) (NP (ADJP (RB well) (JJ nodule)) (NN growth)))))) |ET| |BS|8:C04 45:G07.700.320.249 52:E02 935:D01.268.185.850 1418:D12.776.260.108.875|ES| 7:1 19:1 47:1 102:1 115:1 452:1 546:1 562:1 787:1 838:1 1021:1 2066:1 2337:1 4680:1 5155:1 5156:1 5157:1
1 	|BT| (S (NP (NNP Sesamin)) (ADVP (RB also)) (VP (VP (VBD potentiated) (SBAR (S (NP (NN tumor) (NN necrosis) (JJ factor-alpha-induced) (NN apoptosis)) (VP (VBD correlated) (SBAR (S (NP (NN suppression) (NN gene) (NN product)) (VP (VBN linked) (NP (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (, ,) (NP (NN Bcl-2) (NN survivin))) (-RRB- -RRB-))))))))) (, ,) (PRN (NP (NN proliferation) (-LRB- -LRB-) (FW e.g.) (, ,) (NP (NN cyclin) (NN D1))) (-RRB- -RRB-) (NP (, ,) (NP (NP (NN inflammation)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (, ,) (NP (NN cyclooxygenase-2))) (-RRB- -RRB-))) (, ,) (NP (NP (NN invasion)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (, ,) (NP (NN matrix) (NN metalloproteinase-9)) (, ,) (NP (JJ intercellular) (NN adhesion) (NN molecule) (CD 1))) (-RRB- -RRB-))) (, ,) (NP (NP (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (FW e.g.) (, ,) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor))) (-RRB- -RRB-))))))) |ET| |BS|6:G05.360.340.024.340 24:D08.811.600.720.750 39:G04.299.139.160 54:G05.360.340.024.340.375.500.791.150 108:G04.299.316 215:D12.644.360.262.150.100 371:A07.231 525:C23.550.470 586:D08.811.277.656.300.480.205.360 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1130:D12.644.276.390 1325:D12.776.395.550.200.450|ES| 2:1 5:1 7:1 9:1 10:1 14:1 19:1 61:1 89:1 94:1 98:1 102:1 158:1 180:1 185:1 274:1 299:1 446:1 620:1 675:1 743:1 744:1 753:1 1251:1 1363:1 1997:1 2157:1 2229:1 2453:1 2502:1 2952:1 3064:1 3092:1 3491:1 3679:1 4257:1 5158:1 5159:1
1 	|BT| (S (NP (NN SGE)) (VP (VBD inhibited) (NP (NP (NN induction) (JJ gamma-glutamyltranspeptidase-positive) (NNS hepatocytes)) (, ,) (NP (NN lipid) (NN peroxidation)) (, ,) (NP (NN gene) (NN expression) (NN Cyp1a1)) (, ,)) (VP (VBD caused) (NP (NN DC))))) |ET| |BS|122:C14.280.383 155:G05.355.310 262:A11.436.348 648:D08.811.913.050.200.500 1247:G02.111.087.520 1352:D08.244.453.040.332|ES| 2:1 9:1 19:1 115:1 365:1 736:1 894:1 2401:1 2506:1 4384:1 5160:1 5161:1 5162:1 5163:1
1 	|BT| (S (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (VP (VBD found) (NP (NN repressor) (NN Gadd45b) (NN gene) (NN binding) (JJ upstream) (JJ regulatory) (NN element)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 149:G05.360.340.024.340.364.875.890 209:G02.111.087.847 250:E07.305.812 1419:G02.111.570.080.689|ES| 9:1 10:1 14:1 19:1 37:1 251:1 487:1 860:1 861:1 862:1 1487:1 1817:1 1996:1 2960:1 4855:1 5070:1 5164:1
1 	|BT| (NP (NP (NP (NN Silencing) (NN CXCR4) (VBG impairing) (NN MIF-CXCR4) (NN signaling) (NN pathway) (NN ISO-1)) (, ,) (NP (NN pAb) (NN FL-115)) (, ,) (NP (NN AMD-3100)) (, ,) (NP (JJ monoclonal) (NN antibody) (NN 12G5)) (, ,) (NP (NN BIM-46187)) (VP (VBD abolished) (NP (JJ aggressive) (NN phenotype))))) |ET| |BS|80:G05.695 126:G02.111.087.800 162:F01.145.126.125 1204:D12.776.543.750.100.160.500.400 1420:D12.776.124.486.485.114.224 1421:D06.472.699.327.700.500|ES| 2:1 19:1 195:1 236:1 383:1 538:1 722:1 775:1 1365:1 2611:1 4220:1 4582:1 5165:1 5166:1 5167:1 5168:1 5169:1 5170:1 5171:1
1 	|BT| (S (NP (NN Silibinin)) (ADVP (RB strongly)) (VP (VBD increased) (SBAR (S (JJ phospho-extracellular) (NP (NP (NP (JJ signal-regulated) (NN kinase) (CD 1/2)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN Cip1/p21) (NN Kip1/p27)) (PRN (-LRB- -LRB-) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor)) (-RRB- -RRB-))) (NP (NN level))) (ADVP (RB moderately)) (VP (VBD decreased) (NP (NN Bcl-2) (NN survivin) (NN level))))))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 919:D08.811.913.696.620.682.700.567.249.500 1279:D12.644.360.225|ES| 2:1 10:1 14:1 19:1 47:1 158:1 202:1 249:1 380:1 470:1 635:1 1706:1 1707:1 2229:1 2531:1 4546:1 4592:1 4593:1 4594:1 4966:1 5172:1
1 	|BT| (S (PP (IN Since) (NP (NP (NN fate) (JJ chemotherapy-insensitive) (NN tumor) (NN cell)) (VP (ADVP (RB rarely)) (VBN described)))) (, ,) (NP (VBN performed) (NP (JJ comparative) (NN analysis) (NN 5-FU) (NN toxicity) (JJ p53-deficient) (NN cell))) (VP (VBP conclude) (NP (NP (NN p53) (NN act) (NN facilitator)) (NP (RB rather) (NN gatekeeper) (NN cell) (NN death))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 41:A11 81:E02.095.465.425.400.330.050.400 134:G04.299.139 151:E02.319 557:D02.241.081.069.600.150 560:D03.383.742.698.875.404|ES| 2:1 7:1 12:1 19:1 94:1 246:1 411:1 458:1 634:1 661:1 851:1 1968:1 2308:1 2406:1 2535:1 3001:1 4561:1 5173:1 5174:1 5175:1 5176:1 5177:1
1 	|BT| (S (NP (NN SiRNA) (NN treatment) (NN BNL-CL.2) (NN cell) (NN Tsc-22) (NNS oligonucleotides)) (SBAR (S (NP (JJ nonspecific) (NNS oligonucleotides)) (VP (VBD decreased) (NP (NN RNA) (NN protein) (NN expression) (NN Tsc-22)) (NP (CD 80-90) (NN %))))) (, ,) (NP (NP (NN expression) (NN Gadd45b) (NN gene)) (, ,) (NP (NN Lzts2)) (, ,)) (VP (VBD increased) (S (NP (NN time)) (NP (JJ initial) (NN decrease))))) |ET| |BS|7:D12.776 41:A11 52:E02 117:D13.150.650.700 155:G05.355.310 322:G01.910 1411:D13.695.578.424 1422:D13.444.735|ES| 2:1 4:1 9:1 19:1 47:1 94:1 115:1 202:1 295:1 369:1 515:1 546:1 1081:1 4161:1 4855:1 5178:1 5179:1 5180:1 5181:1 5182:1 5183:1 5184:1
1 	|BT| (S (NP (NP (NNP Sixth)) (, ,) (NP (NN curcumin))) (VP (VBD inhibited) (NP (NP (NN expression) (NN cell) (NN survival) (NN protein) (NN B-cell) (NN lymphoma-2)) (, ,) (NP (NN B-cell) (NN leukemia) (NN protein) (NN xL)) (, ,) (NP (NP (JJ X-linked) (NN inhibitor) (NN apoptosis) (NN protein)) (, ,) (NP (NN c-FLIP))) (, ,) (NP (NP (NP (JJ cellular) (NN inhibitor) (NN apoptosis) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN cIAP)) (-RRB- -RRB-))) (CD -1)) (, ,) (NP (NP (NN cIAP-2) (NN survivin) (NN protein)) (VP (VBN linked) (NP (NN cell) (NP (NN proliferation)) (, ,) (NP (NN cyclin) (NN D1)) (NP (NN c-Myc)))))))) |ET| |BS|7:D12.776 41:A11 108:G04.299.316 122:C14.280.383 183:G04.299.233.750 215:D12.644.360.262.150.100 692:D02.455.326.146.485.222.222 1423:D12.644.360.075.437.750 1424:C04.557.386.480.150 1425:C04.557.337.428.080.125 1426:C04.557.337.428.080|ES| 2:1 4:1 10:1 14:1 19:1 89:1 94:1 115:1 274:1 299:1 365:1 380:1 743:1 744:1 824:1 1363:1 2199:1 2229:1 2498:1 3074:1 5185:1 5186:1 5187:1 5188:1 5189:1 5190:1 5191:1 5192:1 5193:1
1 	|BT| (S (NP (NN SPARC) (NN promoter) (NN hypermethylation) (JJ colorectal) (NN cancer)) (VP (VBD reversed) (S (NP (NN 5-Aza-2) (`` `) (NN deoxycytidine) (NN increase) (NN SPARC) (NN expression)) (VP (VB improve) (NP (NN therapy) (NN response)))))) |ET| |BS|4:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 37:D12.776.157.125.715 52:E02 1427:D03.383.742.680.245.500 1428:D02.886.759.111|ES| 17:1 18:1 19:1 40:1 82:1 83:1 115:1 130:1 494:1 664:1 2466:1 4352:1 5194:1
1 	|BT| (S (NP (ADVP (RB Strikingly)) (, ,) (NP (NP (NN CYR61) (NN overexpression) (JJ impaired) (NN accumulation)) (NP (NP (JJ wild-type) (NN p53)) (PP (VBG following) (NP (NN Taxol) (NN exposure))))) (, ,) (NP (NN inhibition) (NN alphavbeta3) (NN ERK1/ERK2) (NN MAPK) (NN signaling))) (ADVP (RB completely)) (VP (VBD restored) (NP (JJ Taxol-induced) (NN upregulation) (NN p53)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 43:F01.145.544 69:G02.111.087.800 116:D08.811.913.696.620.682.700.567.249.750 249:G05.355.315.800 339:G02.111.087.880 919:D08.811.913.696.620.682.700.567.249.500 1429:D02.455.426.392.368.242.888.777|ES| 2:1 8:1 12:1 19:1 103:1 152:1 195:1 809:1 1126:1 1953:1 2003:1 2120:1 3244:1 3510:1 3792:1 4271:1 4893:1 5195:1 5196:1 5197:1 5198:1
1 	|BT| (S (NP (NP (JJ Subsequent) (NN inhibition) (NN Notch-1) (NN signaling) (NN sulfonamide) (NN GSI)) (PRN (-LRB- -LRB-) (NP (NN GSI34)) (-RRB- -RRB-))) (VP (VBD prevented) (SBAR (S (NP (NN induction) (NN NICD) (NN chemotherapy)) (VP (VBD blunted) (NP (NN Hes-1) (NN activation))))))) |ET| |BS|43:F01.145.544 69:G02.111.087.800 151:E02.319 1430:D02.065.884|ES| 10:1 14:1 19:1 20:1 103:1 195:1 225:1 495:1 736:1 1867:1 1944:1 2277:1 4269:1 4607:1 5199:1 5200:1 5201:1
1 	|BT| (S (NP (NN Sugiol)) (VP (VBD induced) (SBAR (S (NP (NN cell) (NN cycle) (NN arrest)) (VP (VBD decreased) (NP (NP (NP (NN expression) (NN level) (NN STAT3) (NN target) (NN gene)) (, ,) (NP (NN cyclin) (NN D1))) (, ,) (NP (NN cyclin) (NN A)) (, ,) (NP (NN survivin)))))))) |ET| |BS|82:D12.644.360.024.342.300 155:G05.355.310 215:D12.644.360.262.150.100 773:G04.299.134.109 1431:D12.644.360.262.100|ES| 2:1 9:1 19:1 69:1 94:1 115:1 160:1 202:1 249:1 251:1 412:1 601:1 602:1 743:1 744:1 2229:1 5202:1
1 	|BT| (S (NP (NP (NP (NN Sulindac) (NN cyclooxygenase-2) (NN inhibitor)) (, ,) (NP (NN etodolac)) (, ,)) (NN increase) (NN APC) (NN mRNA) (NN colon) (NN rat)) (VP (VBN treated) (NP (NN azoxymethane)))) |ET| |BS|3:C04.557.470.035.215.100 46:A03.556.124.526.356 52:E02 111:D13.444.735.544 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 251:D02.455.426.559.847.486.875 349:D27.505.519.389.310.500 683:D27.505.519.389.310 1317:D03.066.288.200|ES| 2:1 11:1 19:1 40:1 61:1 113:1 325:1 380:1 849:1 1099:1 1993:1 2965:1 4679:1
1 	|BT| (S (NP (NN TAM)) (VP (VBD increased) (NP (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (-LRB- -LRB-) (NN ERK) (-RRB- -RRB-) (NN phosphorylation)) (, ,) (NP (JJ related) (NN proliferation) (NN regeneration) (NN liver))) (VP (VBD decreased) (NP (NN DGAT2) (NN gene) (NN expression))))) |ET| |BS|155:G05.355.310 477:D08.811.913.696.620.682.700.567.249 478:D08.811.913.696.620.682.700.567 640:D02.455.426.559.389.150.700.900 925:G10.261.326.520 972:G02.111.087.677 1432:G02.111.570.060.040.750 1433:C05.651.575|ES| 2:1 9:1 10:1 14:1 19:1 47:1 115:1 202:1 299:1 419:1 470:1 836:1 1707:1 3260:1 3426:1 4812:1 5047:1 5203:1 5204:1
1 	|BT| (NP (DT The) (S (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (NN H-thymidine) (NN incorporation) (NN Western-blot) (NN assay)) (VP (VBD revealed) (SBAR (S (NP (NN cell) (NN proliferation)) (VP (VBD attenuated) (NP (NNP EGCG)) (PP (IN via) (NP (NP (NN upregulation) (NN BTG2) (NN expression)) (VP (VBG causing) (NP (NN cell) (NN cycle) (NN G1) (NN phase) (NN arrest) (NN OSCC) (NN cell))))))))))) |ET| |BS|41:A11 179:D01.248.497.300.459.700 183:G04.299.233.750 249:G05.355.315.800 255:E05.196.401.143 339:G02.111.087.880 1076:G04.299.134.109.249 1434:D03.383.742.680.705|ES| 10:1 14:1 19:1 94:1 115:1 275:1 299:1 310:1 596:1 601:1 602:1 670:1 691:1 808:1 862:1 1126:1 1491:1 2529:1 4885:1 4886:1 5087:1 5205:1 5206:1 5207:1
1 	|BT| (S (NP (DT The) (NN ability) (NN PF-03084014)) (VP (VBP inhibit) (NP (NP (NN gamma-secretase) (NN activity)) (VP (VBN shown) (NP (NP (NP (NN reduction) (JJ endogenous) (NN NICD) (NN level) (NN downregulation) (NN Notch) (NN target) (NN gene) (NN Hes-1) (NN cMyc) (NN T-cell) (JJ acute) (JJ lymphoblastic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN T-ALL)) (-RRB- -RRB-))) (NN cell) (NN line) (NN HPB-ALL)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 85:G02.111.087.225 122:C14.280.383 125:D08.811.277.656.300.032 385:F02.784.629.131 1435:C04.557.337.428.600.620|ES| 9:1 10:1 14:1 19:1 90:1 94:1 160:1 237:1 249:1 256:1 264:1 370:1 399:1 595:1 691:1 1300:1 1370:1 1866:1 2277:1 3870:1 5187:1 5200:1 5208:1 5209:1 5210:1 5211:1 5212:1 5213:1
1 	|BT| (S (NP (DT The) (NN activity) (NN PTEN)) (VP (VBD restored) (NP (VBN treated) (NN NF-kappaB) (NN inhibitor) (NN PDTC)))) |ET| |BS|52:E02 210:D12.776.260.600|ES| 19:1 380:1 399:1 691:1 714:1 1099:1 1936:1 4893:1 5214:1
1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP investigate) (NP (NP (NP (NN contribution) (CD 2) (NN source) (NN ROS)) (, ,) (NP (NP (NN cytochrome) (NN P450) (NN 2E1)) (PRN (-LRB- -LRB-) (NP (NN CYP2E1)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP NAD)) (PRN (-LRB- -LRB-) (NP (NN P)) (-RRB- -RRB-))) (NP (NP (NN H) (NN quinone) (NN oxidoreductase)) (PRN (-LRB- -LRB-) (NP (NN NQO1)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN alcohol) (NN modulation) (NN KLF6)) (PRN (-LRB- -LRB-) (ADJP (JJ Full)) (-RRB- -RRB-))) (NP (NN expression))) (, ,) (NP (NN splicing) (NN KLF6) (CD _) (NN V1) (NN KLF6) (CD _) (NN V2)) (, ,) (NP (NN effect) (NN TNFalpha) (, ,) (JJ downstream) (NN target))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 751:D02.033.375 789:D12.644.276.374.500.800 790:D12.644.276.374.750 822:D02.033 1218:D08.244.453.300 1436:G02.111.087.750.700|ES| 2:1 10:1 14:1 19:1 75:1 115:1 131:1 148:1 160:1 311:1 459:1 560:1 612:1 691:1 1360:1 1567:1 1945:1 2356:1 2549:1 3710:1 3788:1 4270:1 4635:1 4683:1 4684:1 4685:1 4752:1 5215:1 5216:1 5217:1 5218:1 5219:1 5220:1 5221:1
1 	|BT| (NP (NP (DT The) (NN aim) (NN study)) (VP (VBD determine) (S (NN correlation) (NN TS) (: -) (PRN (, ,) (NN TP) (: -)) (, ,) (NP (JJ DPD-gene) (NN expression) (NN response) (JJ 5-FU-based) (JJ long-term) (JJ pre-operative) (NN chemoradiotherapy)) (VP (VBN assessed) (NP (JJ histopathological) (NN tumour) (NN regression)))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 59:E02.186.079 154:Z01.058.266.887 155:G05.355.310 333:D01.045 560:D03.383.742.698.875.404 846:F01.393.784 1342:Z01.639.040 1437:C13.703.420.491.500|ES| 2:1 19:1 74:1 115:1 131:1 494:1 691:1 1011:1 1567:1 1988:1 1989:1 3002:1 3527:1 3544:1 3546:1 3823:1 4785:1 4787:1 4788:1 4789:1
1 	|BT| (S (NP (DT The) (JJ anti-MM) (NN activity) (NN PTC-209)) (VP (VBN accompanied) (NP (NP (JJ significant) (NN decrease) (NN cyclin) (NN D1)) (PRN (-LRB- -LRB-) (NP (NN CCND1)) (-RRB- -RRB-))) (S (NP (NN v-myc) (NP (NP (JJ avian) (NN myelocytomatosis) (JJ viral) (NN oncogene) (NN homolog)) (PRN (-LRB- -LRB-) (NP (NN MYC)) (-RRB- -RRB-))) (NN expression)) (ADVP (RB well)) (VP (NN upregulation) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN 1A)) (PRN (-LRB- -LRB-) (NP (NN CDKN1A)) (-RRB- -RRB-)) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN 1B)) (PRN (-LRB- -LRB-) (NP (NN CDKN1B)) (-RRB- -RRB-)))))) |ET| |BS|215:D12.644.360.262.150.100 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 1299:D12.644.360.225.500|ES| 10:1 14:1 19:1 24:1 115:1 135:1 295:1 380:1 399:1 470:1 472:1 691:1 743:1 744:1 787:1 1025:1 1126:1 2052:1 2801:1 3621:1 3969:1 4546:1 5100:1 5222:1 5223:1 5224:1 5225:1 5226:1 5227:1 5228:1
1 	|BT| (S (NP (DT The) (NN antitumor) (NN activity) (NN SRJ09)) (VP (VBD suggested) (VP (VBN mediated) (PP (IN via) (NP (NN induction) (NN p21) (NN expression) (NN suppression) (NN CDK-4) (NN expression))) (PP (IN without) (S (VP (VBG affecting) (NP (NP (NN cyclin) (NN D1) (NN trigger) (NN G1) (NN arrest)) (VP (VBG leading) (NP (NN apoptosis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 86:D01.268.556.435 215:D12.644.360.262.150.100 573:N05.715.350.200.650 978:D08.811.913.696.620.682.700.646.500|ES| 19:1 89:1 115:1 399:1 437:1 596:1 602:1 639:1 670:1 691:1 736:1 743:1 744:1 925:1 1135:1 1195:1 2015:1 2244:1 2453:1 2530:1 3763:1 5229:1
1 	|BT| (S (NP (DT The) (NN apoptosis)) (VP (VP (VBD induced) (NP (NP (NN PTX-2) (NN Hep3B) (NN cell)) (NP (NP (NP (VBN associated) (NN down-regulation) (JJ anti-apoptotic) (NN Bcl-2) (NN member)) (PRN (-LRB- -LRB-) (NP (NN Bcl-2) (NN Bcl-xL)) (-RRB- -RRB-))) (NP (NN IAP) (NN family) (NN protein))))) (, ,) (NP (NP (NP (NN up-regulation) (JJ pro-apoptotic) (NN Bax) (NN protein) (NN tumor) (NN necrosis) (JJ factor-related) (JJ apoptosis-inducing) (NN ligand)) (PRN (-LRB- -LRB-) (NP (NN TRAIL)) (-RRB- -RRB-))) (: -) (NP (NP (NP (NN receptor) (NN 1/receptor) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN DR4/DR5)) (-RRB- -RRB-))) (NP (JJ mitochondrial) (NN dysfunction)))))) |ET| |BS|39:G04.299.139.160 41:A11 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 142:I01.880.604 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 1272:D03.438.759.758.824.651.700 1438:D12.644.276.374.750.625 1439:D12.644.360.075.437|ES| 2:1 4:1 7:1 10:1 14:1 19:1 89:1 94:1 97:1 148:1 158:1 169:1 257:1 412:1 691:1 758:1 769:1 896:1 1695:1 1835:1 2004:1 4257:1 4502:1 4560:1 4630:1 4814:1 5230:1 5231:1 5232:1 5233:1 5234:1 5235:1 5236:1 5237:1
1 	|BT| (S (NP (DT The) (JJ apoptosis-inducing) (NN effect) (NN gastrin) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ relates) (NP (NP (VBN increased) (NP (NN IEX-1)) (NN expression)) (VP (VBG mediating) (NP (NP (NN NF-kappa) (NN B)) (NN inhibition)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 43:F01.145.544 199:D06.472.317.413 200:D06.472.317.413 210:D12.776.260.600|ES| 17:1 18:1 19:1 47:1 75:1 94:1 103:1 115:1 676:1 691:1 758:1 759:1 760:1 761:1 762:1 763:1
1 	|BT| (S (NP (NP (DT The) (NN AZD6244-doxorubicin)) (NP (NP (VBN combined) (NN protocol)) (VP (VBD promoted) (NP (NN apoptosis))))) (ADVP (RB also)) (VP (VBD induced) (NP (NP (JJ synergistic) (NN effect)) (VP (VBN seen) (NP (JJ single-agent-treated) (NN tumor)))) (, ,) (PP (VBG including) (NP (VBN increased) (NN expression) (NN p130) (NN RB) (NN tumor) (NN suppressor) (NN gene))))) |ET| |BS|8:C04 39:G04.299.139.160 52:E02 136:D02.455.426.559.847.562.050.200.175 155:G05.355.310 206:G05.360.340.024.340.375.249 213:F02.830.816.964 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725|ES| 2:1 5:1 7:1 9:1 19:1 47:1 75:1 89:1 115:1 164:1 412:1 561:1 691:1 700:1 724:1 1209:1 1912:1 2012:1 3216:1 5238:1 5239:1 5240:1
1 	|BT| (S (NP (DT The) (NN downregulation) (NN IRS1) (NN SOX9)) (ADVP (RB also)) (VP (VBD induced) (NP (NN sodium) (NN butyrate)))) |ET| |BS|85:G02.111.087.225 1075:D02.241.081.114.750|ES| 5:1 19:1 407:1 412:1 595:1 691:1 3758:1 5241:1 5242:1
1 	|BT| (S (NP (DT The) (JJ dual) (NN EGFR/HER2) (NN inhibitor) (NN lapatinib)) (ADVP (RB synergistically)) (VP (VBZ enhances) (NP (JJ antitumor) (NN activity) (NN histone) (NN deacetylase) (NN inhibitor) (NN panobinostat) (JJ colorectal) (NN cancer) (NN model)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 153:D27.505.519.389.360|ES| 17:1 18:1 19:1 72:1 380:1 399:1 503:1 504:1 691:1 1356:1 2067:1 2244:1 3347:1 3348:1 3349:1 5243:1
1 	|BT| (S (NP (DT The) (NN effect) (NN chloroform) (NN DCA) (JJ TCA-induced) (NN hypomethylation) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN kidney) (NN tumor)) (VP (VBD determined))) |ET| |BS|155:G05.355.310 242:A03.620 274:C04.588.945.947.535 1196:D02.455.526.439.224 1331:C06.198.439 1332:Z01.107.084.900|ES| 7:1 9:1 19:1 75:1 115:1 455:1 691:1 836:1 1582:1 1717:1 2337:1 4107:1 4179:1 4180:1 5244:1
1 	|BT| (S (NP (DT The) (NN expression) (NN HEF1)) (VP (VP (VBD upregulated) (NP (NN Wnt-3a) (, ,) (NN beta-catenin) (, ,) (NN Dvl2) (JJ dose-dependent) (NN manner))) (, ,) (VP (VBD suppressed) (PP (VBG following) (NP (NN beta-catenin) (NN downregulation) (NN shRNA)))))) |ET| |BS|23:D12.776.091.249 85:G02.111.087.225 1273:D13.150.650.700|ES| 2:1 19:1 60:1 115:1 125:1 307:1 595:1 691:1 974:1 1668:1 2824:1 3510:1 5029:1 5245:1 5246:1
1 	|BT| (S (NP (DT The) (NN expression) (NN Tsc-22)) (ADVP (RB also)) (VP (VBD repressed) (SBAR (S (NP (NN B6C3F1) (NN mouse) (NN liver) (NN tumor)) (VP (VBD induced) (NP (NP (JJ several) (NN chemical) (JJ 2-year) (NN carcinogenicity) (NN study)) (NP (ADJP (RB well) (JJ spontaneous)) (NN liver) (NN tumor)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 279:D27.888.569.100 515:C04.588.274.623|ES| 5:1 7:1 19:1 52:1 115:1 131:1 262:1 283:1 412:1 466:1 691:1 787:1 836:1 2124:1 3583:1 3986:1 4495:1 5180:1
1 	|BT| (S (NP (DT The) (NN inhibition) (NN NAG-1) (NN expression) (JJ small) (VBG interfering) (NN RNA)) (ADVP (RB significantly)) (VP (VBD blocked) (NP (NP (NP (JJ VES-induced) (NN poly)) (PRN (-LRB- -LRB-) (NP (NN ADP-ribose)) (-RRB- -RRB-))) (NN polymerase) (NN cleavage)) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN NAG-1)) (VP (MD may) (VP (VB play) (NP (NP (JJ important) (NN role)) (NP (JJ VES-induced) (NN apoptosis))))))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 39:G04.299.139.160 43:F01.145.544 79:I03.450.642.693 117:D13.150.650.700 470:C02.782.160.927 1248:D08.811.913.400.725.115.690 1440:G04.299.134.220.250|ES| 2:1 10:1 14:1 19:1 31:1 89:1 103:1 115:1 124:1 238:1 394:1 491:1 515:1 691:1 750:1 902:1 1009:1 1661:1 1662:1 2777:1 3019:1 4810:1 4811:1 5247:1
1 	|BT| (S (NP (DT The) (NN inhibition) (NN NF-kappaB) (NN activation)) (ADVP (RB thereby)) (VP (VBD led) (NP (NP (NN down-regulation) (NN gene) (NN product)) (VBN involved) (NP (NP (NN inflammation)) (PRN (-LRB- -LRB-) (NP (NN cyclooxygenase-2)) (-RRB- -RRB-))) (, ,) (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN cyclin) (NN D1) (NN c-myc)) (-RRB- -RRB-))) (, ,) (NP (NP (NN invasion)) (PRN (-LRB- -LRB-) (NP (NN matrix) (NN metalloproteinase-9)) (-RRB- -RRB-))) (, ,) (NP (NP (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (-RRB- -RRB-))) (, ,) (NP (NP (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (NP (NN cIAP1)) (, ,) (NP (NN cIAP2)) (, ,) (NP (NP (JJ X-linked) (NN inhibitor) (NN apoptosis) (NN protein)) (, ,) (NP (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL))))) (-RRB- -RRB-)))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 43:F01.145.544 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 86:D01.268.556.435 108:G04.299.316 210:D12.776.260.600 215:D12.644.360.262.150.100 371:A07.231 525:C23.550.470 586:D08.811.277.656.300.480.205.360 1130:D12.644.276.390|ES| 2:1 4:1 9:1 10:1 14:1 19:1 61:1 89:1 94:1 102:1 103:1 158:1 185:1 225:1 257:1 274:1 299:1 380:1 455:1 620:1 675:1 691:1 714:1 743:1 744:1 774:1 1251:1 2157:1 2228:1 2502:1 3064:1 3092:1 3491:1 4814:1 4896:1 4980:1 5189:1 5248:1
1 	|BT| (S (S (NP (DT The) (JJ knockout) (NN animal)) (VP (VBD increased) (NP (NP (NN lipid) (NN peroxidation)) (VP (VBD enhanced) (NP (NN sensitivity) (JJ CCl4-induced) (NN liver) (NN damage)) (, ,) (PP (ADVP (RB largely)) (JJ due) (NP (NP (VBN increased) (NN CYP2E1) (NN expression) (NN diallyl) (NN sulfide)) (, ,) (NP (NN inhibitor) (NN CYP2E1)) (, ,))))))) (VP (VBD prevented) (NP (JJ CCl4-induced) (NN liver) (NN injury)))) |ET| |BS|12:Z01.542.049 19:B01.050 242:A03.620 1218:D08.244.453.300 1247:G02.111.087.520|ES| 2:1 19:1 46:1 47:1 71:1 115:1 380:1 385:1 607:1 691:1 836:1 1848:1 1944:1 2401:1 2416:1 2520:1 2595:1 2851:1 4270:1 4384:1 4385:1 4386:1
1 	|BT| (S (NP (DT The) (JJ objective) (NN study)) (VP (VBP examine) (NP (NP (NN effect) (JJ EGCG-induced) (NN BTG2) (NN expression) (JJ potential) (NN signal) (NN pathway)) (VP (VBN involved))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 415:F01.658.500 761:G02.111.087.800|ES| 19:1 75:1 115:1 131:1 383:1 691:1 774:1 827:1 859:1 960:1 2916:1 4886:1 5249:1
1 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ explores) (SBAR (S (NP (NP (NN effect) (JJ p53-modulating) (NN agent) (NN CP-31398)) (ADVP (RB alone))) (VP (VBN combined) (NP (NP (NP (NN celecoxib) (JJ azoxymethane-induced) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NN colon) (NN adenocarcinoma) (NN F344) (NN rat))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 46:A03.556.124.526.356 84:C04.557.470.200.025 132:D02.172.080 590:B01.050.050.199.520.760.200 684:D02.065.884.247 824:C04.834.020|ES| 10:1 14:1 19:1 75:1 113:1 131:1 164:1 241:1 255:1 691:1 728:1 849:1 1307:1 1431:1 1725:1 2533:1 2807:1 2913:1 2914:1 3047:1 3185:1 5250:1 5251:1
1 	|BT| (S (NP (NP (DT The) (NN Ras) (NN inhibitor) (JJ farnesylthiosalicyclic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FTS)) (-RRB- -RRB-))) (VP (VBZ prevents) (NP (NN nodule) (NN formation) (NN development) (JJ preneoplastic) (NN focus) (JJ altered) (NNS hepatocytes) (NN rat)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 20:G03.495 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 1062:D01.029|ES| 10:1 14:1 19:1 35:1 43:1 380:1 691:1 693:1 849:1 894:1 1275:1 1431:1 1438:1 1775:1 2718:1 4551:1 4680:1 5252:1
1 	|BT| (NP (NP (DT The) (NN Ras) (NN inhibitor) (NN S-trans)) (, ,) (NP (NP (NP (JJ trans-farnesylthiosalicylic) (NN acid) (NNS chemosensitizes)) (NP (JJ human) (NN tumor) (NN cell))) (PP (IN without) (S (VP (VBG causing) (NP (NN resistance))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 7:1 19:1 36:1 94:1 380:1 691:1 1094:1 1195:1 1275:1 1491:1 1775:1 4549:1 5253:1 5254:1
1 	|BT| (NP (NP (NP (DT The) (NN rate) (NN proliferation) (NN HT29) (JJ human) (NN colon) (NN cancer) (NN cell)) (SBAR (S (NP (VBN reduced) (JJ treated) (NN gamma-secretase) (NN inhibitor) (NN dibenzazepine)) (VP (VBP inhibit) (NP (NP (NN Notch) (NN signaling) (JJ small) (VBG interfering) (NN RNA)) (VP (VBD directed) (NP (NN Notch))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 117:D13.150.650.700 122:C14.280.383 125:D08.811.277.656.300.032 212:E01.370.225.500.385.500 792:A11.251.210.190.475|ES| 18:1 19:1 36:1 41:1 94:1 113:1 195:1 256:1 299:1 380:1 452:1 515:1 691:1 750:1 1099:1 1370:1 1866:1 3017:1 3018:1 3019:1 3020:1
1 	|BT| (S (NP (DT The) (ADJP (RB recently) (VBN completed)) (NN o-nitrotoluene) (NN study)) (VP (VBD provided) (SBAR (S (NP (JJ first) (JJ cecal) (NN tumor) (NN response) (NN opportunity)) (VP (VB evaluate) (NP (NP (NN morphology) (JJ molecular) (NN profile) (NN oncogene) (NN tumor) (NN suppressor) (NN gene) (JJ relevant)) (ADJP (JJ human)))))))) |ET| |BS|9:G05.360.340.024.340.375.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 206:G05.360.340.024.340.375.249 225:E05.337 1441:C04.588.274.476.411.184|ES| 7:1 9:1 19:1 24:1 36:1 131:1 161:1 348:1 494:1 691:1 700:1 772:1 816:1 865:1 890:1 1155:1 1711:1 4417:1 5255:1 5256:1 5257:1
1 	|BT| (NP (NP (DT The) (NN role) (NN p53) (NN mutation) (JJ anti-tumour) (NN response) (JJ selective) (NN COX-2) (NN inhibitor) (NN celecoxib) (JJ human) (NN glioblastoma) (NN cell) (NN unknown))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 15:F01.829.316.616 18:G05.365.590 41:A11 55:B01.050.150.900.649.801.400.112.400.400 349:D27.505.519.389.310.500 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247|ES| 12:1 19:1 31:1 34:1 36:1 76:1 94:1 380:1 494:1 691:1 1749:1 2182:1 2186:1 2434:1 2807:1
1 	|BT| (S (NP (DT The) (JJ tobacco-specific) (NN carcinogen) (NN NNK)) (VP (VBZ induces) (NP (NN DNA) (NN methyltransferase) (CD 1) (NN accumulation) (NN tumor) (NN suppressor) (NN gene) (NN hypermethylation) (NN mouse) (NN lung) (NN cancer) (NN patient)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 50:M01.643 206:G05.360.340.024.340.375.249 279:D27.888.569.100 459:B01.650.940.800.575.100.905.900 460:B01.650.940.800.575.100.905.900 462:J01.637.836 746:D08.811.150.240|ES| 7:1 9:1 18:1 19:1 52:1 98:1 120:1 214:1 328:1 664:1 666:1 691:1 700:1 2120:1 2125:1 2655:1 5258:1 5259:1
1 	|BT| (S (NP (NP (DT The) (NN tumor) (NN suppressor) (NN protein) (NN phosphatase) (NN tensin) (NN homologue)) (VP (VBN deleted) (S (NP (NP (NN chromosome) (CD ten)) (PRN (-LRB- -LRB-) (NP (NN PTEN)) (-RRB- -RRB-)))))) (VP (VBP play) (NP (NP (JJ important) (NN role)) (JJ intestinal) (NN cell) (NN proliferation) (NN differentiation) (NN tumor) (NN suppression)) (S (VP (VBG antagonizing) (NP (NN phosphatidylinositol) (NN 3-kinase)))))) |ET| |BS|8:C04 12:Z01.542.049 15:F01.829.316.616 47:A03.556.124 74:G04.299.151 79:I03.450.642.693 173:C07.465.864.500 183:G04.299.233.750 289:A11.284.187 1035:D08.811.277.352.650 1377:D08.811.913.696.620.500.100 1442:D12.776.624.776|ES| 4:1 7:1 10:1 14:1 19:1 31:1 94:1 109:1 215:1 226:1 238:1 299:1 574:1 691:1 700:1 902:1 1001:1 1005:1 1936:1 2453:1 3394:1 3619:1 3620:1 4969:1 5260:1
1 	|BT| (S (ADVP (RB Therefore)) (, ,) (VP (VBD investigated) (SBAR (IN whether) (S (NP (JJ lipogenic) (NN gene) (NN expression) (NN tumor) (NN cell)) (ADVP (RB differently)) (VP (VBD regulated) (NP (JJ omega-6) (NN omega-3) (NNS PUFAs))))))) |ET| |BS|41:A11 142:I01.880.604 537:G05.360.340.024.340.375 1308:D10.212.302.380.410|ES| 2:1 7:1 9:1 19:1 94:1 115:1 221:1 403:1 1620:1 1664:1 5261:1 5262:1 5263:1 5264:1 5265:1
1 	|BT| (S (NP (NP (DT These) (NN animal)) (NP (VP (VP (VBN reduced)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (JJR <) (CD 0.05))) (-RRB- -RRB-))) (NP (JJ colonic) (NN RFC1) (NN mRNA)))) (VP (VBD exhibited) (NP (JJ 2-fold) (NN reduction) (NN plasma) (NN S-adenosylmethionine/S-adenosylhomocysteine)))) |ET| |BS|19:B01.050 46:A03.556.124.526.356 111:D13.444.735.544 175:J01.897.280.500.269 232:D02.886.030.676.180 657:A12.207.152.693|ES| 10:1 14:1 19:1 46:1 311:1 312:1 325:1 370:1 452:1 609:1 677:1 792:1 2400:1 3549:1 3849:1 5266:1 5267:1
1 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (S (NP (NN resveratrol)) (VP (VBP prevent) (NP (NP (NN formation) (NN growth) (JJ colorectal) (NN tumor)) (VP (VBG downregulating) (NP (NNP Kras) (NN expression))))))))) |ET| |BS|20:G03.495 45:G07.700.320.249 388:G05.360.340.024.340.375.500.791.550 1031:C04.588.274.476.411.307|ES| 7:1 17:1 19:1 43:1 102:1 115:1 733:1 792:1 793:1 1479:1 1712:1 2065:1 5142:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (SBAR (S (NP (VBN demonstrated) (NNS SK-Hep1-NIS)) (VP (MD could) (VP (ADVP (RB selectively)) (VBN killed) (NP (JJ induced) (NN 131I) (NN 188Re-perrhenate) (NN accumulation) (NN NIS) (NN gene) (NN expression)))))))) |ET| |BS|155:G05.355.310 1443:I01.198.240.470|ES| 9:1 19:1 101:1 115:1 412:1 792:1 908:1 1175:1 2120:1 3523:1 5268:1 5269:1 5270:1 5271:1 5272:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VB establish) (SBAR (S (NP (JJ mechanistic) (NN rationale) (NN Src) (NN inhibition) (NN dasatinib) (JJ therapeutic) (NN target) (NN treatment) (JJ pancreatic) (NN cancer)) (VP (VBP identify) (NP (JJ potential) (NNS biomarkers) (NN resistance) (NN Src) (NN inhibition)))))))) |ET| |BS|43:F01.145.544 52:E02 158:D23.101 1386:D02.886.675.184|ES| 18:1 19:1 101:1 103:1 160:1 220:1 467:1 541:1 546:1 792:1 827:1 832:1 1094:1 1269:1 1495:1 1890:1 3674:1 5017:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (SBAR (S (NP (VBP suggest) (NN alteration) (NN TSLC) (NN cascade)) (VP (MD might) (NP (NN role) (NN hepatocarcinogenesis)) (S (VP (VBG using) (NP (NNP DEN) (NN rat))))))))) |ET| |BS|15:F01.829.316.616 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 19:1 31:1 101:1 350:1 792:1 796:1 798:1 849:1 900:1 951:1 1875:1 5273:1 5274:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN SGE)) (VP (VBZ suppresses) (NP (NN induction) (NN Cyp1a1)) (, ,) (S (VP (VBG leading) (SBAR (S (NP (NN inhibition) (NN ROS) (NN generation)) (ADVP (RB consequently)) (VP (VBD inhibited) (NP (NN hepatocarcinogenesis)) (, ,) (NP (ADVP (RB probably)) (NP (JJ due) (NN suppression) (NN Ahr) (NN activity)))))))))))))) |ET| |BS|43:F01.145.544 86:D01.268.556.435 122:C14.280.383 506:F01.829.263.315 1352:D08.244.453.040.332|ES| 2:1 19:1 101:1 103:1 365:1 399:1 639:1 686:1 736:1 792:1 796:1 900:1 1787:1 2356:1 2453:1 2851:1 4415:1 5160:1 5162:1 5275:1 5276:1
1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBN suggested) (SBAR (S (NP (JJ gestational) (JJ arsenic) (NN exposure)) (VP (VBZ induces) (SBAR (S (NP (NP (JJ tumor-augmenting) (NN change)) (, ,) (PP (VBG including) (NP (NP (JJ oxidative) (NN stress) (NN L1) (NN activation)) (, ,) (NP (JJ late-onset) (NN manner)) (, ,)))) (VP (MD would) (VP (ADVP (RB particularly)) (VB promote) (NP (JJ tumorigenic) (NN expansion) (NN cell) (NN C61A) (NN Ha-ras) (NN mutation)))))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 41:A11 216:Z01.107.084.900.425 716:G03.495.710 1158:D01.268.513.249 1266:G08.686.785.760.769 1444:N05.715.350.075.100|ES| 2:1 19:1 34:1 94:1 101:1 200:1 214:1 225:1 561:1 679:1 747:1 792:1 866:1 925:1 1362:1 1668:1 1809:1 1953:1 2380:1 2522:1 2583:1 3473:1 3976:1 4106:1 5277:1 5278:1 5279:1
1 	|BT| (S (NP (DT This) (JJ toxicogenomic) (NN analysis)) (VP (VBD revealed) (NP (NP (JJ several) (JJ aberrant) (NN gene) (NN expression) (NN change)) (VP (VBN associated) (NP (JJ transplacental) (JJ arsenic) (NN carcinogenesis)))))) |ET| |BS|33:C04.697.098 155:G05.355.310 1158:D01.268.513.249|ES| 9:1 19:1 115:1 169:1 200:1 207:1 262:1 275:1 661:1 807:1 1725:1 4106:1 5280:1 5281:1
1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (CD 1,25) (NN D) (NN VDR)) (VP (VBP regulate) (NP (NN c-MYC/MXD1) (NN network)) (VP (VBP suppress) (NP (NN c-MYC) (NN function)) (, ,) (S (VP (VBG providing) (NP (JJ molecular) (NN basis) (NN cancer) (JJ preventive) (NN action) (NN vitamin) (NN D))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 588:I01.880.853.500.600 720:D04.808.247.222.474 721:D04.808.812.768|ES| 2:1 18:1 19:1 33:1 161:1 625:1 858:1 1140:1 1691:1 1883:1 2013:1 2154:1 2441:1 2591:1 2592:1 3025:1 4529:1 5129:1 5282:1
1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (JJ final) (NN death) (NN outcome) (JJ 5-FU-treated) (NN p53)) (: -) (: /) (: -) (NP (NP (NN cell) (VBD demonstrated) (ADJP (ADJP (JJ caspase-dependent)) (, ,) (ADJP (JJ due) (JJ slow))) (NN pace)) (, ,) (NP (NN accumulation) (JJ mitochondrial) (JJ reactive) (NN oxygen) (NN specie))) (VP (VBZ contributes) (NP (JJ necrotic) (NN characteristic)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 52:E02 134:G04.299.139 135:C23.550.260 560:D03.383.742.698.875.404 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 636:D01.339.431 1216:C23.550.717 1367:D08.811.277.656.262.500.126 1445:D08.811.277.656.300.760.353|ES| 2:1 19:1 94:1 336:1 411:1 547:1 845:1 1175:1 1505:1 1691:1 2004:1 2120:1 2353:1 2354:1 2355:1 2851:1 5283:1 5284:1 5285:1 5286:1 5287:1 5288:1
1 	|BT| (NP (NP (NP (NP (NNP Thymidylate) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN TS)) (-RRB- -RRB-))) (NP (NP (NP (NN overexpression) (JJ key) (NN determinant) (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NN resistance) (JJ human) (NN cancer) (NN cell))))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862|ES| 10:1 14:1 18:1 19:1 36:1 66:1 94:1 152:1 159:1 509:1 1094:1 2307:1 2308:1 3081:1 4359:1
1 	|BT| (S (S (VP (TO To) (VP (VB examine) (NP (NP (JJ possible) (JJ direct) (JJ transcriptional) (NN regulation)) (NP (NN rat) (NN Bcl-2) (NN beta-catenin/Tcf)))))) (, ,) (VP (VBN cloned) (VP (VBN characterized) (SBAR (S (NP (JJ corresponding) (NN promoter) (NN region)) (VP (VBD found) (NP (NP (ADJP (CD 70.1) (NN %)) (NN similarity) (JJ human) (NN counterpart)) (, ,) (NP (NN BCL2))))))))) |ET| |BS|23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 196:G02.111.570.080.689.675 209:G02.111.087.847 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 301:A11.251.353|ES| 2:1 19:1 36:1 37:1 83:1 158:1 369:1 438:1 559:1 667:1 828:1 849:1 960:1 985:1 1048:1 1359:1 1891:1 3526:1 4231:1 4999:1 5289:1 5290:1 5291:1
1 	|BT| (S (VP (ADVP (RB Together)) (, ,) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NN silibinin)) (VP (VBZ inhibits) (NP (NP (NN growth) (NN SW480) (NN tumor)) (VP (VBG carrying) (NP (JJ mutant) (NN APC) (NN gene) (NN down-regulating) (NN CDK8) (NN beta-catenin) (NN signaling)))) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD could) (NP (JJ effective) (NN agent) (NN CRC))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 247:G01.374.676.530 351:A17.360|ES| 2:1 7:1 9:1 11:1 19:1 60:1 102:1 195:1 218:1 245:1 615:1 728:1 796:1 811:1 850:1 908:1 927:1 1639:1 2635:1 3095:1 3096:1 3097:1 3098:1
1 	|BT| (S (NP (NN TOPflash) (NN luciferase) (NN reporter) (NN assay)) (VP (VBD showed) (S (NP (NP (JJ transcriptional) (NN activity) (NN T-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TCF)) (-RRB- -RRB-))) (ADJP (: /) (SBAR (S (NP (JJ lymphoid) (NN enhancer) (NN factor) (-LRB- -LRB-) (NN LEF) (-RRB- -RRB-)) (VP (VBD reduced) (SBAR (S (NP (NP (NN NDRG2) (NN introduction)) (, ,) (NP (NN introduction) (JJ mutant) (NN NDRG2))) (VP (VBD generated) (NP (NN deletion) (JJ site-directed) (NN mutagenesis)))))))))))) |ET| |BS|106:E05.091 209:G02.111.087.847 306:G05.355.600.800 1375:D08.811.682.517 1446:A11.118.637.555.567 1447:E05.393.420.601.575|ES| 2:1 10:1 14:1 19:1 73:1 132:1 185:1 288:1 310:1 399:1 452:1 559:1 811:1 972:1 1059:1 4864:1 4952:1 4963:1 5210:1 5292:1 5293:1 5294:1 5295:1 5296:1 5297:1
1 	|BT| (S (NP (NN Toxaphene)) (VP (VBD induced) (NP (NP (JJ significant) (NP (NP (NN increase) (NN expression) (JJ constitutive) (NN androstane) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN CAR)) (-RRB- -RRB-))) (NN target) (NN gene)) (PRN (-LRB- -LRB-) (NP (NP (NN Cyp2b10)) (, ,) (NP (NN Cyp3a11))) (-RRB- -RRB-))) (NP (QP (CD 32) (CD 320)) (NN ppm) (NN toxaphene)))) |ET| |BS|6:G05.360.340.024.340 1149:D02.455.526.439.913|ES| 2:1 9:1 10:1 14:1 19:1 40:1 115:1 135:1 160:1 186:1 412:1 421:1 604:1 605:1 2546:1 3233:1 3985:1 4164:1 4299:1 5298:1 5299:1
1 	|BT| (S (NP (NN Treatment) (NN HepG2) (NN cell) (NN APAP)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NN expression) (NN DAX-1) (JJ concentration-dependent) (NN manner)))) |ET| |BS|52:E02 661:D02.065.199.092.040 905:F02.830.104.214 1015:A11.251.860.180.432|ES| 19:1 94:1 115:1 124:1 452:1 1668:1 3106:1 3481:1 4193:1 4537:1 5300:1
1 	|BT| (NP (NP (NN Treatment) (NP (NP (NN rat) (NN DHEA) (NN influence) (NN expression) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN P450)) (-RRB- -RRB-))) (NN gene)) (, ,) (FRAG (VBG including) (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN alpha)) (-LRB- -LRB-) (NP (NP (NP (NP (NN PPAR) (NN alpha) (-RRB- -RRB-)) (: -) (NP (NP (NN pregnane) (NN X) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN PXR)) (-RRB- -RRB-)))) (: -) (NP (VBN mediated) (NN induction) (NNS CYP4As) (NN CYP3A23)) (, ,) (NP (NN suppression) (NN CYP2C11)))))) |ET| |BS|6:G05.360.340.024.340 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 536:D12.776.826.239.500 740:D04.808.054.079.429.625 1079:D08.244.453 1448:D08.244.453.450|ES| 2:1 9:1 10:1 14:1 19:1 115:1 186:1 561:1 736:1 849:1 867:1 929:1 1801:1 1836:1 1887:1 2453:1 2549:1 2633:1 2691:1 3106:1 3227:1 3788:1 4048:1 4899:1 5301:1 5302:1 5303:1 5304:1
1 	|BT| (S (NP (NN Treatment) (NN cell) (NN oxazepam) (CD 48) (NN h)) (ADVP (RB also)) (VP (VBD resulted) (SBAR (S (NP (VBN decreased) (NN Tsc-22)) (VP (VBD increased) (NP (NN Gadd45b) (NN expression))))))) |ET| |BS|41:A11 52:E02 179:D01.248.497.300.459.700 1329:D03.438.079.080.070.663|ES| 5:1 19:1 47:1 94:1 115:1 202:1 594:1 3106:1 4741:1 4855:1 5180:1 5305:1 5306:1
1 	|BT| (S (NP (NN Treatment) (NN 5-AzaC)) (ADVP (RB concomitantly)) (NP (VBN upregulated) (NN expression) (NN miR-9-3) (NN miR-193a)) (, ,) (VP (VBD downregulated) (NP (JJ respective) (NN target) (NN gene) (NN NF-kappaB) (NN Mcl-1)))) |ET| |BS|6:G05.360.340.024.340 52:E02 210:D12.776.260.600|ES| 2:1 9:1 19:1 115:1 125:1 160:1 426:1 714:1 3106:1 5307:1 5308:1 5309:1 5310:1 5311:1 5312:1
1 	|BT| (S (NP (NN Troglitazone)) (VP (VBZ induces) (NP (JJ p27Kip1-associated) (NP (JJ cell-cycle) (NN arrest) (JJ down-regulating) (NN Skp2) (JJ human) (NN hepatoma) (NN cell))))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 338:D12.644.360.225.600 351:A17.360 507:D12.776.157.743 515:C04.588.274.623 773:G04.299.134.109|ES| 19:1 36:1 94:1 214:1 602:1 1785:1 3097:1 3116:1 3896:1 5313:1 5314:1
1 	|BT| (S (NP (NN Troglitazone)) (ADVP (RB potently)) (VP (VBD inhibited) (SBAR (S (NP (NN proteasome) (NN activity)) (VP (VBD decreased) (NP (NN Skp2) (NN protein) (NN level))))))) |ET| |BS|122:C14.280.383 507:D12.776.157.743 1281:D05.500.562.500|ES| 4:1 19:1 202:1 249:1 365:1 399:1 1785:1 3116:1 3128:1 4559:1
1 	|BT| (S (NP (NN TS)) (ADVP (RB also)) (VP (ADVP (RB acutely)) (VBN up-regulated) (NP (NP (NN 5-FU) (NN treatment)) (, ,) (, ,) (ADVP (RB thus)) (, ,) (NP (NP (JJ novel) (NN strategy)) (VP (VBG targeting) (NP (NN TS) (NN down-regulation))))) (VP (VBP seem) (NP (JJ promising) (NN term) (VBG modulating) (NN 5-FU) (NN resistance))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 85:G02.111.087.225 142:I01.880.604 150:Z01.542.248.960 154:Z01.058.266.887 259:D12.776.395.240.150.500 560:D03.383.742.698.875.404 849:G08.686.785.760.769.490.500|ES| 2:1 5:1 19:1 257:1 509:1 546:1 616:1 891:1 995:1 1094:1 1114:1 1301:1 1334:1 1517:1 2308:1 2435:1 5315:1 5316:1
1 	|BT| (NP (NP (NP (NN Upregulation) (NN B-cell) (NN translocation) (NN gene) (CD 2) (JJ epigallocatechin-3-gallate)) (PP (IN via) (NP (NN p38) (NN ERK) (NN signaling) (NN block) (NN cell) (NN proliferation) (JJ human) (JJ oral) (JJ squamous) (NN cell) (NN carcinoma) (NN cell))))) |ET| |BS|6:G05.360.340.024.340 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 122:C14.280.383 183:G04.299.233.750 249:G05.355.315.800 310:A11.063.438 339:G02.111.087.880 463:C23.550.210.870 929:C04.557.470.200.400|ES| 9:1 19:1 36:1 94:1 148:1 195:1 299:1 304:1 596:1 742:1 1067:1 1618:1 1666:1 2199:1 2629:1 5047:1 5317:1 5318:1
1 	|BT| (S (NP (JJ Ursodeoxycholic) (NN acid)) (VP (VBZ inhibits) (NP (NP (NN Ras) (NN mutation)) (, ,) (NP (NP (JJ wild-type) (NN Ras)) (NN activation)) (, ,) (NP (NN cyclooxygenase-2) (NN expression) (NN colon) (NN cancer))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 24:D08.811.600.720.750 122:C14.280.383 737:D04.808.105.225.272.962|ES| 2:1 8:1 18:1 19:1 34:1 61:1 113:1 115:1 225:1 615:1 1275:1 1775:1 3121:1
1 	|BT| (S (S (VP (VBG Using) (NP (NN xenograft) (ADJP (NN tumor) (NN model) (JJ severe)) (JJ combined) (JJ immune) (NN deficiency) (NN mouse)))) (, ,) (VP (MD could) (VP (VB show) (SBAR (S (NP (NP (JJ experimental) (JJ systemic) (NN hypergastrinemia)) (VP (VBD induced) (NP (NN administration) (NN omeprazole)))) (VP (VBD led) (NP (VBN enhanced) (NN apoptosis)) (ADVP (RB well)) (NP (NP (JJ marked) (NN increase) (NN IEX-1) (NN expression) (NN Colo320wt) (NN tumor)) (, ,) (NP (NN Colo320mut) (NN tumor))))))))) |ET| |BS|8:C04 39:G04.299.139.160 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 984:D02.886.640.074.500 1449:B01.050.150.900.649.865.635.505.500.550.780|ES| 2:1 7:1 19:1 40:1 52:1 72:1 89:1 115:1 164:1 253:1 263:1 265:1 385:1 412:1 429:1 760:1 787:1 908:1 1719:1 2228:1 2575:1 2802:1 3169:1 3467:1 4693:1 5037:1 5044:1 5319:1 5320:1
1 	|BT| (S (S (VP (VBG Using) (NP (JJ several) (JJ experimental) (NN approach)))) (, ,) (VP (VBP conclude) (SBAR (S (NP (JJ RNA-rather) (JJ DNA-related) (NN stress)) (VP (VBZ follows) (NP (NP (NN caspase) (NN activation)) (RRC (ADVP (RB irrespectively)) (NP (NN p53) (NN status))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 198:D13.444.308 557:D02.241.081.069.600.150 1367:D08.811.277.656.262.500.126 1422:D13.444.735|ES| 2:1 12:1 19:1 225:1 262:1 263:1 416:1 911:1 1719:1 1968:1 2522:1 4796:1 5321:1 5322:1 5323:1 5324:1
1 	|BT| (S (NP (NN UV) (NN exposure)) (VP (VBP result) (NP (NP (NP (JJ ligand-independent) (NN activation) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (JJ subsequent) (NN activation)) (JJ mitogen-activated) (NN protein) (NN kinase) (NN phosphatidylinositol) (NN 3-kinase/Akt) (NN pathway)) (VP (VBG leading) (NP (JJ transcriptional) (NN activation) (NN COX-2) (NN gene)))))) |ET| |BS|6:G05.360.340.024.340 64:D08.811.913.696.620.682.725.400.009.300 86:D01.268.556.435 170:D27.720.470.480 209:G02.111.087.847 249:G05.355.315.800 264:G05.355.315.800 378:D08.811.913.696.620.682.700.755 478:D08.811.913.696.620.682.700.567 1377:D08.811.913.696.620.500.100 1450:G01.358.500.505.650.891 1451:Z01.058.290.190.245|ES| 4:1 9:1 19:1 76:1 101:1 102:1 184:1 185:1 186:1 225:1 383:1 470:1 559:1 639:1 1319:1 1953:1 2081:1 3295:1 4969:1 5325:1 5326:1
1 	|BT| (S (NP (NN Vitamin) (NN D)) (VP (VBZ Enhances) (NP (NNP Efficacy) (NNP Irinotecan) (JJ miR-627-Mediated) (NN Inhibition) (NNP Intratumoral) (NNP Drug) (NNP Metabolism)))) |ET| |BS|43:F01.145.544 67:D26 720:D04.808.247.222.474 721:D04.808.812.768 898:G03.495|ES| 19:1 2345:1 2592:1 2703:1 3665:1 4953:1 5327:1 5328:1 5329:1 5330:1 5331:1
1 	|BT| (S (NP (NN Vitamin) (NN D) (NN signaling)) (VP (VBP suppress) (NP (NP (NN expression) (NN gene) (VBN regulated) (NN c-MYC)) (, ,) (NP (NP (NP (NN transcription) (NN factor) (NN control)) (JJ epidermal) (NN differentiation) (NN cell) (NN proliferation)) (SBAR (WHNP (WP$ whose) (NN activity)) (S (VP (ADVP (RB frequently)) (JJ elevated) (NP (NN cancer))))))))) |ET| |BS|69:G02.111.087.800 74:G04.299.151 142:I01.880.604 155:G05.355.310 166:D12.776.930 183:G04.299.233.750 720:D04.808.247.222.474 721:D04.808.812.768 1095:A10.272.497|ES| 2:1 9:1 18:1 19:1 94:1 115:1 184:1 185:1 195:1 215:1 289:1 299:1 399:1 487:1 625:1 698:1 756:1 919:1 1664:1 2441:1 2592:1 3665:1
1 	|BT| (S (NP (NN Vitamin) (NN E) (NN succinate)) (VP (VBZ induces) (NP (NN NAG-1) (NN expression) (NN p38) (JJ kinase-dependent) (NN mechanism)))) |ET| |BS|469:D08.811.913.696 1452:D03.383.663.283.909.750.249|ES| 19:1 115:1 162:1 214:1 1662:1 1666:1 1667:1 2085:1 3665:1 5332:1
1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD observed) (SBAR (S (NP (NN flavokawain) (NN B)) (VP (VBD caused) (NP (NP (NP (NN G2/M) (NN phase) (NN arrest) (JJ mediated) (NN reduction) (NN level) (NN cyclin) (NN A)) (, ,) (NP (NN cyclin) (NN B1))) (, ,) (NP (NN Cdc2) (NN Cdc25C) (NN increase) (NN p21/WAF1)) (, ,) (NP (NN Wee1) (NN p53) (NN level)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 122:C14.280.383 979:D12.644.360.262.120.100 1431:D12.644.360.262.100 1453:G04.299.134.500.340|ES| 2:1 5:1 12:1 19:1 40:1 69:1 249:1 261:1 370:1 437:1 602:1 743:1 763:1 843:1 2506:1 2528:1 2529:1 3455:1 5333:1 5334:1 5335:1 5336:1 5337:1
1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD demonstrated) (S (NP (NP (NN FOXM1)) (PRN (-LRB- -LRB-) (NP (NN 1B) (NN 1C) (NNS isoforms)) (-RRB- -RRB-))) (ADVP (RB directly)) (VP (VBP bind) (ADVP (RB transcriptionally)) (VP (VBZ regulates) (NP (NP (NP (NN eEF2K) (NN gene) (NN expression) (NN chromatin) (NN immunoprecipitation)) (PRN (-LRB- -LRB-) (NP (NN ChIP)) (-RRB- -RRB-))) (NN luciferase) (NN gene) (NN reporter) (NN assay))))))) |ET| |BS|6:G05.360.340.024.340 106:E05.091 155:G05.355.310 238:D12.776.800 1375:D08.811.682.517 1454:E05.393.170|ES| 5:1 9:1 10:1 14:1 19:1 115:1 288:1 310:1 603:1 621:1 821:1 843:1 1175:1 1346:1 1854:1 4857:1 4963:1 5100:1 5338:1 5339:1 5340:1 5341:1 5342:1
1 	|BT| (S (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD found) (SBAR (S (NP (NN pectolinarigenin)) (ADVP (RB significantly)) (VP (VBD suppressed) (NP (NN osteosarcoma) (NN cell) (NN proliferation))))))) (, ,) (VP (VBD induced) (NP (NP (NP (NP (NP (NN apoptosis)) (VP (VBN reduced) (NP (NN level) (NN STAT3) (JJ downstream) (NN protein) (NN cyclin) (NN D1)))) (, ,) (NP (NN Survivin)) (, ,)) (NP (NP (NN B-cell) (NN lymphoma) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN Bcl-2)) (-RRB- -RRB-)))) (, ,) (NP (NP (NP (NN B-cell) (NN lymphoma) (NN extra-large)) (PRN (-LRB- -LRB-) (NP (NN Bcl-xl)) (-RRB- -RRB-))) (NP (NP (JJ myeloid) (NN cell) (NN leukemia) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN Mcl-1)) (-RRB- -RRB-))))))) |ET| |BS|39:G04.299.139.160 41:A11 82:D12.644.360.024.342.300 183:G04.299.233.750 215:D12.644.360.262.150.100 361:C04.557.337 447:C04.557.450.565.575.650 1424:C04.557.386.480.150 1455:A11.148.378.590 1456:C04.557.337.539 1457:A11.627|ES| 2:1 4:1 5:1 10:1 14:1 19:1 37:1 89:1 94:1 98:1 124:1 148:1 158:1 249:1 251:1 299:1 307:1 412:1 452:1 560:1 591:1 743:1 744:1 843:1 1562:1 2199:1 2785:1 3779:1 5187:1 5312:1 5343:1 5344:1 5345:1
1 	|BT| (FRAG (NP (PRP We)) (VBD characterized) (SBAR (S (NP (NP (NN effect) (JJ gefitinib) (NN EGFR)) (, ,) (NP (NN HER2)) (, ,) (NP (NN ErbB-3) (NN phosphorylation) (NN Western) (NN blot))) (VP (VBD determined) (NP (NN effect) (JJ downstream) (NN signaling) (NN growth))))) (, ,) (NP (NP (NN survival)) (, ,) (NP (NN stress) (NN pathway) (NN effect) (NN proliferation)) (, ,) (NP (NN cell) (NN cycle)) (, ,) (NP (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 45:G07.700.320.249 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 96:I03.784 255:E05.196.401.143 256:E05.196.401.143 353:G04.299.134 972:G02.111.087.677 1350:G05.360.340.024.340.375.500.791.295|ES| 2:1 19:1 75:1 89:1 94:1 102:1 187:1 188:1 195:1 274:1 299:1 383:1 560:1 601:1 843:1 872:1 873:1 985:1 1582:1 2522:1 3310:1 3426:1 4818:1
1 	|BT| (S (NP (PRP We)) (VP (VBD found) (NP (NP (NP (CD 7) (RB differentially) (VBN expressed) (NN gene)) (, ,) (NP (NN cyclin) (NN D1))) (, ,) (NP (NP (NN cyclin) (NN E)) (, ,) (NP (NN c-myc)) (, ,) (NP (NN Fosl1)) (, ,) (NP (NN c-fos)) (, ,) (NP (NN Cd44) (NN follistatin)) (, ,) (NP (NP (VBN known) (NN target) (NN beta-catenin)) (CC and/or) (NP (NN ra))) (NP (NN pathway)))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 6:G05.360.340.024.340 23:D12.776.091.249 165:G05.360.340.024.340.375.500.791.330 215:D12.644.360.262.150.100 1366:D12.776.260.108.765 1458:D12.644.360.262.180 1459:D12.776.157.247|ES| 2:1 6:1 9:1 19:1 37:1 60:1 149:1 160:1 383:1 455:1 556:1 562:1 743:1 744:1 843:1 988:1 1115:1 1139:1 2085:1 5346:1 5347:1 5348:1
1 	|BT| (S (NP (PRP We)) (VP (VBD found) (NP (NP (NN Tsc-22) (NN downregulation) (NN liver) (NN B6C3F1) (NN mouse)) (PP (VBG following) (NP (NP (NN treatment) (CD 2) (NN week)) (NP (NP (NP (JJ carcinogenic) (NNS dos) (JJ antianxiety) (NN drug) (NN oxazepam)) (PRN (-LRB- -LRB-) (NP (CD 2500) (NN ppm)) (-RRB- -RRB-))) (NP (NP (NP (NN peroxisome) (NN proliferator) (NN Wyeth-14,643)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN ppm)) (-RRB- -RRB-))) (NP (NP (CD two) (NN carcinogen) (NN o-nitrotoluene) (NN methyleugenol) (CD three) (NNS noncarcinogens)) (PP (VBG including) (NP (NP (NN p-nitrotoluene)) (, ,) (NP (NN eugenol)) (, ,) (NP (NN acetaminophen)))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 85:G02.111.087.225 242:A03.620 279:D27.888.569.100 661:D02.065.199.092.040 912:D27.888.569.100.675 1165:D02.241.223.200.054.500 1329:D03.438.079.080.070.663 1460:D27.505.696.277.950.015|ES| 2:1 10:1 14:1 19:1 37:1 52:1 148:1 191:1 482:1 546:1 561:1 595:1 783:1 836:1 843:1 933:1 1887:1 1888:1 2125:1 2412:1 2653:1 3233:1 3346:1 3510:1 3986:1 4023:1 4293:1 4417:1 4741:1 5180:1 5349:1 5350:1 5351:1 5352:1 5353:1 5354:1
1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (S (NP (NN TCE)) (VP (VBD decreased) (SBAR (S (NP (NN methylation) (NN c-jun) (NN c-myc) (NN gene)) (VP (VBD increased) (NP (NN level) (NNS mRNAs)))))))))) |ET| |BS|36:G02.111.087.029.538 111:D13.444.735.544 186:G05.360.340.024.340.375.500.791.420|ES| 9:1 19:1 47:1 81:1 202:1 249:1 447:1 455:1 843:1 993:1 1527:1 5355:1 5356:1
1 	|BT| (S (NP (PRP We)) (VP (VBD hypothesized) (SBAR (S (NP (JJ novel) (NN class) (NN oligoamine) (NN analogue)) (VP (MD would) (VP (ADVP (RB effectively)) (VB inhibit) (NP (NN LSD1)) (RB thus) (VP (VBP cause) (S (NP (NN reexpression)) (VP (ADVP (RB aberrantly)) (NP (VBN silenced) (NN gene))))))))))) |ET| |BS|6:G05.360.340.024.340 122:C14.280.383 259:D12.776.395.240.150.500|ES| 9:1 19:1 843:1 866:1 891:1 1334:1 1370:1 1380:1 1750:1 1779:1 2656:1 2657:1 2658:1 2814:1 2977:1 5062:1 5357:1
1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NN function) (NN vitamin) (JJ D-regulated) (NN miR-627) (JJ intratumoral) (NN CYP3A4) (NN suppression) (NN role)) (VP (VBG enhancing) (NP (NN efficacy) (NN chemotherapy)))))) |ET| |BS|15:F01.829.316.616 142:I01.880.604 151:E02.319 720:D04.808.247.222.474 721:D04.808.812.768 1348:D08.244.453.400|ES| 19:1 31:1 33:1 403:1 495:1 843:1 2304:1 2453:1 2527:1 2591:1 4804:1 4805:1 5358:1 5359:1
1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (JJ anti-glioblastoma) (NN response) (NN celecoxib)) (JJ p53-dependent) (, ,) (SBAR (IN whether) (FRAG (NP (NP (ADJP (NN celecoxib) (VBD induced)) (NN DNA) (NN damage)) (VP (VBG leading) (NP (JJ p53-dependent) (NN G1) (NN cell) (NN cycle) (NN arrest)))))) (, ,) (VP (VBD followed) (NP (JJ autophagy) (NN apoptosis))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 86:D01.268.556.435 390:G04.299.139.399 526:G05.355.180 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 2:1 19:1 88:1 89:1 94:1 221:1 403:1 412:1 494:1 601:1 602:1 639:1 666:1 670:1 843:1 1317:1 1848:1 2807:1 3130:1 5360:1
1 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (NP (ADJP (NP (NN induction) (NN G)) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (: -)) (NN S-phase) (NN arrest) (JJ caspase-mediated) (NN apoptosis)) (NP (JJ androgen-dependent) (NP (JJ human) (NN LNCaP) (NN cell)))) (, ,) (S (VP (VBP express) (NP (JJ wild-type) (NN p53))) (, ,) (NP (JJ androgen-independent) (, ,) (NP (JJ p53-mutant) (NN DU145) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 892:D27.505.696.399.472.161 1367:D08.811.277.656.262.500.126|ES| 2:1 8:1 10:1 12:1 14:1 19:1 36:1 89:1 94:1 98:1 208:1 261:1 602:1 736:1 843:1 2691:1 3423:1 3520:1 4880:1 4904:1 4905:1 4925:1 5099:1 5361:1
1 	|BT| (S (NP (PRP We)) (VP (VBP provide) (NP (NN evidence) (NN HDACi) (NN treatment) (NN lead) (JJ potent) (JJ transcriptional) (NN repression) (NN TS) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 52:E02 86:D01.268.556.435 154:Z01.058.266.887 208:F01.393.821 209:G02.111.087.847|ES| 9:1 19:1 22:1 38:1 254:1 505:1 509:1 546:1 559:1 706:1 711:1 843:1
1 	|BT| (S (NP (PRP We)) (VP (VBP show) (ADVP (RB herein)) (NP (NN induction) (NP (NP (NN tumor) (NN suppressor) (NN gene) (JJ COOH-terminal) (NN Src) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN Csk)) (-RRB- -RRB-))) (NN NSAID) (JJ important) (JJ antiproliferative) (RB hence) (JJ chemopreventive) (NN effect)))) |ET| |BS|206:G05.360.340.024.340.375.249 469:D08.811.913.696 487:G05.355.315.800 624:D27.505.696.706.018 796:D27.505.696.663.850.014.040.500|ES| 7:1 9:1 10:1 14:1 19:1 75:1 429:1 470:1 700:1 736:1 843:1 902:1 1736:1 1946:1 3120:1 3674:1 4230:1 4499:1 5362:1 5363:1
1 	|BT| (S (NP (PRP We)) (VP (VBP show) (SBAR (S (NP (JJ individual) (JJ homozygous) (JJ minor) (NN ODC) (NN A-allele)) (VP (VBD reported) (S (VP (VBG using) (NP (NN aspirin)) (NP (NP (QP (RB approximately) (CD 0.10)) (NN time)) (NP (NP (JJ likely) (NN adenoma) (NN recurrence) (JJ non-aspirin) (NN user)) (NP (JJ homozygous) (JJ major) (NN G-allele))))))))))) |ET| |BS|12:Z01.542.049 17:C04.557.470.035 30:Z01.058.290.190.800 31:D08.811.520.224.800 77:G05.360.340.024.340.030 322:G01.910 493:M01 496:C23.550.291.937 670:D02.455.426.559.389.657.410.595.176 1108:M01.416 1283:G05.380.554 1461:E05.318.740.600|ES| 19:1 42:1 350:1 429:1 462:1 843:1 993:1 1081:1 1328:1 1843:1 2487:1 2512:1 2697:1 3881:1 4564:1 5364:1 5365:1 5366:1 5367:1 5368:1 5369:1
1 	|BT| (S (NP (PRP We)) (VP (VBD showed) (SBAR (S (ADJP (RB previously) (JJ S-trans)) (, ,) (NP (NP (JJ trans-farnesylthiosalicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FTS)) (-RRB- -RRB-))) (VP (VBZ disrupts) (SBAR (S (NP (NN Ras) (NN membrane) (NN anchorage) (NN disturbance)) (VP (VBZ contributes) (NP (NN inhibition) (NN cell) (NN transformation) (NN tumor) (NN growth)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 45:G07.700.320.249 1344:A10.615|ES| 2:1 7:1 10:1 14:1 19:1 94:1 102:1 103:1 132:1 843:1 845:1 1275:1 1384:1 1527:1 1775:1 3622:1 4549:1 4551:1 5253:1 5370:1 5371:1 5372:1
1 	|BT| (NP (NP (NP (NN YGK)) (NP (ADVP (RB significantly)) (VBD repressed) (NP (NN E6/E7) (NN oncogene) (JJ transcriptional) (NN level)) (, ,) (NP (NP (JJ subsequent) (NN reactivation) (NN p53) (NN p21) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 9:G05.360.340.024.340.375.500 208:F01.393.821 209:G02.111.087.847|ES| 2:1 10:1 12:1 14:1 19:1 24:1 115:1 124:1 249:1 311:1 312:1 315:1 466:1 559:1 1135:1 1319:1 1913:1 5373:1 5374:1
-1 	|BT| (S (NP (JJ Other) (NN expression) (NN alteration)) (VP (VBN observed) (S (NP (JJ arsenic-treated) (JJ male) (NN mouse) (JJ newborn) (NN liver)) (VP (VBD included) (SBAR (S (NP (NP (NN overexpression) (NNS cdk-inhibitors) (NN stress) (NN response) (NN gene)) (PP (VBG including) (NP (VBN increased) (NN expression) (NN metallothionein-1)))) (VP (VBD decreased) (NP (NN expression) (NN betaine-homocysteine) (NN methyltransferase) (NN thioether) (NN S-methyltransferase))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 52:E02 242:A03.620 978:D08.811.913.696.620.682.700.646.500 1158:D01.268.513.249 1462:D08.811.913.555.500.175 1463:D08.811.913.555.500 1464:D01.248.497.158.874 1465:M01.060.703.520 1466:D12.776.556.670|ES| 9:1 19:1 47:1 52:1 115:1 152:1 202:1 261:1 494:1 561:1 836:1 951:1 1402:1 1528:1 2522:1 2655:1 5375:1 5376:1 5377:1 5378:1 5379:1 5380:1 5381:1 5382:1
-1 	|BT| (S (NP (DT A) (JJ recent) (NN study)) (VP (VBD revealed) (SBAR (S (NP (NP (JJ long-term) (NN exposure)) (ADJP (RB relatively) (JJ low-dose)) (NN DEHP) (PRN (-LRB- -LRB-) (NP (CD 0.05) (NN %)) (-RRB- -RRB-))) (VP (VBD caused) (NP (NP (NN liver) (NN tumor)) (PP (VBG including) (NP (NP (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (JJ hepatocellular) (NN adenoma)) (, ,) (NP (NP (NP (NP (ADJP (NP (JJ chologiocellular) (NN carcinoma)) (JJR higher)) (NN incidence) (NN Ppar) (JJ alpha-null) (NN mouse)) (PRN (-LRB- -LRB-) (NP (CD 25.8) (NN %)) (-RRB- -RRB-))) (NP (JJ wild-type) (NN mouse))) (PRN (-LRB- -LRB-) (NP (CD 10.0) (NN %)) (-RRB- -RRB-))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 104:C04.557.470.200.025.255 265:C04.557.470.200 434:E05.318.308.985.525.375 515:C04.588.274.623 536:D12.776.826.239.500 849:G08.686.785.760.769.490.500 911:D02.241.223.805.250 1194:C04.557.470.035.120|ES| 2:1 7:1 8:1 10:1 14:1 19:1 42:1 52:1 69:1 131:1 170:1 275:1 303:1 304:1 369:1 561:1 659:1 836:1 1511:1 1953:1 2506:1 3049:1 3205:1 3546:1 3849:1 3924:1 5383:1 5384:1 5385:1 5386:1 5387:1
-1 	|BT| (S (NP (NP (NN Activation) (JJ nonsteroidal) (JJ anti-inflammatory) (JJ drug-activated) (NN gene-1)) (PP (IN via) (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (CD 1/2) (JJ mitogen-activated) (NN protein) (NN kinase)))) (VP (VBD revealed) (NP (JJ isochaihulactone-triggered) (JJ apoptotic) (NN pathway) (NP (JJ human) (NN lung) (NN cancer) (NN A549) (NN cell))))) |ET| |BS|39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 264:G05.355.315.800 469:D08.811.913.696 477:D08.811.913.696.620.682.700.567.249 573:N05.715.350.200.650 796:D27.505.696.663.850.014.040.500|ES| 4:1 18:1 19:1 36:1 87:1 94:1 275:1 328:1 364:1 383:1 470:1 596:1 1707:1 1859:1 2223:1 2795:1 3046:1 3295:1 4812:1 4966:1 4978:1 5388:1
-1 	|BT| (S (S (S (ADVP (RB Additionally)) (, ,) (NP (NN co-treatment) (NN RV) (NN erlotinib)) (VP (VBD repressed) (NP (NP (NN expression) (JJ anti-apoptosis) (NN protein)) (, ,) (NP (NN survivin) (NN Mcl-1)))) (, ,)) (IN whereas) (NP (VBN promoted) (NN p53) (NN PUMA) (NN expression) (NN caspase) (CD 3) (NN activity)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 52:E02 906:D08.811.277.656.262.500.126.350.300 1042:Z01.107.757.284 1467:B01.050.150.900.649.147.354.630 1468:E01.370.386.700.485.750.275.650 1469:D12.644.360.075|ES| 2:1 4:1 12:1 19:1 115:1 372:1 399:1 466:1 862:1 1912:1 2229:1 2342:1 4068:1 4796:1 5312:1 5389:1 5390:1 5391:1 5392:1
-1 	|BT| (NP (NP (JJ Altered) (NN expression) (NN c-myc)) (, ,) (NP (NN p16) (NN p27) (NN rat) (NN colon) (NN tumor) (NN reversal) (JJ short-term) (NN treatment) (JJ chemopreventive) (NN agent))) |ET| |BS|51:C04.588.274.476.411.307.180 52:E02 203:G05.360.340.024.340.375.249.375 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 833:D27.505.696.706.018 849:G08.686.785.760.769.490.500|ES| 2:1 7:1 19:1 113:1 115:1 455:1 546:1 728:1 849:1 971:1 1124:1 1313:1 1946:1 3022:1 3770:1
-1 	|BT| (S (NP (NNP Assessment) (NN effect) (NN betaine) (NN p16) (NN c-myc) (NN DNA) (NN methylation) (NN mRNA) (NN expression) (NN chemical)) (VP (VBD induced) (NP (NN rat) (NN liver) (NN cancer) (NN model)))) |ET| |BS|111:D13.444.735.544 203:G05.360.340.024.340.375.249.375 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 366:G02.111.087.029.538.161 743:D02.092.877.883.077 838:E05.599.495|ES| 18:1 19:1 72:1 75:1 81:1 115:1 325:1 412:1 455:1 666:1 836:1 849:1 1313:1 2124:1 2636:1 5393:1
-1 	|BT| (NP (NP (DT Both) (NP (NNP BaA) (NNPS MeBaAs) (JJ similar) (NN effect) (NN expression) (NN cytochrome) (NN P450) (NN 1B1) (JJ aldo-keto) (NN reductase) (NN 1C9) (NN rat) (NN liver) (JJ epithelial) (NN WB-F344) (NN cell)))) |ET| |BS|75:A11.436 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 590:B01.050.050.199.520.760.200|ES| 19:1 75:1 94:1 96:1 115:1 127:1 332:1 836:1 849:1 2549:1 3276:1 3788:1 4678:1 5394:1 5395:1 5396:1 5397:1 5398:1
-1 	|BT| (S (NP (NNP CAPE) (CC plus) (NNP DEN)) (VP (VBD diminished) (NP (NP (NN expression) (NN cytochrome) (VBN involved) (NN DEN) (NN bioactivation) (NN CYP2B1)) (VP (ADVP (RB well)) (NP (NP (NN expression) (NN regulator) (JJ oxidative) (NN stress) (NN glutathione) (NN reductase)) (, ,) (NP (NN GST-kappa) (NN GST-theta)) (, ,) (NP (NN cell) (NN cycle) (NN regulator)) (NP (NN p53))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 7:D12.776 30:Z01.058.290.190.800 31:D08.811.520.224.800 155:G05.355.310 353:G04.299.134 716:G03.495.710 1470:D08.244.453.040.550 1471:D08.811.682.667.092 1472:D08.244|ES| 2:1 4:1 9:1 12:1 19:1 94:1 96:1 115:1 162:1 235:1 569:1 601:1 637:1 693:1 712:1 774:1 787:1 831:1 900:1 911:1 1719:1 1875:1 2332:1 2353:1 2522:1 2583:1 2744:1 3045:1 3146:1 3374:1 3788:1 4156:1 4350:1 4720:1 4888:1 5399:1 5400:1 5401:1 5402:1 5403:1 5404:1
-1 	|BT| (S (NP (NN Coexpression) (NN K-rasVal12) (NN TAgWt)) (VP (VBP produce) (NP (NN dysplasia)))) |ET| |BS||ES| 19:1 203:1 1565:1 5405:1 5406:1 5407:1
-1 	|BT| (S (NP (JJ Consistent) (NN finding) (, ,) (NN treatment) (NP (NP (NN protein) (NN kinase) (NN A)) (PRN (-LRB- -LRB-) (NP (NN PKA)) (-RRB- -RRB-))) (NN inhibitor)) (VP (VBD decreased) (NP (NN MMP2) (NN MMP9) (NN expression) (NN level) (JJ ADCY3-overexpressing) (NN cell)))) |ET| |BS|41:A11 52:E02 586:D08.811.277.656.300.480.205.360 1417:D08.811.277.656.300.480.205.352|ES| 2:1 4:1 10:1 14:1 19:1 69:1 94:1 115:1 202:1 249:1 380:1 470:1 546:1 927:1 3395:1 5408:1 5409:1 5410:1 5411:1
-1 	|BT| (S (NP (NN Curcumin)) (VP (VBZ sensitizes) (NP (NP (JJ human) (JJ colorectal) (NN cancer) (NN xenograft) (JJ nude) (NN mouse) (NN gamma-radiation)) (VP (VBG targeting) (NP (JJ nuclear) (JJ factor-kappaB-regulated) (NN gene) (NN product)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 816:G01.358.500.505.300 973:E05.393.335|ES| 9:1 17:1 18:1 19:1 36:1 52:1 265:1 266:1 616:1 675:1 1256:1 2062:1 3429:1 3430:1 3431:1
-1 	|BT| (S (NP (NN DEN) (NN treatment)) (VP (VP (VBD increased) (NP (NP (NN expression) (NN gene)) (VP (VBN associated) (NP (JJ oxidative) (NN stress) (NN glutathione) (NN reductase))))) (, ,) (NP (NP (NN gene) (VBN involved) (NN cell) (NN cycle) (NN regulation)) (PP (VBG including) (NP (NP (NN p53)) (, ,) (NP (VBN modified) (NN cytochrome) (NN P450))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 6:G05.360.340.024.340 52:E02 155:G05.355.310 716:G03.495.710 1079:D08.244.453 1259:G04.299.134.109 1471:D08.811.682.667.092|ES| 2:1 9:1 12:1 19:1 47:1 94:1 96:1 115:1 169:1 438:1 546:1 561:1 601:1 774:1 1875:1 2335:1 2522:1 2549:1 2583:1 2744:1 3788:1
-1 	|BT| (NP (NP (NP (NN DEN) (NN treatment) (VBN modified) (NN expression) (CD 665) (NN gene)) (, ,) (NP (NP (NN CAPE)) (CC plus) (NP (NN DEN))) (VP (VBD induced) (NP (NN change) (CD 1371) (NN gene))))) |ET| |BS|6:G05.360.340.024.340 52:E02 155:G05.355.310|ES| 2:1 9:1 19:1 115:1 200:1 412:1 546:1 1875:1 2332:1 2335:1 4888:1 5412:1 5413:1
-1 	|BT| (NP (NP (JJ Different) (NN mechanism) (JJ DEHP-induced) (JJ hepatocellular) (NN adenoma) (NN tumorigenesis) (JJ wild-type) (NN Ppar) (JJ alpha-null) (NN mouse))) |ET| |BS|29:B01.050.050.136.500.500 32:C04.697.098.500 33:C04.697.098 536:D12.776.826.239.500 911:D02.241.223.805.250 1194:C04.557.470.035.120|ES| 8:1 19:1 42:1 52:1 78:1 162:1 303:1 5384:1 5385:1 5414:1 5415:1
-1 	|BT| (S (NP (NP (NN DNA) (NN binding) (NN activity) (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-))) (VP (VBZ transactivates) (NP (NP (NP (NN miR-155) (NN gene)) (ADJP (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.002)))) (-RRB- -RRB-))) (JJ elevated) (NN liver) (JJ nuclear) (NN extract) (NN mouse)) (VBN fed) (NNP CDAA) (NN diet)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 198:D13.444.308 210:D12.776.260.600 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 1473:D20.777.351|ES| 9:1 10:1 14:1 19:1 52:1 124:1 185:1 311:1 399:1 581:1 666:1 714:1 756:1 763:1 836:1 1254:1 1256:1 1487:1 1911:1 2191:1 2426:1 2496:1 3184:1 3750:1 5066:1
-1 	|BT| (FRAG (NP (NP (NP (NP (RB Early) (NN detection)) (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LRB-) (JJ 4,5-b) (-RRB- -RRB-) (NN pyridine) (-LRB- -LRB-) (NN PhIP) (-RRB- -RRB-) (: -)) (VBN induced) (NN mutation)) (PP (IN within) (NP (NN Apc) (NN gene) (NN rat) (NN colon))))) |ET| |BS|18:G05.365.590 21:G05.360.340.024.340.375.249.050 46:A03.556.124.526.356 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 494:E01.390 744:D03.383.725|ES| 9:1 10:1 14:1 19:1 34:1 113:1 280:1 409:1 849:1 1023:1 2122:1 2638:1 2639:1 2640:1 2641:1 4135:1
-1 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN PhIP)) (VP (VBD appeared) (NP (NP (NP (JJ carcinogenic) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NN mouse) (JJ subtoxic) (NNS dos)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 279:D27.888.569.100|ES| 2:1 10:1 14:1 19:1 45:1 52:1 1929:1 2641:1 2653:1 3346:1 3836:1 5416:1 5417:1
-1 	|BT| (S (ADVP (RB Finally)) (, ,) (VP (VBP demonstrate) (NP (NP (JJ NSAID-mediated) (JJ nucleolar) (NN translocation) (NN RelA)) (VP (VBN associated) (NP (NP (NN downregulation) (JJ NF-kappaB-driven) (NN transcription) (NN NF-kappaB) (NN target) (NN gene)) (, ,) (NP (NN ICAM-1))))))) |ET| |BS|6:G05.360.340.024.340 66:F01.658.293 85:G02.111.087.225 209:G02.111.087.847 210:D12.776.260.600 463:C23.550.210.870 796:D27.505.696.663.850.014.040.500 1325:D12.776.395.550.200.450|ES| 2:1 9:1 19:1 160:1 169:1 250:1 487:1 502:1 595:1 714:1 1618:1 1929:1 4732:1 5418:1 5419:1 5420:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ stress-associated) (NN hormone)) (, ,) (NP (NN isoproterenol)) (, ,)) (VP (MD could) (VP (VP (VB increase) (NP (NN expression) (NN level) (`` ``) (NN stem) ('' ''))) (: -) (S (NP (NP (JJ related) (NN protein)) (, ,) (NP (NN CD44)) (, ,) (NP (NNP Nanog)) (, ,) (NP (NN Rex-1)) (, ,)) (VP (VBP induce) (NP (NN chemoresistance) (JJ gastric) (NN cancer) (NN cell))))))) |ET| |BS|7:D12.776 41:A11 161:D06.472 309:A18.024.937 1474:D02.033.100.291.439|ES| 2:1 4:1 18:1 19:1 40:1 86:1 94:1 115:1 182:1 243:1 249:1 334:1 542:1 908:1 1106:1 1282:1 1581:1 3268:1 3269:1 5421:1 5422:1 5423:1 5424:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN UDCA)) (VP (VBD inhibited) (NP (NP (NN Cox-2) (NN induction) (JJ Ras-dependent)) (: -) (NP (JJ independent) (NN mechanism))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 122:C14.280.383 737:D04.808.105.225.272.962|ES| 2:1 19:1 62:1 162:1 334:1 365:1 736:1 2631:1 5425:1 5426:1
-1 	|BT| (NP (NP (NP (JJ Genotype-phenotype) (NN correlation) (JJ murine) (NN Apc) (NN mutation)) (: :) (NP (NN difference) (NN enterocyte) (NN migration) (NN response) (NN sulindac)))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 251:D02.455.426.559.847.486.875 1475:A03.556.124.369.290 1476:E05.393.385|ES| 19:1 34:1 104:1 280:1 494:1 514:1 627:1 869:1 1674:1 3544:1 5427:1 5428:1
-1 	|BT| (S (NP (NN Hesperidin) (NN treatment)) (VP (VBD caused) (SBAR (S (NP (JJ significant) (NP (NP (NN up-regulation) (NN tumour) (NN suppressor) (NN phosphatase) (NN tensin) (NN homologue)) (PRN (-LRB- -LRB-) (NP (NN PTEN)) (-RRB- -RRB-))) (NN reduction) (NN expression) (NNP AOM)) (VP (VBD mediated) (NP (NN p-PI3K) (NN p-Akt))))))) |ET| |BS|52:E02 132:D02.172.080 142:I01.880.604 206:G05.360.340.024.340.375.249 378:D08.811.913.696.620.682.700.755 1035:D08.811.277.352.650 1290:D08.811.913.696.620.500 1477:D03.383.663.283.266.450.252.500|ES| 10:1 14:1 19:1 115:1 135:1 226:1 370:1 437:1 546:1 700:1 896:1 1011:1 1936:1 1994:1 2506:1 3619:1 3620:1 5429:1 5430:1 5431:1
-1 	|BT| (S (NP (NP (ADJP (RB Highly) (JJ metastatic)) (JJ hepatocellular) (NN carcinoma)) (VP (VBD induced) (NP (NP (JJ male) (NN F344) (NN rat)) (NP (VBN treated) (NN N-nitrosomorpholine) (NN combination) (NNS hepatocarcinogens))))) (VP (VBP show) (NP (JJ high) (NN incidence) (NN p53) (NN gene) (NN mutation)) (PP (IN along) (NP (JJ altered) (NN mRNA) (NN expression) (JJ tumor-related) (NN gene))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 18:G05.365.590 52:E02 104:C04.557.470.200.025.255 111:D13.444.735.544 149:G05.360.340.024.340.364.875.890 155:G05.355.310 434:E05.318.308.985.525.375 590:B01.050.050.199.520.760.200|ES| 9:1 12:1 19:1 34:1 115:1 178:1 303:1 304:1 325:1 337:1 412:1 429:1 530:1 693:1 849:1 1099:1 1402:1 1511:1 2666:1 2705:1 3185:1 3989:1 5432:1 5433:1
-1 	|BT| (NP (NP (NP (NP (NN Histogenesis) (NN role) (NN p53) (NN K-ras) (NN mutation) (NN hepatocarcinogenesis) (NN glyceryl) (NN trinitrate)) (PRN (-LRB- -LRB-) (NP (NN nitroglycerin)) (-RRB- -RRB-))) (JJ male) (NN F344) (NN rat))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 15:F01.829.316.616 18:G05.365.590 590:B01.050.050.199.520.760.200 1478:D02.033.800.421.560|ES| 10:1 12:1 14:1 19:1 31:1 34:1 849:1 900:1 1121:1 1402:1 3185:1 5434:1 5435:1 5436:1 5437:1
-1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN IBN-65)) (VP (VP (VBD induced) (NP (NP (NN apoptosis)) (NP (JJ down-regulating) (NNP Survivin)))) (, ,) (NP (NP (NN Bcl-2) (VBG up-regulating) (NN Bax)) (, ,) (VP (VBG leading) (NP (JJ sequential) (NN activation) (NN Caspase-3))) (, ,) (NP (NP (NN Caspase-9) (NN cleavage) (NN poly) (-LRB- -LRB-) (NN ADP-ribose) (-RRB- -RRB-) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NN PARP)) (-RRB- -RRB-)))))) |ET| |BS|39:G04.299.139.160 54:G05.360.340.024.340.375.500.791.150 86:D01.268.556.435 150:Z01.542.248.960 342:D12.644.360.075.718.400 351:A17.360 906:D08.811.277.656.262.500.126.350.300 1248:D08.811.913.400.725.115.690 1349:D08.811.277.656.262.500.126.550.900 1440:G04.299.134.220.250|ES| 2:1 10:1 14:1 19:1 89:1 158:1 225:1 244:1 394:1 412:1 468:1 639:1 1876:1 3097:1 3190:1 3779:1 4630:1 4810:1 4811:1 5247:1 5438:1 5439:1 5440:1 5441:1
-1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN metformin)) (VP (VBD induced) (NP (NP (NN apoptosis) (NN OSCC) (NN cell)) (, ,) (VP (ADVP (RB significantly)) (VBG down-regulating) (NP (NP (JJ anti-apoptotic) (NN protein) (NN Bcl-2) (NN Bcl-xL)) (VP (VBG up-regulating) (NP (JJ pro-apoptotic) (NN protein) (NN Bax)))))))) |ET| |BS|39:G04.299.139.160 41:A11 54:G05.360.340.024.340.375.500.791.150 150:Z01.542.248.960 342:D12.644.360.075.718.400 351:A17.360 784:D02.078.370.141.450 1469:D12.644.360.075|ES| 2:1 4:1 19:1 89:1 94:1 124:1 158:1 244:1 412:1 468:1 1876:1 3097:1 4630:1 4814:1 5087:1 5230:1 5232:1 5442:1
-1 	|BT| (S (PP (IN In) (NP (NN HT-29) (NN cell))) (, ,) (NP (NN pterostilbene)) (VP (VBD reduced) (SBAR (S (NP (NP (NN protein) (NN level) (NN beta-catenin)) (, ,) (NP (NN cyclin) (NN D1) (NN c-MYC)) (, ,) (NP (JJ altered) (JJ cellular) (NN localization) (NN beta-catenin))) (VP (VBD inhibited) (NP (NN phosphorylation) (NN p65))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 41:A11 122:C14.280.383 215:D12.644.360.262.150.100 792:A11.251.210.190.475 972:G02.111.087.677|ES| 2:1 4:1 19:1 60:1 94:1 244:1 249:1 365:1 452:1 625:1 693:1 743:1 744:1 2428:1 2484:1 2782:1 3074:1 3426:1 5016:1
-1 	|BT| (S (PP (IN In) (NP (NN HT-29) (NN cell))) (, ,) (NP (NN pterostilbene)) (VP (VBD reduced) (SBAR (S (NP (NP (NN protein) (NN level) (NN beta-catenin)) (, ,) (NP (NN cyclin) (NN D1) (NN c-MYC)) (, ,) (NP (JJ altered) (JJ cellular) (NN localization) (NN beta-catenin))) (VP (VBD inhibited) (NP (NN phosphorylation) (NN p65))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 41:A11 46:A03.556.124.526.356 122:C14.280.383 158:D23.101 183:G04.299.233.750 215:D12.644.360.262.150.100 792:A11.251.210.190.475 972:G02.111.087.677|ES| 2:1 4:1 18:1 19:1 60:1 78:1 94:1 113:1 159:1 216:1 244:1 249:1 299:1 365:1 378:1 452:1 534:1 625:1 658:1 693:1 743:1 744:1 787:1 793:1 796:1 827:1 1474:1 1659:1 2250:1 2428:1 2430:1 2484:1 2782:1 3074:1 3426:1 5016:1
-1 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (VBN shown) (JJ first) (NN time) (NN UDCA)) (VP (VBD suppressed) (SBAR (S (NP (NN development) (NN tumor) (NN Ras) (NN mutation)) (VP (VBD blocked) (NP (NN activation) (NNP WT) (NN Ras))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 322:G01.910 737:D04.808.105.225.272.962|ES| 2:1 7:1 19:1 34:1 35:1 225:1 237:1 244:1 307:1 490:1 816:1 1081:1 1775:1 1995:1 2631:1 2777:1
-1 	|BT| (FRAG (PP (IN In) (NP (NP (NNP AOM)) (ADVP (RB alone)))) (NP (NP (NN group)) (, ,) (NP (NN Cox-2)) (VP (VBD up-regulated) (SBAR (S (NP (ADJP (JJR >) (JJ 50-fold)) (NN tumor) (JJ normal) (NP (NN Ras)) (NN activity)) (VP (VBD enhanced) (NP (NN tumor) (JJ mutant) (JJ signaling-activated) (NN Ras)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 69:G02.111.087.800 132:D02.172.080 142:I01.880.604 150:Z01.542.248.960 829:M01.686|ES| 2:1 7:1 19:1 62:1 118:1 241:1 244:1 385:1 399:1 811:1 1301:1 1466:1 1775:1 1994:1 2300:1 5443:1 5444:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN study))) (, ,) (NP (VBN examined) (NN role) (NN Ras) (NN Cox-2) (NN inhibition) (NN UDCA))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 15:F01.829.316.616 43:F01.145.544 737:D04.808.105.225.272.962|ES| 2:1 19:1 31:1 62:1 103:1 131:1 244:1 324:1 1775:1 2631:1
-1 	|BT| (S (NP (NN Induction) (NN apoptosis) (NN pectenotoxin-2)) (VP (VBD mediated) (NP (NP (NP (NN induction) (NN DR4/DR5)) (, ,) (NP (NN Egr-1) (NN NAG-1))) (, ,) (NP (NN activation) (NN caspase) (NN modulation) (NN Bcl-2) (NN family) (JJ p53-deficient) (NN Hep3B) (JJ hepatocellular) (NN carcinoma) (NN cell))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 44:F01.829.263 54:G05.360.340.024.340.375.500.791.150 104:C04.557.470.200.025.255 580:D12.776.260.158.500 1367:D08.811.277.656.262.500.126|ES| 2:1 19:1 89:1 94:1 97:1 158:1 225:1 303:1 304:1 437:1 736:1 1662:1 1945:1 2020:1 4498:1 4502:1 4561:1 4796:1 5236:1 5445:1
-1 	|BT| (S (NP (NN Induction) (NN SPARC)) (VP (VBD demonstrated) (NP (NN treatment) (JJ demethylating) (NN agent) (NN 5Aza-dC) (CD 5) (CD 7) (NN cell) (NN line)))) |ET| |BS|37:D12.776.157.125.715 94:A11.251.210 775:E02.760.058|ES| 19:1 82:1 94:1 264:1 546:1 578:1 728:1 988:1 1175:1 2020:1 5446:1 5447:1
-1 	|BT| (S (NP (NN IR-5) (NN bear) (JJ novel) (NN point) (NN mutation) (NN HER2/neu)) (VP (VP (VBZ corresponds) (SBAR (S (NP (NN L726I) (JJ ATP-binding) (NN pocket)) (VP (VBP correlate) (NP (NN log) (NN decrease) (NN sensitivity) (NN gefitinib)))))) (, ,) (NP (NP (VBD increased) (NN heterodimerization) (NN EGFR) (NN HER3)) (, ,) (NP (JJ impaired) (NN down-regulation))))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 85:G02.111.087.225 259:D12.776.395.240.150.500 438:G05.365.590.675 455:B01.050.150.900.649.147.890 1064:Z01.252.245.500.350 1065:D01.268.556.401|ES| 2:1 19:1 34:1 47:1 187:1 257:1 295:1 607:1 891:1 901:1 1740:1 2003:1 2121:1 3310:1 3505:1 4281:1 4955:1 4956:1 4957:1 4958:1 4959:1 4960:1 4961:1
-1 	|BT| (S (S (S (NP (NN Levamisole)) (VP (VBD increased) (NP (NNS ECs) (JJ integrin-dependent) (NN matrix) (NN adhesion)))) (PRN (, ,) (VP (VBD inhibited) (NP (NP (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (CD -70) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN reduced) (NN expression) (NN survival) (NN factor) (NN clusterin)) (PRN (-LRB- -LRB-) (NP (CD -30) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NN endothelin-1) (PRN (-LRB- -LRB-) (NP (CD -43) (NN %)) (-RRB- -RRB-)))) (, ,) (NP (NN bcl-2) (PRN (-LRB- -LRB-) (NP (CD -34) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ endothelial) (NN NO-synthase)) (PRN (-LRB- -LRB-) (NP (CD -32) (NN %)) (-RRB- -RRB-))) (NP (NN pRb) (-LRB- -LRB-) (NN Retinoblastoma) (NN protein) (: :))) (NP (CD -89) (NN %))) (-RRB- -RRB-) (, ,)) (NP (NP (NP (NP (VBN increased) (NN growth) (NN arrest/death) (NN signal) (NN p21)) (PRN (-LRB- -LRB-) (NP (CD +73) (NN %)) (-RRB- -RRB-))) (NN bak)) (PRN (-LRB- -LRB-) (NP (CD +50) (NN %)) (-RRB- -RRB-))))) |ET| |BS|45:G07.700.320.249 54:G05.360.340.024.340.375.500.791.150 96:I03.784 122:C14.280.383 135:C23.550.260 871:D02.886.675.346 920:D12.776.543.750.705.408 1479:D12.776.260.704 1480:D08.811.682.664.500.772.750 1481:D12.644.276.400.225 1482:C23.550.355.274.840 1483:D12.776.395.207 1484:F04.570.200.583|ES| 2:1 4:1 10:1 14:1 19:1 47:1 102:1 104:1 115:1 151:1 185:1 274:1 299:1 365:1 369:1 452:1 753:1 859:1 1135:1 3088:1 3092:1 3093:1 3491:1 5448:1 5449:1 5450:1 5451:1 5452:1 5453:1 5454:1 5455:1 5456:1 5457:1 5458:1 5459:1 5460:1 5461:1 5462:1 5463:1
-1 	|BT| (S (NP (JJ Long-term) (JJ pharmacological) (NN MAP) (NN kinase) (NN inhibition) (NN MEK) (NN inhibitor) (NN PD98059)) (VP (VBD induced) (NP (NP (NN expression) (JJ terminal) (NN differentiation) (NN marker) (NN ITF)) (, ,) (NP (NN sucrase-isomaltase)) (, ,) (NP (NN mucin) (NN gene) (NN MUC2))))) |ET| |BS|6:G05.360.340.024.340 43:F01.145.544 71:D12.776.395.560.631 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565 478:D08.811.913.696.620.682.700.567 849:G08.686.785.760.769.490.500 1045:D23.050.301.264 1059:H01.158.703 1485:D08.811.277.450.770 1486:V01.185.687|ES| 2:1 9:1 19:1 103:1 115:1 209:1 212:1 215:1 380:1 412:1 470:1 534:1 3707:1 4968:1 5110:1 5464:1 5465:1 5466:1 5467:1 5468:1
-1 	|BT| (S (NP (NNS METHODS) (: :)) (PP (IN In) (NP (NN study))) (VP (VBD used) (NP (NP (NN p53)) (VP (VBN mutated) (VP (VB knock) (S (NP (NP (NN colon) (NN cancer) (NN cell) (NN xenograft) (NN tumour) (NN study)) (NN role) (NN p53) (NN apoptosis)) (VP (VBD mediated) (NP (NNS diaminothiazoles))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 41:A11 92:E04.936.764 93:A01.941.875 168:E05.581|ES| 12:1 18:1 19:1 31:1 89:1 94:1 104:1 113:1 131:1 229:1 244:1 265:1 437:1 476:1 565:1 1011:1 5469:1 5470:1
-1 	|BT| (S (NP (NN MicroRNA-122)) (VP (VBZ inhibits) (SBAR (S (NP (JJ tumorigenic) (NN property) (JJ hepatocellular) (NN carcinoma) (NN cell)) (VP (VBZ sensitizes) (NP (NN cell) (NN sorafenib))))))) |ET| |BS|41:A11 104:C04.557.470.200.025.255 122:C14.280.383 184:D13.150.650.319 575:V02.050|ES| 19:1 94:1 303:1 304:1 615:1 841:1 1797:1 1809:1 2062:1 2063:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN inhibition) (NN autophagy) (NN sensitization) (NN cisplatin) (NN NAC1) (NN knockdown) (NN inactivation)) (VP (VBN accompanied) (NP (NN induction) (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 390:G04.299.139.399 498:D01.210.375|ES| 2:1 19:1 89:1 103:1 464:1 622:1 736:1 1314:1 1317:1 1761:1 2137:1 2801:1 5471:1
-1 	|BT| (NP (NP (NP (NN Mutation) (NN analysis) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NP (NN mouse) (VBG carrying) (NN lacZ) (NN reporter) (NN gene)) (, ,) (S (VP (VBD indicated) (SBAR (S (NP (VBN observed) (NN toxicity) (NN PhIP)) (VP (MD might) (VP (VBD caused) (NP (JJ genotoxic) (NN effect) (JJ small) (NN intestine)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 100:G05.360.340.024.686.545 218:A03.556.124.684 247:G01.374.676.530|ES| 2:1 9:1 10:1 14:1 19:1 45:1 52:1 75:1 261:1 288:1 356:1 641:1 661:1 750:1 798:1 850:1 1541:1 2406:1 2506:1 2641:1 3329:1 5416:1 5472:1
-1 	|BT| (S (NNS Mutations) (NP (NN codon) (NP (CD 13) (CD 117) (CC plus) (NP (JJ second) (NN exon) (NN insert)))) (VP (VBD contributed) (NP (CD 4) (NN %)) (NP (JJ total) (JJ H-ras) (NN frequency) (NN trichloroethylene) (NN tetrachloroethylene)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 113:C04.697.650 179:D01.248.497.300.459.700 335:D13.444.735.544.355 372:G05.360.340.024.340.137.232 1235:D02.455.526.439.939 1236:D02.455.526.439.880|ES| 19:1 319:1 369:1 1119:1 1247:1 1255:1 1410:1 1532:1 2347:1 3132:1 4416:1 4888:1 5473:1 5474:1 5475:1 5476:1 5477:1
-1 	|BT| (S (NP (NNP Nestin) (NN silencing)) (VP (ADVP (RB also)) (VP (VBD upregulated) (NP (NP (NN Axin) (, ,) (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (, ,)) (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN PPARa)) (-RRB- -RRB-))))) (, ,) (VP (VBD downregulated) (NP (NP (NN beta-catenin)) (, ,) (NP (NN c-Myc)) (, ,) (NP (NP (NN cyclin) (NN D)) (NN MMP-7) (NN expression) (NNP CSC)))))) |ET| |BS|3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 536:D12.776.826.239.500 556:C11.768.175 937:D08.811.277.656.300.480.525.700.250 1046:D12.644.360.262.150 1047:D05.750.078.593.540|ES| 2:1 5:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 60:1 66:1 92:1 100:1 115:1 125:1 186:1 426:1 743:1 824:1 1801:1 1836:1 1887:1 1972:1 2592:1 3577:1 3650:1 3651:1 3652:1 3653:1 3654:1 3655:1
-1 	|BT| (S (ADVP (RB Notably)) (, ,) (NP (NN AcEGCG)) (VP (VP (VBD inhibited) (NP (NP (NN expression) (NN p53) (, ,) (NN p21) (, ,) (NN c-Myc) (, ,) (NN cyclin) (NN B)) (, ,) (NP (NN p-CDK1) (NN Cdc25A))) (ADVP (RB also)) (VP (VBD restored) (NP (NN activation) (NP (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (CD 1/2)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2)) (-RRB- -RRB-)))))) (, ,) (VP (VBD decreased) (NP (JJ DMBA/TPA-induced) (NN increase) (NN tumor) (NN proliferation) (JJ mitotic) (NN index))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 116:D08.811.913.696.620.682.700.567.249.750 122:C14.280.383 212:E01.370.225.500.385.500 1487:D08.811.913.696.620.682.700.646.500.500.250 1488:D02.455.426.559.847.149.301 1489:D08.811.277.656.300.760.875 1490:D12.644.360.262.120|ES| 2:1 5:1 7:1 10:1 12:1 14:1 19:1 40:1 115:1 202:1 225:1 299:1 365:1 470:1 720:1 721:1 743:1 763:1 824:1 1135:1 1707:1 2798:1 4594:1 4812:1 4893:1 4966:1 5478:1 5479:1 5480:1 5481:1
-1 	|BT| (S (NP (NN OBJECTIVE) (: :)) (NP (NN FBXW7)) (VP (VBZ encodes) (NP (SBAR (S (NP (JJ substrate) (NN recognition) (NN component) (NN ubiquitin) (NN ligase)) (VP (VBZ degrades) (NP (NN target) (NN Notch1))))) (, ,) (NP (NN c-Jun)) (, ,) (NP (NN c-Myc) (NN cyclin) (NN E))))) |ET| |BS|415:F01.658.500 1458:D12.644.360.262.180 1491:F02.463.425.540.706 1492:D12.776.947.500 1493:D08.811.464|ES| 2:1 19:1 104:1 160:1 651:1 743:1 824:1 1021:1 1417:1 1686:1 2085:1 2211:1 3470:1 3757:1 5127:1 5482:1 5483:1 5484:1
-1 	|BT| (S (SBAR (IN Of) (S (NP (CD two) (NN gene)) (VP (VBP encode) (NP (NP (NN methionine) (NN adenosyltransferase)) (PRN (-LRB- -LRB-) (NP (NN MAT1Aand) (NN MAT2A)) (-RRB- -RRB-)))))) (, ,) (NP (NN MAT1A)) (ADVP (RB mainly)) (VP (VBD expressed) (NP (JJ adult) (NN liver)) (SBAR (IN whereas) (S (NP (NN MAT2A)) (VP (VBD expressed) (NP (JJ extrahepatic) (NN tissue))))))) |ET| |BS|6:G05.360.340.024.340 98:A10 119:M01.060.116 242:A03.620 574:D08.811.913.225.650|ES| 2:1 6:1 9:1 10:1 14:1 19:1 272:1 355:1 372:1 836:1 933:1 1429:1 1792:1 2050:1 2051:1 5485:1 5486:1 5487:1 5488:1 5489:1
-1 	|BT| (S (NP (RB Only) (NN 10-MeBaA)) (VP (VBD induced) (S (NP (NP (NN apoptosis) (NN accumulation)) (VP (VBN phosphorylated) (S (NP (NN p53))))) (, ,) (VP (MD could) (NP (NP (VBN associated) (NN induction) (JJ oxidative) (NN stress)) (, ,) (NP (JJ similar) (NN DMBA))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 716:G03.495.710 1488:D02.455.426.559.847.149.301|ES| 2:1 12:1 19:1 89:1 169:1 332:1 412:1 736:1 908:1 2120:1 2522:1 2583:1 4930:1 5490:1 5491:1 5492:1
-1 	|BT| (S (NP (PRP$ Our) (NN model)) (VP (VBZ predicts) (NP (NP (NP (NN 5FU) (NN sensitivity) (NN tumor)) (VP (VBN modified) (S (NP (NN aneuploidy)) (VP (VBG producing) (NP (NN copy) (NN number) (NN change) (NN TS) (NN allele) (CD one) (NN following)))))) (: :) (NP (NP (NN LOH)) (, ,) (NP (NN amplification)) (, ,) (, ,) (NP (VBN presented) (, ,) (NP (NN copy) (NN number) (NN change) (JJ due) (NN polysomy))))))) |ET| |BS|8:C04 77:G05.360.340.024.340.030 154:Z01.058.266.887 290:G05.365.590.029.530 560:D03.383.742.698.875.404 1494:C23.550.210.050|ES| 2:1 7:1 19:1 72:1 104:1 200:1 230:1 509:1 607:1 646:1 658:1 921:1 963:1 1004:1 1010:1 1751:1 2335:1 2851:1 3510:1 5493:1 5494:1 5495:1 5496:1 5497:1
-1 	|BT| (S (NP (PRP$ Our) (NN study)) (ADVP (RB also)) (VP (VBP demonstrate) (NP (VBN utilized) (NN DEN/PB) (NN protocol) (NNP WT) (NN C57BL/6) (NN mouse) (JJ select) (NN beta-catenin) (NN gene) (NN mutation) (NN hepatocarcinogenesis)))) |ET| |BS|18:G05.365.590 23:D12.776.091.249 593:B01.050.050.199.520.520.420|ES| 5:1 9:1 19:1 34:1 52:1 60:1 131:1 502:1 658:1 900:1 1182:1 1995:1 2192:1 3216:1 4183:1 5498:1
-1 	|BT| (S (NP (NN Panobinostat) (NN treatment)) (VP (VBD induced) (NP (NP (NP (NN downregulation) (NN EGFR)) (, ,) (NP (NN HER2)) (, ,)) (NN HER3) (ADJP (NN mRNA) (NN protein) (JJ transcriptional) (JJ posttranslational)) (NN mechanism)))) |ET| |BS|7:D12.776 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 85:G02.111.087.225 111:D13.444.735.544 209:G02.111.087.847|ES| 2:1 4:1 19:1 162:1 187:1 188:1 325:1 412:1 546:1 559:1 595:1 4961:1 5499:1 5500:1
-1 	|BT| (FRAG (NP (NP (NP (NN PhIP) (NN diet)) (NP (ADJP (JJR >) (ADJP (CD 43) (NN week))) (NP (JJ present) (NN colon) (NN tumor) (JJ specific) (CD -1) (NN G) (NN mutation)))) (PP (IN within) (NP (QP (CD 5) ('' ')) (: -) (NN GGGA-3) ('' ') (NN sequence) (NN APC))) (: :)) (NP (NN gene))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 18:G05.365.590 26:G02.111.570.080 51:C04.588.274.476.411.307.180 595:G07.203.650.240 596:E02.642.249|ES| 7:1 9:1 11:1 19:1 34:1 104:1 113:1 293:1 540:1 783:1 1307:1 1466:1 1489:1 2122:1 2191:1 2641:1 5501:1 5502:1 5503:1
-1 	|BT| (S (NP (NN Ras) (NN transformation)) (VP (VP (VBZ requires) (NP (NN Ras) (NN membrane) (NN anchorage))) (, ,) (VP (VBD promoted) (NP (NN farnesylcysteine) (NN carboxymethyl) (NN ester) (JJ additional) (NN sequence) (JJ specific) (NN Ras) (NN isoform))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 26:G02.111.570.080 238:D12.776.800 1344:A10.615 1495:D02.241.400|ES| 2:1 19:1 293:1 540:1 980:1 1384:1 1775:1 1912:1 2226:1 2331:1 3622:1 5371:1 5504:1 5505:1 5506:1
-1 	|BT| (FRAG (ADJP (NN Reentry) (JJ dependent)) (SBAR (IN upon) (S (NP (NN ability) (NN TAg)) (VP (VBP bind) (S (NP (NN pRB)) (VP (VBN associated) (NP (JJ p53-independent) (NN apoptosis)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 385:F02.784.629.131 1479:D12.776.260.704|ES| 19:1 89:1 169:1 321:1 1300:1 1951:1 4857:1 5507:1 5508:1 5509:1 5510:1
-1 	|BT| (S (NP (NN RT-PCR) (NN Western) (NN blot) (NN assay)) (NP (VBN detected) (NN expression) (VBN known) (NN target) (NN miR-372) (JJ malignant) (NN tumor)) (VP (VBD found) (SBAR (S (NP (NP (NN Cyclin) (NN A1) (JJ Cyclin-dependent) (NN Kinase) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN CDK2)) (-RRB- -RRB-))) (VP (VBD downregulated) (NP (NN miR-372))))))) |ET| |BS|255:E05.196.401.143 272:E05.393.620.500.725 1365:D08.811.913.696.620.682.700.646.500.750 1496:D12.644.360.262.100.100|ES| 7:1 10:1 14:1 19:1 37:1 115:1 148:1 160:1 310:1 426:1 556:1 802:1 872:1 873:1 1007:1 1148:1 1543:1 2984:1 2992:1 4742:1 5511:1 5512:1
-1 	|BT| (S (NP (NN SAHA)) (VP (VBD mediated) (NP (NP (NN acetylation) (NN histone) (NN H3)) (ADVP (RB globally))) (, ,) (ADVP (RB well)) (, ,) (S (VP (VBN associated) (NP (NP (NP (NN p21)) (PRN (-LRB- -LRB-) (NP (NN WAF1)) (-RRB- -RRB-))) (NN promoter)))) (, ,) (NP (VBN measured) (NN chromatin) (NN immunoprecipitation)))) |ET| |BS|228:E05.978 1416:D12.776.660.470 1454:E05.393.170 1497:G02.111.087.019.052|ES| 2:1 10:1 14:1 19:1 83:1 169:1 437:1 503:1 787:1 789:1 1135:1 1346:1 4915:1 5145:1 5341:1 5513:1 5514:1 5515:1
-1 	|BT| (S (NP (NNP Saracatinib)) (VP (VBD enhanced) (NP (NP (NN effect) (NN lapatinib) (, ,) (NN EGFR/HER2) (JJ dual) (NN inhibitor)) (, ,) (NP (NN SNU216) (NN NCI-N87) (NN cell))))) |ET| |BS|41:A11 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 120:I01.409.418.750.600.480.150|ES| 2:1 19:1 75:1 94:1 380:1 385:1 2067:1 3347:1 5243:1 5516:1 5517:1 5518:1
-1 	|BT| (S (NP (JJ Short) (JJ G-rich) (JJ repetitive) (NN sequence)) (ADVP (RB previously)) (VBN identified) (NP (NNS hot-spots) (NN frameshift) (NN mutagenesis)) (VP (VBD induced) (NP (NP (JJ large) (NN variety) (NN carcinogen)) (VP (VBG belonging) (NP (JJ several) (NN family) (JJ widespread) (JJ environmental) (NN pollutant)))))) |ET| |BS|44:F01.829.263 279:D27.888.569.100 287:G05.365.590.265 612:G02.111.570.080.708 1359:G05.355.600 1498:G01.906.595.543 1499:D27.888.284 1500:C17.800.257|ES| 19:1 97:1 262:1 293:1 412:1 623:1 952:1 1527:1 2125:1 2264:1 3446:1 4073:1 4864:1 5519:1 5520:1 5521:1 5522:1 5523:1 5524:1 5525:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NN DEHP)) (VP (MD may) (VP (VB induce) (SBAR (S (NP (NP (JJ hepatocellular) (NN adenoma)) (, ,) (NP (NN part)) (, ,) (SBAR (IN via) (S (NP (NN suppression) (NN G2/M) (NN arrest)) (VP (VBN regulated) (NP (NN Gadd45a) (NN caspase) (JJ 3-dependent) (NN apoptosis) (NN Ppar) (JJ alpha-null) (NN mouse))))) (, ,) (NP (NN gene))) (VP (MD may) (NP (VBN involved) (NN tumorigenesis) (JJ wild-type) (NN mouse)))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 142:I01.880.604 536:D12.776.826.239.500 906:D08.811.277.656.262.500.126.350.300 911:D02.241.223.805.250 1194:C04.557.470.035.120|ES| 2:1 8:1 9:1 19:1 42:1 52:1 78:1 89:1 243:1 303:1 451:1 491:1 596:1 602:1 774:1 1537:1 1538:1 1664:1 2453:1 2528:1 3205:1 4796:1 5384:1 5385:1 5526:1 5527:1
-1 	|BT| (FRAG (NP (NP (DT The) (JJ chemopreventive) (NN effect)) (NP (NP (NNP Protandim)) (: :) (NP (NN modulation) (NN p53) (JJ mitochondrial) (NN translocation) (NN apoptosis) (NN skin) (NN carcinogenesis))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 33:C04.697.098 39:G04.299.139.160 463:C23.550.210.870 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 624:D27.505.696.706.018 785:A17.815|ES| 12:1 19:1 75:1 89:1 104:1 207:1 691:1 1618:1 1945:1 1946:1 2004:1 2319:1 5088:1
-1 	|BT| (NP (NP (NP (DT The) (ADJP (RB classically) (VBN recognized)) (NN target) (NN NSAID) (NN action)) (NP (NP (CD two) (NNS isoforms) (NP (NP (NN cyclooxygenase)) (PRN (-LRB- -LRB-) (NP (NN COX)) (-RRB- -RRB-))) (NN gene)) (, ,) (NP (JJ responsible) (NN prostaglandin) (NN production))))) |ET| |BS|6:G05.360.340.024.340 238:D12.776.800 796:D27.505.696.663.850.014.040.500 1119:D08.811.600.720.500 1501:D08.811.600.720 1502:D10.251.355.255.550|ES| 2:1 9:1 10:1 14:1 19:1 160:1 691:1 821:1 933:1 2013:1 2084:1 2132:1 2677:1 3180:1 3181:1 3237:1 4499:1 5528:1
-1 	|BT| (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NP (NN TS) (NN copy) (NN number) (NN patient) (POS 's)) (NN tumor)) (VP (MD may) (VP (VBG dominating) (PP (JJ variable) (S (VP (VBG affecting) (NP (NN 5FU) (NN responsiveness))))))))))) |ET| |BS|8:C04 50:M01.643 154:Z01.058.266.887 560:D03.383.742.698.875.404|ES| 7:1 19:1 120:1 461:1 491:1 509:1 646:1 691:1 793:1 796:1 963:1 2530:1 3864:1 5493:1 5529:1 5530:1
-1 	|BT| (S (NP (NP (DT The) (JJ dysplastic) (NN epithelium) (NN K-rasVal12)) (CC x) (NP (NN TAgWt) (NN mouse))) (VP (VBP develop) (NP (NN neoplasm)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 62:A10.272|ES| 19:1 52:1 173:1 648:1 691:1 1523:1 5406:1 5407:1 5531:1 5532:1
-1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
-1 	|BT| (NP (NP (NP (DT The) (JJ H-ras) (NN codon) (CD 61) (NN mutation) (NN frequency) (JJ tetrachloroethylene-induced) (NN tumor)) (NP (NP (ADJP (RB significantly) (JJR lower) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))) (JJ combined) (NN control)) (NP (RB also) (CD two) (NN chemical))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 179:D01.248.497.300.459.700 194:G05.355.044.250.750 335:D13.444.735.544.355 1236:D02.455.526.439.880|ES| 5:1 7:1 10:1 14:1 19:1 34:1 117:1 124:1 164:1 289:1 369:1 691:1 933:1 1119:1 1247:1 2124:1 4338:1 5475:1 5533:1 5534:1
-1 	|BT| (NP (NP (DT The) (JJ K-rasVal12-augmented) (NN apoptosis) (JJ unrelated) (NN dysplasia)) (: ;) (S (NP (VBN enhanced) (NN apoptosis)) (ADVP (RB also)) (VP (VBD observed) (SBAR (S (NP (NN cycling) (JJ nondysplastic) (NNS enterocytes)) (VP (VBP produce) (NP (NN K-rasVal12) (NN TAg) (JJ COOH-terminal) (NN truncation)))))))) |ET| |BS|39:G04.299.139.160 1475:A03.556.124.369.290|ES| 5:1 19:1 89:1 203:1 217:1 261:1 385:1 691:1 1565:1 5362:1 5406:1 5508:1 5535:1 5536:1 5537:1 5538:1 5539:1 5540:1
-1 	|BT| (S (NP (DT The) (NN mutation) (NN spectrum) (JJ H-ras) (NN codon)) (NP (CD 61) (NN mutation)) (VP (VBD showed) (NP (NP (JJ significant) (NN decrease) (NN AAA) (NN increase) (NN CTA) (NN mutation) (JJ dichloroacetic) (NN acid)) (: -) (S (NP (JJ trichloroethylene-induced) (NN tumor)) (VP (VBN compared) (NP (JJ combined) (NN control))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 179:D01.248.497.300.459.700 335:D13.444.735.544.355 1219:D02.241.081.018.214.500 1235:D02.455.526.439.939|ES| 7:1 19:1 34:1 40:1 50:1 132:1 135:1 164:1 289:1 295:1 691:1 1119:1 2249:1 4273:1 4336:1 5475:1 5533:1 5541:1 5542:1 5543:1
-1 	|BT| (S (NP (NP (DT The) (NN result) (NN show) (NN PhIP)) (NP (NP (ADJP (RB extremely) (JJ toxic)) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-)) (NP (NN mouse)) (, ,))) (ADVP (RB even)) (VP (VBZ dos) (NP (RB 10-fold) (JJR lower) (VBN tolerated) (JJ wild-type) (NN C57BL/6) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 593:B01.050.050.199.520.520.420|ES| 2:1 8:1 10:1 14:1 19:1 45:1 52:1 101:1 117:1 429:1 691:1 1533:1 2192:1 2641:1 2653:1 5416:1 5544:1 5545:1 5546:1 5547:1
-1 	|BT| (S (NP (EX There)) (ADVP (RB also)) (NP (NP (JJR higher) (NN incidence) (NN K-ras) (NN activation)) (PRN (-LRB- -LRB-) (NP (CD 13) (NN %)) (-RRB- -RRB-))) (NP (JJ tetrachloroethylene-induced) (NN tumor)) (VP (ADVP (RB chemically)) (VBN induced) (NP (NN control) (NN tumor)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 434:E05.318.308.985.525.375 1236:D02.455.526.439.880|ES| 5:1 7:1 10:1 14:1 19:1 170:1 225:1 289:1 369:1 412:1 1121:1 1511:1 1532:1 2581:1 3217:1 4338:1
-1 	|BT| (S (NP (NP (DT These) (NN animal)) (NP (VP (VP (VBN reduced)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (JJR <) (CD 0.05))) (-RRB- -RRB-))) (NP (JJ colonic) (NN RFC1) (NN mRNA)))) (VP (VBD exhibited) (NP (JJ 2-fold) (NN reduction) (NN plasma) (NN S-adenosylmethionine/S-adenosylhomocysteine)))) |ET| |BS|19:B01.050 46:A03.556.124.526.356 111:D13.444.735.544 175:J01.897.280.500.269 232:D02.886.030.676.180 657:A12.207.152.693|ES| 10:1 14:1 19:1 46:1 311:1 312:1 325:1 370:1 452:1 609:1 677:1 792:1 2400:1 3549:1 3849:1 5266:1 5267:1
-1 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NP (NN exposure) (JJ dichloroacetic) (NN acid)) (, ,) (NP (NN trichloroethylene) (NN tetrachloroethylene))) (VP (VBZ provides) (S (NP (JJ selective) (NN growth) (NN advantage)) (ADVP (RB spontaneously)) (VP (VBG occurring) (NP (NP (NN mutation) (NN codon) (CD 61) (NNS H-ras)) (, ,) (NP (NN time)) (, ,) (NP (NP (JJ responsible) (JJ small) (NN number) (JJ unique) (JJ molecular) (NN lesion)) (VP (JJ suggestive) (NP (CC either) (NP (JJ random) (JJ genotoxic) (NN mode) (NN action) (JJ non-specific) (NN result) (JJ secondary) (NN DNA) (NN damage)))))))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 45:G07.700.320.249 113:C04.697.650 179:D01.248.497.300.459.700 322:G01.910 335:D13.444.735.544.355 526:G05.355.180 1219:D02.241.081.018.214.500 1235:D02.455.526.439.939 1236:D02.455.526.439.880 1503:E05.318.780.700|ES| 2:1 19:1 34:1 39:1 101:1 102:1 161:1 646:1 666:1 750:1 792:1 796:1 815:1 927:1 1081:1 1119:1 1131:1 1275:1 1469:1 1506:1 1737:1 1749:1 1848:1 1953:1 2013:1 2132:1 3329:1 4273:1 4419:1 5475:1 5476:1 5477:1 5533:1 5548:1 5549:1 5550:1 5551:1 5552:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (, ,) (NP (NP (ADVP (RB together)) (NP (NNP National) (NNP Toxicology) (NNP Program) (NN study)) (VP (VBG showing) (NP (NN evidence) (NN cytotoxicity) (NN genotoxicity) (NN oxazepam)))) (, ,) (S (VP (VBP suggest) (SBAR (S (NP (NN oxazepam)) (ADVP (RB preferentially)) (VP (VBZ promotes) (NP (NN cell) (VBG activating) (NN lesion) (NN ra)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 13:D01.339.387 41:A11 946:D27.888.569.213 1265:H01.158.891 1329:D03.438.079.080.070.663|ES| 2:1 19:1 38:1 94:1 101:1 131:1 298:1 792:1 796:1 1115:1 1131:1 1538:1 1958:1 2201:1 3317:1 3336:1 4491:1 4492:1 4493:1 4741:1 4819:1
-1 	|BT| (S (NP (NP (NP (NNP Thymidylate) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN TS)) (-RRB- -RRB-))) (JJ important) (NN target) (NN 5-fluorouracil) (-LRB- -LRB-) (NN 5FU) (-RRB- -RRB-) (: -)) (VP (VBN based) (NP (NN therapy)))) |ET| |BS|52:E02 333:D01.045 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862|ES| 10:1 14:1 19:1 66:1 130:1 160:1 509:1 902:1 2307:1 2895:1 3081:1 5493:1
-1 	|BT| (S (NP (NNS Tumors)) (VP (VBD isolated) (SBAR (S (NP (NP (NNS trout)) (VP (VBN treated) (NP (NP (NN DHEA)) (ADVP (RB alone))))) (VP (VBD contained) (NP (NP (NP (NN mutation) (NN Ki-ras)) (, ,) (NP (ADVP (RB primarily)) (NN codon) (CD 12) (-LRB- -LSB-) (CD 1) (-RRB- -RSB-) (NN G))) (: --) (NP (NP (JJR >) (DT A) (NN transition)) (, ,) (S (VP (VBG providing) (ADVP (JJ first)) (SBAR (S (NP (JJ suggestive) (NN evidence) (NN DHEA)) (VP (MD could) (NP (JJ genotoxic) (NN carcinogen)))))))))))))) |ET| |BS|8:C04 18:G05.365.590 52:E02 279:D27.888.569.100 335:D13.444.735.544.355 740:D04.808.054.079.429.625 1504:B01.050.150.900.493.817.750.825|ES| 2:1 19:1 34:1 38:1 53:1 69:1 98:1 241:1 552:1 816:1 908:1 1099:1 1119:1 1120:1 1373:1 1378:1 1466:1 1653:1 1970:1 2123:1 2125:1 2633:1 3025:1 3329:1 3720:1 4880:1 5549:1 5553:1 5554:1
-1 	|BT| (S (NP (NN UDCA)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NP (NN Cox-2) (NN protein) (NN mRNA) (NN level)) (NP (NN tumor) (JJ normal) (NP (NN Ras)) (NN activity))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 7:D12.776 8:C04 111:D13.444.735.544 122:C14.280.383 737:D04.808.105.225.272.962|ES| 4:1 7:1 19:1 62:1 118:1 124:1 249:1 325:1 365:1 399:1 1775:1 2631:1
-1 	|BT| (S (S (S (VP (VBG Using) (NP (JJ genetic) (NN engineering)))) (, ,) (NP (VBN deleted) (NP (NP (JJ short) (JJ tandem) (NN repeat)) (PRN (-LRB- -LRB-) (NP (CD two) (NN repeat)) (-RRB- -RRB-))) (NN allele)) (VP (VBD retained) (S (NP (JJ long) (PRN (-LRB- -LRB-) (NP (CD three) (NN repeat)) (-RRB- -RRB-)) (NN allele)) (VP (VBP produce) (NP (JJ artificial) (NN LOH) (NN TS) (NN gene))))) (: ;)) (S (NN TS) (-LRB- -LRB-) (NP (CC +) (: /) (: -) (-RRB- -RRB-) (NN line)) (VP (VBD reduced) (NP (NP (NN TS) (NN protein) (NN expression) (JJ hypersensitive) (NN 5FU) (NN 5-fluoro-2)) ('' ') (: -) (ADVP (FW deoxyuridine) (FW vitro))) (NP (VBN compared) (JJ syngeneic) (NN control) (NN line))))) |ET| |BS|7:D12.776 30:Z01.058.290.190.800 31:D08.811.520.224.800 77:G05.360.340.024.340.030 154:Z01.058.266.887 290:G05.365.590.029.530 394:G02.111.570.080.708.800.500 560:D03.383.742.698.875.404 1505:G05.360.340.024.340.465 1506:E05.393.420|ES| 2:1 4:1 9:1 10:1 14:1 19:1 44:1 50:1 115:1 216:1 217:1 230:1 264:1 289:1 452:1 482:1 509:1 812:1 864:1 933:1 1001:1 1004:1 1565:1 1577:1 1719:1 2325:1 5493:1 5555:1 5556:1 5557:1 5558:1 5559:1 5560:1 5561:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD analyzed) (SBAR (S (NP (NP (NN matrilysin) (NN expression) (JJ benign) (JJ intestinal) (NP (NN tumor) (NN mouse) (JJ heterozygous) (NN ApcMin) (NN allele))) (PRN (-LRB- -LRB-) (NP (NN Min)) (: /) (NP (CC +)) (-RRB- -RRB-))) (VP (VBD found) (SBAR (S (NP (NN mRNA)) (VP (VBD induced) (NP (NP (NP (NN majority)) (PRN (-LRB- -LRB-) (NP (CD 88) (NN %)) (-RRB- -RRB-))) (NN adenoma)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 47:A03.556.124 77:G05.360.340.024.340.030 111:D13.444.735.544 157:G05.380.383 381:C04 937:D08.811.277.656.300.480.525.700.250|ES| 7:1 10:1 14:1 19:1 37:1 42:1 52:1 109:1 115:1 198:1 230:1 325:1 369:1 412:1 705:1 786:1 843:1 1168:1 1194:1 1288:1 3289:1 5562:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD explored) (NP (JJ tumor-promoting) (NN change) (JJ gestational) (JJ arsenic) (NN exposure) (NN focus) (NN Ha-ras) (NN mutation) (NN gene) (NN expression) (NN change)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 155:G05.355.310 216:Z01.107.084.900.425 1158:D01.268.513.249 1266:G08.686.785.760.769|ES| 9:1 19:1 34:1 115:1 200:1 499:1 747:1 843:1 1431:1 1953:1 3776:1 3976:1 4106:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (SBAR (S (NP (NN miR-122)) (VP (VBD suppressed) (NP (NP (JJ insulin-like) (NN growth) (NN factor) (CD 1) (NN receptor) (-LRB- -LRB-) (NN IGF-1R) (-RRB- -RRB-) (NN translation)) (VP (VBD sustained) (NP (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (NN activity))))))))) |ET| |BS|145:G02.111.087.675.871 518:D08.811.913.696.620.682.725.400.185 809:L01.178.682.920|ES| 10:1 14:1 19:1 66:1 92:1 98:1 102:1 185:1 186:1 307:1 399:1 473:1 843:1 1175:1 1789:1 1847:1 1972:1 2093:1 3652:1 3653:1 5563:1
-1 	|BT| (NP (NP (NN OBJECTIVE)) (: :) (NP (NP (PRP We)) (VP (VBD aimed) (NP (NN test) (IN whether) (NP (NP (NN association) (JJ colorectal) (NN polyp) (NN intake) (NN calcium)) (, ,) (NP (NN magnesium)) (, ,) (NP (NP (NN Thr1482Ile) (NN polymorphism) (NN TRPM7) (NN gene)) (VP (VBN modified) (NP (NN Ca)))) (: :)) (NN Mg) (NN intake))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 307:G05.365.795 386:F02.463.425.069 415:F01.658.500 444:C23.300.825 1026:Z01.252.474.651 1507:A08.186.211.464.405 1508:D01.268.552.437 1509:D01.268.552.100 1510:D01.146.315|ES| 2:1 9:1 17:1 19:1 104:1 221:1 647:1 843:1 844:1 1060:1 1298:1 1417:1 1418:1 2335:1 2563:1 5564:1 5565:1 5566:1 5567:1 5568:1 5569:1
-1 	|BT| (S (ADVP (RB Altogether)) (, ,) (VP (VBP result) (SBAR (S (NP (NN show) (NN identification) (JJ BET-dependent) (NN gene)) (VP (VBZ provides) (NP (NN guidance) (NN choice) (NN drug) (NN combination) (NN cancer) (NN treatment))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 374:F01.393.446 1511:F02.463.785.373.346 1512:F01.145.722.408 1513:D26.310|ES| 2:1 9:1 18:1 19:1 101:1 191:1 429:1 530:1 546:1 815:1 3469:1 5570:1 5571:1 5572:1 5573:1
-1 	|BT| (S (NP (NNS Analyses) (NN xenograft)) (VP (VBD showed) (SBAR (S (NP (NP (JJ similar) (NN cell) (NN culture) (NN finding)) (, ,) (NP (NN silibinin) (NN decrease) (NN proliferation) (NN expression) (NN beta-catenin)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (NP (NN c-Myc)) (, ,) (NP (NN CDK8)))) (VP (VBZ induces) (NP (NN apoptosis)) (ADVP (FW vivo))))))) |ET| |BS|23:D12.776.091.249 39:G04.299.139.160 92:E04.936.764 93:A01.941.875 215:D12.644.360.262.150.100 1514:E01.370.225.500.223|ES| 2:1 19:1 60:1 89:1 94:1 115:1 132:1 214:1 265:1 295:1 299:1 332:1 378:1 743:1 744:1 824:1 927:1 2635:1 3098:1 5574:1 5575:1
-1 	|BT| (FRAG (PP (IN Because) (NP (NP (NN combination) (JJ anti-EGFR) (NN 5-fluorouracil) (-LRB- -LRB-) (NP (NN 5-FU) (-RRB- -RRB-) (: -)) (VP (VBN based) (NP (NN chemotherapy) (JJ promising) (NN treatment)))) (, ,) (SBAR (S (NP (VBN analyzed) (NN effect) (NN K-Ras) (NN mutation) (NN patient)) (VP (VBD received) (NP (JJ exclusive) (NN 5-FU) (NN therapy)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 50:M01.643 52:E02 151:E02.319 333:D01.045 560:D03.383.742.698.875.404|ES| 2:1 10:1 13:1 14:1 19:1 34:1 75:1 120:1 130:1 495:1 530:1 546:1 549:1 1168:1 1517:1 1862:1 2307:1 2308:1 2895:1 4339:1 5576:1
-1 	|BT| (S (S (NP (DT Both) (NNP Tyr) (-LRB- -LRB-) (CD 705) (-RRB- -RRB-) (NN phosphorylation) (NN binding) (NN STAT3) (NN MICA) (NN promoter)) (VP (VBD reduced) (NP (NN GSK3) (NN inhibitor)))) (: ;) (S (NP (NP (NN addition)) (, ,) (NP (NP (NN overexpression)) (NP (ADJP (RB constitutively) (JJ active)) (NN form) (NN STAT3)))) (ADVP (RB significantly)) (VP (VBZ inhibits) (NP (NNP MICA) (NN upregulation))))) |ET| |BS|82:D12.644.360.024.342.300 122:C14.280.383 189:V02.460 249:G05.355.315.800 339:G02.111.087.880 519:D05.500.117.875 634:D12.125.072.050.875 972:G02.111.087.677 1206:D08.811.682.690.708.125.500|ES| 2:1 10:1 14:1 19:1 83:1 124:1 152:1 196:1 197:1 217:1 251:1 380:1 452:1 468:1 615:1 630:1 1126:1 1487:1 3426:1 4232:1 4678:1 5577:1 5578:1 5579:1
-1 	|BT| (SINV (PP (IN By) (NP (NN sequencing) (NN Apc) (NN Ctnnb1) (NN gene))) (, ,) (VBD found) (S (S (NP (JJ PhIP-induced) (JJ small) (JJ intestinal) (NN tumor) (JJ obese) (NN mouse)) (VP (VBD carried) (NP (JJ single) (JJ heterozygous) (NN mutation) (NN Apc)) (PP (IN By) (NP (JJ bisulfite-sequencing) (NN CpG) (NN island) (NN Apc))))) (, ,) (VP (VBD found) (NP (NP (NN DNA) (NN hypermethylation) (NN CpG) (NN cluster) (JJ located) (NN transcription) (NN initiation) (NN site)) (, ,) (SBAR (S (ADVP (JJ likely)) (VP (VBD caused) (NP (NN inactivation) (JJ wild-type) (NN Apc) (NN allele))))))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 8:C04 18:G05.365.590 23:D12.776.091.249 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 38:Z01.058.290.120.180 40:Z01.542.248.700 77:G05.360.340.024.340.030 157:G05.380.383 195:G02.111.570.080.380.160 198:D13.444.308 218:A03.556.124.684 247:G01.374.676.530 765:B01.050.150.900.649.865.635.505.500.550.530 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 1515:G05.360.340.024.340.137.750.840 1516:G02.111.570.080.380.160|ES| 2:1 7:1 8:1 9:1 19:1 34:1 37:1 52:1 109:1 230:1 280:1 487:1 637:1 662:1 663:1 664:1 666:1 750:1 786:1 1003:1 1314:1 1328:1 1839:1 1868:1 2205:1 2468:1 2506:1 2846:1 4032:1 4435:1 5580:1 5581:1 5582:1
-1 	|BT| (S (NNS Changes) (NP (JJ circadian) (NN cycle) (NN gene)) (: -) (S (NP (RB primarily) (NP (NN transcription) (NN factor)) (: -)) (VP (VBD showed) (SBAR (S (NP (ADJP (NP (JJ strong) (JJ concentration-related) (NN response)) (JJR higher)) (NN concentration)) (-LRB- -LRB-) (S (NP (NP (NN Arntl)) (, ,) (NP (NN Npas2)) (, ,) (NP (NN Clock))) (VP (VBD down-regulated))) (: ;) (PRN (NP (NP (NN Cry2)) (, ,) (NP (NN Wee1)) (, ,) (NP (NN Bhlhe40)) (, ,) (NP (NN Per3)) (, ,) (NP (NN Nr1d1)) (, ,) (NP (NN Nr1d2) (NN Dbp))) (-RRB- -RRB-) (S (VP (VBD up-regulated) (NP (JJ similar) (NN directionality) (NN tissue)))))))))) |ET| |BS|98:A10 142:I01.880.604 150:Z01.542.248.960 166:D12.776.930 351:A17.360 776:G01.910.645 905:F02.830.104.214|ES| 2:1 9:1 10:1 14:1 19:1 132:1 170:1 185:1 217:1 272:1 332:1 487:1 494:1 601:1 1283:1 1301:1 1970:1 2691:1 3189:1 3578:1 5337:1 5583:1 5584:1 5585:1 5586:1 5587:1 5588:1 5589:1 5590:1 5591:1 5592:1 5593:1 5594:1 5595:1
-1 	|BT| (S (NP (JJ Chemopreventive) (NN activity) (NN plant) (NN flavonoid) (NN isorhamnetin) (JJ colorectal) (NN cancer)) (VP (VBN mediated) (NP (JJ oncogenic) (NN Src) (NN beta-catenin)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 279:D27.888.569.100 328:B01.650 534:D03.383.663.283.266.450|ES| 17:1 18:1 19:1 60:1 399:1 437:1 953:1 1098:1 1886:1 3673:1 3674:1 3972:1
-1 	|BT| (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (JJ potential) (JJ novel) (JJ epigenetic) (NN mechanism)) (VP (VBZ underlies) (SBAR (S (NP (NP (JJ chemopreventive) (NN effect) (NN ASA)) (, ,) (NP (NN mechanism)) (VP (VBZ attenuates) (NP (NNP CAC) (JJ AOM/DSS-induced) (NN CF-1) (NN mouse)) (PP (IN via) (NP (NN inhibition) (NNS HDACs) (NN modification) (NN H3K27ac) (NN mark))))) (VP (VBP suppress) (NP (NP (NN iNOS)) (, ,) (NP (NN TNF-alpha)) (NP (NN IL-6)))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 132:D02.172.080 201:D12.644.276.374.465.224 259:D12.776.395.240.150.500 624:D27.505.696.706.018 670:D02.455.426.559.389.657.410.595.176 671:G05.355.315.203 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1008:D08.811.277.087.520 1114:D08.811.277.352.827.070.250|ES| 2:1 19:1 52:1 67:1 75:1 101:1 103:1 162:1 596:1 796:1 827:1 891:1 1603:1 1872:1 1946:1 2374:1 2423:1 2441:1 2451:1 2775:1 3066:1 3148:1 4755:1 5596:1 5597:1 5598:1 5599:1 5600:1
-1 	|BT| (S (ADVP (RB Consistently)) (, ,) (VP (VBD found) (SBAR (S (NP (NN simvastatin)) (ADVP (RB also)) (VP (VBD increased) (NP (NP (NN p21) (NN p27) (NN expression) (NN tumor) (NN section)) (VP (VBG reducing) (NP (NP (NN Skp2) (NN expression)) (VP (VBG inducing) (NP (NN AMPK) (NN activation) (NN STAT3) (NN suppression) (NN tumor) (NN tissue))))))))))) |ET| |BS|8:C04 82:D12.644.360.024.342.300 98:A10 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900|ES| 2:1 5:1 7:1 19:1 37:1 47:1 115:1 225:1 251:1 272:1 1124:1 1135:1 1785:1 1864:1 2453:1 2679:1 3331:1 4686:1 4691:1 4692:1
-1 	|BT| (S (NP (NN CpG) (NN island) (NN methylation) (NN expression) (NN ALX4)) (VP (VP (VBD evaluated) (NP (NP (JJ methylation-specific) (NN polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN PCR)) (-RRB- -RRB-)))) (, ,) (NP (NP (JJ bisulfite) (JJ genomic) (NN sequencing)) (, ,) (NP (JJ reverse-transcription) (NN PCR) (NN Western) (NN blotting))))) |ET| |BS|36:G02.111.087.029.538 195:G02.111.570.080.380.160 225:E05.337 256:E05.196.401.143 268:H01.158.273.180.350 269:G05.360.340 272:E05.393.620.500.725 448:E05.393.620.500|ES| 2:1 10:1 14:1 19:1 81:1 115:1 394:1 662:1 663:1 768:1 780:1 872:1 875:1 910:1 941:1 4584:1 5580:1 5601:1 5602:1 5603:1 5604:1
-1 	|BT| (S (NP (NN Demethylation) (NN experiment)) (VP (VBD confirmed) (NP (NP (NN loss) (NN ALX4) (NN expression)) (VP (VBN regulated) (NP (NN CpG) (NN island) (NN hypermethylation)))))) |ET| |BS|142:I01.880.604 195:G02.111.570.080.380.160|ES| 19:1 32:1 115:1 662:1 663:1 664:1 938:1 1664:1 2632:1 5601:1 5605:1
-1 	|BT| (S (NP (JJ DEN-induced) (NN rat)) (VP (VBD exhibited) (NP (NP (VBN increased) (NN gene) (NN expression) (NN NF-kappaB)) (, ,) (NP (NN COX-2)) (, ,) (NP (NN CYP2E1)) (, ,) (NP (NN VEGF)) (, ,) (NP (NN Bcl-2)) (, ,) (NP (NN PI3K/AKT/mTOR))) (S (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NN gene) (NN expression) (NN p53)) (, ,) (NP (NN Bax)) (, ,) (NP (NN caspase-9) (NN caspase-3))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 54:G05.360.340.024.340.375.500.791.150 155:G05.355.310 175:J01.897.280.500.269 210:D12.776.260.600 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 342:D12.644.360.075.718.400 378:D08.811.913.696.620.682.700.755 906:D08.811.277.656.262.500.126.350.300 1218:D08.244.453.300 1290:D08.811.913.696.620.500 1349:D08.811.277.656.262.500.126.550.900|ES| 2:1 9:1 12:1 19:1 47:1 76:1 115:1 124:1 158:1 202:1 609:1 714:1 849:1 2066:1 2735:1 4270:1 4630:1 4807:1 4808:1 5606:1
-1 	|BT| (NP (NP (NP (NN Dependence) (NNS diaminothiazoles)) (, ,) (NP (NN compound)) (VP (VBD gained) (NP (NP (NP (NP (NN importance)) (ADJP (RB recently) (JJ due))) (JJ anticancer) (JJ anti) (JJ angiogenic) (NN activity)) (, ,) (NP (NP (VBN tested) (NN cancer) (NN model)) (VP (VBG varying) (NP (NN p53) (NN Ras/Raf) (JJ mutational) (NN status)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 18:G05.365.590 1517:F01.752.330|ES| 2:1 12:1 18:1 19:1 72:1 399:1 416:1 772:1 1244:1 1660:1 1880:1 2433:1 2851:1 2988:1 3790:1 5470:1 5607:1 5608:1 5609:1 5610:1 5611:1
-1 	|BT| (FRAG (NP (NP (NP (NP (RB Early) (NN detection)) (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LRB-) (JJ 4,5-b) (-RRB- -RRB-) (NN pyridine) (-LRB- -LRB-) (NN PhIP) (-RRB- -RRB-) (: -)) (VBN induced) (NN mutation)) (PP (IN within) (NP (NN Apc) (NN gene) (NN rat) (NN colon))))) |ET| |BS|18:G05.365.590 21:G05.360.340.024.340.375.249.050 46:A03.556.124.526.356 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 494:E01.390 744:D03.383.725|ES| 9:1 10:1 14:1 19:1 34:1 113:1 280:1 409:1 849:1 1023:1 2122:1 2638:1 2639:1 2640:1 2641:1 4135:1
-1 	|BT| (S (NP (NNP Emodin)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (NN growth) (NN lung) (NN xenograft) (NN tumor) (NN Sp1)) (, ,) (NP (VBD increased) (NN IGFBP1) (NN PPARgamma) (NN protein) (NN expression)) (ADVP (FW In) (FW vivo))))) |ET| |BS|7:D12.776 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 122:C14.280.383 237:C04.588.894.797.520 719:D12.776.826.239.588 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400|ES| 2:1 4:1 5:1 7:1 19:1 47:1 102:1 115:1 244:1 265:1 328:1 365:1 378:1 2588:1 4856:1 5612:1 5613:1
-1 	|BT| (S (NP (JJ Enzymatic) (NN assay)) (VP (VBD showed) (SBAR (S (NP (NN genistein) (NN 5Aza-C) (VBD decreased) (NN DNA) (NN Methyltransferase) (, ,) (JJ methyl-CpG-binding) (NN domain) (CD 2) (NN activity)) (VP (VBD increased) (NP (NN HAT) (NN activity))))))) |ET| |BS|746:D08.811.150.240 944:D03.383.663.283.266.450.400.375 1519:E05.196.427|ES| 2:1 19:1 47:1 132:1 148:1 202:1 310:1 399:1 666:1 1173:1 3314:1 4828:1 5614:1 5615:1 5616:1 5617:1
-1 	|BT| (S (S (NP (NN ERK)) (VP (VBD mediated) (SBAR (S (NP (NN upregulation) (NN death) (NN receptor) (CD 5)) (VP (VBZ overcomes) (SBAR (S (NP (NN lack) (NN p53) (NN functionality) (NN diaminothiazole) (NN DAT1)) (VP (VBD induced) (NP (NN apoptosis) (NN colon) (NN cancer) (NN model)))))))))) (: :) (S (NP (NN efficiency) (NN DAT1) (NN Ras-Raf)) (NP (VBN mutated) (NN cell)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 249:G05.355.315.800 252:F02.784.692.351 339:G02.111.087.880|ES| 12:1 18:1 19:1 72:1 89:1 94:1 104:1 113:1 186:1 229:1 411:1 412:1 437:1 578:1 868:1 1126:1 3239:1 3910:1 3915:1 3937:1 5047:1 5618:1 5619:1
-1 	|BT| (S (NP (NN Evodiamine)) (ADVP (RB also)) (VP (VBD suppressed) (SBAR (S (NP (NN STAT3) (NN DNA) (NN binding) (NN activity)) (VP (VBD down-regulated) (NP (NP (NN expression) (JJ STAT3-mediated) (NN gene)) (VP (VBG leading) (NP (NN suppression) (NN proliferation)))))))) (, ,) (NP (NN induction) (NN cell) (NN apoptosis) (NN cell) (NN cycle) (NN arrest))) |ET| |BS|39:G04.299.139.160 41:A11 82:D12.644.360.024.342.300 86:D01.268.556.435 142:I01.880.604 155:G05.355.310 198:D13.444.308 351:A17.360 773:G04.299.134.109|ES| 2:1 5:1 9:1 19:1 89:1 94:1 115:1 251:1 299:1 307:1 399:1 601:1 602:1 639:1 666:1 736:1 1283:1 1487:1 2453:1 5620:1 5621:1
-1 	|BT| (S (NP (NN Exposure) (NN alternol)) (VP (VBD resulted) (NP (NP (NP (NP (JJ excessive) (JJ reactive) (NN oxygen) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-))) (NP (NP (NN generation) (NN Jun) (JJ amino-terminal) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN JNK)) (-RRB- -RRB-)))) (, ,) (NP (NP (NP (JJ extracellular) (JJ signal-regulated) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2)) (-RRB- -RRB-))) (NN p38) (NN activation))))) |ET| |BS|116:D08.811.913.696.620.682.700.567.249.750 469:D08.811.913.696 477:D08.811.913.696.620.682.700.567.249 478:D08.811.913.696.620.682.700.567 506:F01.829.263.315 636:D01.339.431|ES| 2:1 10:1 14:1 19:1 225:1 470:1 594:1 1666:1 1707:1 1787:1 2353:1 2354:1 2355:1 2356:1 3982:1 4276:1 4594:1 4812:1 5622:1 5623:1 5624:1 5625:1
-1 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN RNAseq) (NN analysis)) (VP (VBD indicated) (SBAR (S (NP (NP (NN p53) (NN signaling) (NN Lgr5)) (CC +) (NP (NN stem) (NN cell) (NN mouse))) (VP (VBN exposed) (NP (NNP AOM)) (ADVP (RB uniquely)) (VP (VBD upregulated) (PP (VBG following) (NP (JJ n-3) (NN PUFA) (CC +) (NN curcumin) (NN cotreatment))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 132:D02.172.080 308:A11.872 618:E02.186 692:D02.455.326.146.485.222.222 1308:D10.212.302.380.410|ES| 2:1 12:1 19:1 52:1 94:1 125:1 195:1 661:1 1106:1 1541:1 1929:1 1994:1 2652:1 3102:1 3510:1 4673:1 5626:1 5627:1 5628:1 5629:1
-1 	|BT| (S (NP (NP (JJ Forced) (NN inhibition) (NN p38) (NN MAPK) (NN activity) (JJ specific) (JJ pharmacological) (NN inhibitor) (NN SB203580) (NN p38) (NN MAPK) (NN gene) (NN knockdown)) (VP (VBG using) (NP (NP (JJ small-interfering) (NN RNA)) (PRN (-LRB- -LRB-) (NP (NN siRNA)) (-RRB- -RRB-))))) (VP (VBD counteracted) (NP (NN effect) (NN FL3)) (, ,) (S (VP (VBG demonstrating) (NP (NP (JJ chemopreventive) (NN action) (JJ related) (NN growth) (NN inhibition)) (NP (NP (JJ p38-dependent) (JJ caspase-3-dependent) (NN induction) (NN apoptosis)) (NP (JJ Oct4-expressing) (NNS CSCs)))))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 45:G07.700.320.249 117:D13.150.650.700 400:E05.393.335.500 556:C11.768.175 906:D08.811.277.656.262.500.126.350.300 1059:H01.158.703 1520:D08.811.913.696.620.682.700.567.843 1521:D12.776.260.655.500.300|ES| 2:1 9:1 10:1 14:1 19:1 75:1 89:1 102:1 103:1 350:1 351:1 380:1 399:1 419:1 464:1 515:1 527:1 540:1 736:1 809:1 1666:1 1946:1 1966:1 2013:1 3707:1 4883:1 5630:1 5631:1 5632:1 5633:1 5634:1 5635:1 5636:1
-1 	|BT| (SBAR (IN From) (S (NP (NN list)) (ADVP (RB differentially)) (VP (VBD expressed) (NP (NP (NP (NN gene) (VBN prioritized) (NN transcriptome) (NN profiling)) (, ,) (NP (NN Mmp7)) (, ,) (NP (NN S100a9)) (, ,) (NP (NP (NN Nppb) (NN Aldh1a3)) (NP (VBN defined) (NN key) (NN oncogene) (NN candidate)))) (VP (VBD downregulated) (NP (NN colon) (NN tumor) (NNP TA) (NN treatment))))))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 51:C04.588.274.476.411.307.180 52:E02 937:D08.811.277.656.300.480.525.700.250 1286:E05.393.332|ES| 2:1 6:1 7:1 9:1 19:1 24:1 113:1 159:1 426:1 546:1 680:1 1139:1 1243:1 2148:1 5637:1 5638:1 5639:1 5640:1 5641:1 5642:1 5643:1 5644:1 5645:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN exposure) (NN cell) (NN Japonicone) (NN A)) (VP (VBD caused) (NP (NN inactivation) (NN TNF-alpha-TAK1-IKK-NF-kappaB) (NN axis) (NN inhibition) (JJ TNF-alpha-stimulated) (NN NF-kappaB) (NN activity) (JJ nuclear) (NN translocation)))) (, ,) (VP (VBD followed) (NP (NP (NN downregulation) (NN NF-kappaB) (NN target) (NN gene)) (VP (VBN involved) (NP (NP (NP (NN cell) (NN apoptosis)) (PRN (-LRB- -LRB-) (NP (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (NN XIAP)) (, ,) (NP (NN TRAF2))) (-RRB- -RRB-))) (NP (NP (NN cell) (NN cycle) (NN growth)) (PRN (-LRB- -LRB-) (NP (NN cyclin) (NN D)) (, ,) (NP (NN c-Myc)) (-RRB- -RRB-)))))))) |ET| |BS|6:G05.360.340.024.340 39:G04.299.139.160 41:A11 43:F01.145.544 45:G07.700.320.249 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 210:D12.776.260.600 353:G04.299.134 463:C23.550.210.870 579:A02.835.232.834.151.383 789:D12.644.276.374.500.800 790:D12.644.276.374.750 1046:D12.644.360.262.150 1522:D12.644.360.024.500.750|ES| 2:1 9:1 10:1 14:1 19:1 69:1 89:1 94:1 102:1 103:1 158:1 160:1 334:1 399:1 595:1 601:1 714:1 743:1 774:1 824:1 1256:1 1314:1 1618:1 1953:1 2089:1 2506:1 2592:1 3130:1 4814:1 5646:1 5647:1 5648:1 5649:1 5650:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN hesperidin) (NN administration)) (VP (VBD restored) (SBAR (S (NP (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (NN activity) (NN turn)) (VP (VBD prevented) (NP (NN accumulation) (NNS oncoproteins)) (NP (NP (NN beta-catenin)) (, ,) (NP (NN c-jun) (NN c-myc)))))))) |ET| |BS|23:D12.776.091.249 584:D12.776.624.664 1477:D03.383.663.283.266.450.252.500|ES| 2:1 10:1 14:1 19:1 60:1 66:1 92:1 334:1 399:1 455:1 1944:1 1972:1 2120:1 2575:1 3652:1 3653:1 4893:1 5356:1 5651:1 5652:1 5653:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (PP (IN upon) (NP (NN TQ) (NN treatment))) (, ,) (NP (NN beta-catenin)) (VP (VP (VBD retained) (SBAR (S (NP (NN membrane) (NN c-myc)) (VP (VBD decreased) (NP (NN nucleus)))))) (, ,) (S (VP (VBN associated) (NP (VBN reduced) (NN cell) (NN proliferation) (NN villus)))))) |ET| |BS|23:D12.776.091.249 52:E02 183:G04.299.233.750 1104:A11.284.430.106 1344:A10.615|ES| 2:1 19:1 60:1 94:1 169:1 202:1 299:1 334:1 452:1 455:1 460:1 546:1 1577:1 1951:1 3622:1 3873:1 5654:1
-1 	|BT| (FRAG (ADVP (RB Here)) (, ,) (NP (NP (NN report) (ADJP (RB inversely) (JJ related)) (NN expression) (NN miR-137) (NN CAR) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell)) (, ,) (SBAR (WHADVP (WRB wherein)) (S (NP (NN miR-137)) (VP (VBD downregulated) (NP (JJ resistant) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320 139:J01.937.500.100|ES| 2:1 19:1 94:1 115:1 400:1 417:1 418:1 419:1 420:1 421:1 422:1 423:1 424:1 425:1 426:1 427:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (VP (VBZ remains) (ADJP (JJ unknown) (SBAR (IN whether) (S (NP (NP (NN neoplasia)) (VP (VBN associated) (NP (NNP Pten) (ADJP (NN loss) (JJ dependent)) (JJ upstream) (NN IGF) (NN ligand) (NN supply) (FW vivo))))))))) |ET| |BS|8:C04 170:D27.720.470.480 581:D12.644.276.937|ES| 2:1 19:1 32:1 169:1 221:1 321:1 378:1 433:1 442:1 640:1 1835:1 1996:1 2182:1 3728:1 5655:1 5656:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (NP (JJ combined) (NN effect) (NN mda-7) (NN sulindac)) (ADVP (RB previously)) (VP (VBN tested))) |ET| |BS|251:D02.455.426.559.847.486.875|ES| 2:1 19:1 75:1 164:1 433:1 869:1 1527:1 2988:1 5657:1
-1 	|BT| (S (NP (NN Hypermethylation) (NN miR-137) (NN promoter) (JJ negative) (NN regulation) (NN miR-137) (NN CAR)) (VP (VP (VBP contribute) (NP (NP (NN part)) (VP (VBD reduced) (NP (NN miR-137) (NN expression))))) (VP (VBD increased) (NP (NN CAR) (NN MDR1) (NN expression) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 142:I01.880.604|ES| 19:1 47:1 83:1 94:1 115:1 420:1 421:1 423:1 424:1 438:1 448:1 449:1 450:1 451:1 452:1 453:1
-1 	|BT| (NP (NP (NP (NN Immunohistochemistry) (NN beta-catenin)) (, ,) (NP (NN c-myc)) (, ,) (NP (NP (NN Ki-67) (NN TUNEL-staining)) (VP (VBN performed) (VP (VBP investigate) (NP (NP (NN TQ) (POS 's)) (NN effect) (JJ major) (JJ colorectal) (NN cancer) (NN pathway))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 143:E01.370.225.500.607.512 144:E05.393.475|ES| 2:1 17:1 18:1 19:1 60:1 75:1 383:1 454:1 455:1 456:1 457:1 458:1 459:1 460:1 461:1 462:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN ERK5) (NN inhibition)) (VP (VBD increased) (NP (NP (NN response) (NN HCT116) (NN p53)) (CC +) (NP (: /) (CC +) (NN cell) (NN 5-FU)))) (, ,)) (VBD failed) (VB sensitize) (NP (NP (NN HCT116) (NN p53)) (: -)) (: /) (: -) (NP (NP (NN cell) (JJ cytotoxic) (NN effect) (JJ chemotherapeutic) (NN agent)) (, ,) (VP (VBG suggesting) (NP (NP (JJ p53-dependent) (NN axis)) (VP (VBG mediating) (NP (NN 5-FU) (NN sensitization))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 560:D03.383.742.698.875.404 579:A02.835.232.834.151.383 660:D27.505.954.248 717:A11.251.210.190.380|ES| 2:1 19:1 47:1 75:1 88:1 94:1 103:1 244:1 468:1 494:1 566:1 728:1 761:1 1009:1 1457:1 1505:1 1762:1 2089:1 2308:1 5471:1 5658:1 5659:1 5660:1 5661:1
-1 	|BT| (S (PP (IN In) (NP (JJ intestinal) (JJ epithelial) (NN cell) (NN IEC-6) (NN colon) (NN cancer) (NN cell) (NN HCT-116))) (, ,) (NP (NN IL-6) (NN expression) (NN signaling)) (VP (VBN assessed) (NP (NP (NNP SHH) (NN inhibitor) (NN level) (JJ inflammatory) (NN mediator)) (, ,) (NP (NP (NN proliferation)) (, ,) (NP (NN apoptosis)) (, ,) (NP (NN tumorsphere) (NN formation))) (, ,) (NP (NP (NN tumorigenesis)) (VP (ADVP (RB also)) (VBN measured)))))) |ET| |BS|20:G03.495 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 47:A03.556.124 69:G02.111.087.800 75:A11.436 201:D12.644.276.374.465.224 228:E05.978 1523:E01.370.225.625.400 1524:E04.936.225.687.500|ES| 2:1 5:1 18:1 19:1 43:1 78:1 89:1 94:1 109:1 113:1 115:1 127:1 195:1 244:1 249:1 299:1 380:1 738:1 789:1 2430:1 3148:1 3351:1 3823:1 5662:1 5663:1 5664:1
-1 	|BT| (S (S (PP (IN In) (NP (NN mouse) (NN model))) (, ,) (NP (NN SHH) (NN inhibitor)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (NN tumor) (NN incidence) (NN multiplicity)) (, ,) (VP (VBD decreased) (NP (NP (NN expression) (NN IL-6)) (, ,) (NP (NN TNF-alpha)) (, ,) (NP (NN COX-2)) (, ,) (NP (NN STAT3)) (, ,) (NP (NN NF-kappaB)) (, ,)))) (VP (ADVP (RB significantly)) (VBD induced) (NP (NN apoptosis)))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 82:D12.644.360.024.342.300 201:D12.644.276.374.465.224 210:D12.776.260.600 434:E05.318.308.985.525.375 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 7:1 19:1 52:1 72:1 76:1 89:1 115:1 124:1 202:1 244:1 251:1 380:1 412:1 452:1 714:1 1511:1 2775:1 2863:1 3148:1 5664:1
-1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD demonstrated) (NP (NP (JJ simvastatin-induced) (NN G0/G1) (NN arrest)) (VP (VBG inducing) (NP (NN p21) (NN p27) (NN accumulation) (NN HepG2) (NN Hep3B) (NN cell)))))) |ET| |BS|41:A11 754:D02.455.426.559.847.638.400.900|ES| 2:1 19:1 94:1 131:1 244:1 602:1 1124:1 1135:1 1175:1 1864:1 2120:1 3481:1 4502:1 5665:1 5666:1
-1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD identified) (NP (NP (JJ novel) (NN CEBPD) (NN activator)) (, ,) (NP (NP (LST (LS 1) (: -)) (-LRB- -LRB-) (JJ 2-hydroxy-5-methylphenyl) (-RRB- -RRB-) (NN -3-phenyl-1,3-propanedione)) (PRN (-LRB- -LRB-) (NP (NN HMDB)) (-RRB- -RRB-)))))) |ET| |BS|259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 131:1 244:1 623:1 861:1 891:1 5667:1 5668:1 5669:1 5670:1 5671:1
-1 	|BT| (S (ADVP (FW In) (FW vitro)) (, ,) (VP (NP (NN TQ)) (VP (VBD activated) (NP (NN GSK-3beta))) (, ,) (VP (VBD induced) (NP (JJ membranous) (NN localization) (NN beta-catenin))) (VP (VBD reduced) (NP (JJ nuclear) (NN c-myc) (NN expression))))) |ET| |BS|23:D12.776.091.249 1344:A10.615|ES| 2:1 19:1 60:1 115:1 163:1 216:1 244:1 412:1 452:1 455:1 460:1 1256:1 2484:1 3653:1 5672:1
-1 	|BT| (S (NP (NN Iso-3)) (VP (VBD induced) (NP (NP (NP (NN growth) (NN arrest) (NN cancer) (NN cell) (NN G0/G1)) (JJ concomitant)) (SBAR (S (NP (VBN increased) (NN p21) (NN p27) (NN expression)) (VP (VBD reduced) (NP (NP (NN cyclin) (NN E1)) (, ,) (NP (NN PCNA) (NN c-myc) (NN level))))))))) |ET| |BS|41:A11 45:G07.700.320.249 768:D12.776.660.740|ES| 2:1 18:1 19:1 47:1 94:1 102:1 115:1 249:1 412:1 452:1 455:1 602:1 743:1 1124:1 1135:1 1580:1 1681:1 2698:1 5666:1 5673:1
-1 	|BT| (S (NP (NN Isorhamnetin)) (VP (VBD inhibited) (NP (JJ AOM/DSS-induced) (JJ oncogenic) (NN c-Src) (NN activation) (NN beta-catenin) (JJ nuclear) (NN translocation)) (, ,) (S (VP (VBG promoting) (NP (NP (NP (NN expression) (JJ C-terminal) (NN Src) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN CSK)) (-RRB- -RRB-))) (, ,) (NP (JJ negative) (NN regulator) (NN Src) (NN family) (NN tyrosine) (NN kinase))))))) |ET| |BS|23:D12.776.091.249 122:C14.280.383 132:D02.172.080 279:D27.888.569.100 463:C23.550.210.870 1525:D08.811.913.696.620.682.725.800|ES| 2:1 10:1 14:1 19:1 60:1 97:1 115:1 225:1 235:1 365:1 449:1 470:1 881:1 953:1 1256:1 1618:1 2341:1 3674:1 3676:1 5018:1 5596:1 5674:1 5675:1
-1 	|BT| (S (NP (NN K-Ras) (NN mutation) (NN treatment) (NN outcome) (JJ colorectal) (NN cancer) (NN patient)) (VP (VBG receiving) (NP (JJ exclusive) (NN fluoropyrimidine) (NN therapy)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800|ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1
-1 	|BT| (NP (NP (NP (JJ K-ras) (NN mutation)) (NP (VBN assessed) (NN PCR) (NN mRNA) (NN egfr) (NN ligand) (JJ quantitative) (JJ real-time) (NN PCR)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 111:D13.444.735.544 170:D27.720.470.480 257:E05.393.620.500.706 346:E05.393.620.500.706 448:E05.393.620.500|ES| 19:1 34:1 325:1 817:1 874:1 875:1 1121:1 1835:1 3823:1 5676:1
-1 	|BT| (NP (NP (NNS METHODS)) (: :) (S (NP (NP (NP (JJ Stable) (JJ transient) (NN RNA) (NN silencing) (NN GAST) (NN gene)) (VP (VBD induced) (NP (NP (JJ human) (NN tumor) (NN cell) (NN mouse)) (VP (VBG carrying) (NP (NP (JJ heterozygous) (NN Apc) (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN APCDelta14)) (-RRB- -RRB-))))))) (, ,) (VP (VBP overexpress) (NP (NN progastrin)))) (VP (VBD amidated) (NP (JJ glycine-extended) (NN gastrin))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 41:A11 42:G05.355.315.203.374 55:B01.050.150.900.649.801.400.112.400.400 156:G05.355.315.203.374.790 157:G05.380.383 168:E05.581 199:D06.472.317.413 200:D06.472.317.413 247:G01.374.676.530 1003:D12.125.481 1422:D13.444.735|ES| 2:1 7:1 9:1 10:1 14:1 19:1 34:1 36:1 52:1 94:1 100:1 104:1 280:1 412:1 515:1 565:1 671:1 676:1 745:1 786:1 850:1 2513:1 5677:1 5678:1 5679:1 5680:1 5681:1
-1 	|BT| (S (S (NP (NNP Mevalonate)) (VP (VBD decreased) (NP (NP (JJ simvastatin-induced) (NN AMPK) (NN activation)) (VP (VBD rescued) (NP (JJ phospho-STAT3) (NN Skp2) (NN expression) (NN HCC) (NN cell)))))) (, ,) (VP (VBD resulted) (NP (NN prevention) (NN G0/G1) (NN arrest) (NN inhibition) (NN p21) (NN p27) (NN accumulation)))) |ET| |BS|41:A11 43:F01.145.544 82:D12.644.360.024.342.300 104:C04.557.470.200.025.255 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900 1526:D02.241.511.579|ES| 2:1 19:1 94:1 103:1 115:1 202:1 225:1 441:1 594:1 602:1 1124:1 1135:1 1474:1 1785:1 2120:1 4692:1 5665:1 5666:1 5682:1 5683:1 5684:1
-1 	|BT| (S (S (NP (NN miR-137) (NN overexpression)) (VP (VBD resulted) (NP (NP (NN downregulation) (NN CAR) (NN protein) (NN mRNA)) (PRN (-LRB- -LRB-) (PP (IN via) (NP (NN mRNA) (NN degradation))) (-RRB- -RRB-))))) (: ;) (S (VBN sensitized) (NP (JJ doxorubicin-resistant) (NN cell) (NN doxorubicin)) (-LRB- -LRB-) (VP (VP (VBN shown) (S (VP (VBN reduced) (NP (NN proliferation))))) (, ,) (VP (VBD increased) (NP (NN apoptosis))) (VP (VBD increased) (NP (JJ G2-phase) (NN cell) (NN cycle) (NN arrest))) (SINV (-RRB- -RRB-) (NP (VBD reduced) (FW vivo) (NN growth) (NN rate) (NN neuroblastoma) (NN xenograft)))))) |ET| |BS|7:D12.776 39:G04.299.139.160 41:A11 45:G07.700.320.249 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 111:D13.444.735.544 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 177:G04.299.134.109.500 178:G02.111.780|ES| 2:1 4:1 10:1 14:1 19:1 41:1 47:1 89:1 94:1 102:1 152:1 217:1 237:1 265:1 299:1 325:1 378:1 420:1 421:1 423:1 424:1 452:1 594:1 595:1 596:1 597:1 598:1 599:1 600:1 601:1 602:1
-1 	|BT| (S (NP (NN miR-137)) (VP (VBZ regulates) (SBAR (S (NP (JJ constitutive) (NN androstane) (NN receptor)) (VP (VBZ modulates) (NP (NN doxorubicin) (NN sensitivity) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320|ES| 19:1 94:1 186:1 420:1 422:1 423:1 424:1 599:1 603:1 604:1 605:1 606:1 607:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN inhibition) (NN SHP-1) (NN gene) (JJ small) (NN interference) (NN RNA)) (VP (VBD abolished) (SBAR (S (NP (NN ability) (NN evodiamine)) (VP (VBP inhibit) (NP (NP (NP (JJ IL-6-induced) (NN STAT3)) (PRN (-LRB- -LRB-) (NP (NP (NN Tyr)) (PRN (-LRB- -LRB-) (NP (CD 705)) (-RRB- -RRB-))) (-RRB- -RRB-))) (NN activation))))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 82:D12.644.360.024.342.300 122:C14.280.383 201:D12.644.276.374.465.224 385:F02.784.629.131 634:D12.125.072.050.875 1206:D08.811.682.690.708.125.500 1422:D13.444.735|ES| 2:1 9:1 10:1 14:1 19:1 103:1 225:1 251:1 515:1 516:1 622:1 682:1 750:1 1300:1 1370:1 4232:1 4582:1 5577:1 5685:1 5686:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN miR-221) (NN reduction)) (VP (VBD resulted) (NP (NN alteration) (JJ EMT-associated) (NN gene) (NN E-cadherin) (NN vimentin)) (NP (RB well) (ADJP (RB significantly) (JJR slower)) (NN xenograft) (NN tumor) (NN growth) (JJ nude) (NN mouse)))) |ET| |BS|8:C04 18:G05.365.590 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 820:D12.776.395.550.200.200 1527:D05.750.078.593.900|ES| 2:1 7:1 9:1 19:1 52:1 102:1 124:1 140:1 265:1 266:1 370:1 594:1 622:1 787:1 951:1 2267:1 5687:1 5688:1 5689:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN silencing) (NN IGFBP1) (NN gene)) (VP (VBD blunted) (NP (JJ emodin-induced) (NN inhibition) (NN cell) (NN growth) (NN cell) (NN cycle) (NN arrest)))) |ET| |BS|41:A11 42:G05.355.315.203.374 43:F01.145.544 45:G07.700.320.249 773:G04.299.134.109 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400|ES| 2:1 9:1 19:1 94:1 100:1 102:1 103:1 601:1 602:1 622:1 5201:1 5613:1 5690:1
-1 	|BT| (S (NP (JJ Natural) (JJ lipophilic) (NNS polyphenols)) (VP (JJ long-chain) (NP (NP (JJ polyunsaturated) (JJ fatty) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNS PUFAs)) (-RRB- -RRB-))) (SBAR (S (ADVP (RB generally)) (VBP suppress) (NN Wnt) (: -) (NN NF-kappaB) (: -) (-LRB- -LRB-) (NP (JJ nuclear) (NN factor-kappa) (NN light-chain) (NN enhancer)) (VP (VP (VBD activated) (NP (NN B-cell))) (-RRB- -RRB-) (NP (JJ related) (NN pathway))))))) |ET| |BS|41:A11 56:D02.455.426.559.389.657.715 210:D12.776.260.600 425:G01.358.500.505.650 1528:D10.251.355|ES| 10:1 14:1 19:1 154:1 163:1 383:1 419:1 972:1 1256:1 1275:1 2070:1 2199:1 2441:1 2780:1 3364:1 4674:1 5265:1 5691:1 5692:1 5693:1 5694:1 5695:1 5696:1
-1 	|BT| (NP (NP (NP (JJ Oral) (NN administration)) (SBAR (S (NP (NP (CD 50) (NN mg/kg) (NN CX-5461)) (VP (VBD induced) (NP (NN TP53) (NN expression) (NN activity)))) (VP (VBD reduced) (NP (NP (NP (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN MKI67)) (-RRB- -RRB-))) (NN invasion)) (PRN (-LRB- -LRB-) (NP (NN loss) (JJ ductal) (NN actin)) (-RRB- -RRB-))) (NN Hi-MYC) (NN tumor))))) (, ,) (NP (NP (NN PTEN-null)) (PRN (-LRB- -LRB-) (JJ low) (NN MYC) (-RRB- -RRB-))) (NP (NN tumor)))) |ET| |BS|8:C04 739:E02.319.267.100 1025:Z01.252.100.450 1026:Z01.252.474.651 1529:C16.131.831.512.400.410 1530:Z01.107.567.875.580.375 1531:D12.776.660.625.500 1532:D05.750.078.730.250|ES| 2:1 7:1 10:1 14:1 19:1 32:1 115:1 299:1 368:1 399:1 412:1 452:1 472:1 531:1 620:1 1018:1 2575:1 3585:1 5071:1 5697:1 5698:1 5699:1 5700:1 5701:1 5702:1
-1 	|BT| (S (NP (NP (JJ Other) (NN study)) (, ,) (ADVP (RB therefore)) (, ,)) (VP (VBN performed) (NP (NN SW480) (NN cell) (NN silibinin)) (SBAR (S (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NP (JJ beta-catenin-dependent) (NN T-cell) (NN factor-4)) (PRN (-LRB- -LRB-) (NP (NN TCF-4)) (-RRB- -RRB-))) (JJ transcriptional) (NN activity) (NN protein) (NN expression) (NN beta-catenin) (NN target) (NN gene) (NN c-Myc) (NN cyclin) (NN D1))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 41:A11 155:G05.355.310 209:G02.111.087.847 215:D12.644.360.262.150.100 1533:D12.776.260.730.875 1534:C10.597.350.400 1535:D12.776.220.145|ES| 2:1 4:1 9:1 10:1 14:1 19:1 60:1 94:1 115:1 124:1 131:1 160:1 202:1 218:1 399:1 458:1 559:1 743:1 744:1 824:1 2635:1 3096:1 5210:1 5375:1 5703:1 5704:1 5705:1
-1 	|BT| (S (NP (PRP$ Our) (NN observation)) (VP (VBP suggest) (NP (NP (JJ chemoprotective) (NN effect) (NN isorhamnetin) (NN colon) (NN cancer)) (VP (VBN linked) (NP (NP (JJ anti-inflammatory) (NN activity) (NN inhibition) (JJ oncogenic) (NN Src) (NN activity) (JJ consequential) (NN loss)) (VP (JJ nuclear) (NP (NP (NN beta-catenin)) (, ,) (NP (NN activity)) (NP (JJ dependent) (NN CSK) (NN expression))))))))) |ET| |BS|23:D12.776.091.249 43:F01.145.544 279:D27.888.569.100 429:N04.761.559.590.900 430:E05.581.249 686:D27.505.954.158|ES| 2:1 18:1 19:1 32:1 60:1 75:1 103:1 113:1 115:1 321:1 399:1 658:1 796:1 953:1 1256:1 1363:1 1477:1 2795:1 3672:1 3673:1 3674:1 3675:1 3676:1
-1 	|BT| (S (NP (PRP$ Our) (NN result)) (VP (VBD showed) (S (NP (NNP ADN) (NN time)) (NP (ADVP (RB dependently)) (NP (VBD stimulated) (NP (NN WIF1) (NN gene) (NN protein) (NN expression) (NN MDA-MB-231) (NN cell))))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 41:A11 322:G01.910 759:D02.092.471.683.152.660 760:Z01.107.084.900.600 763:Z01.542.248.540|ES| 4:1 9:1 19:1 94:1 101:1 115:1 132:1 658:1 1081:1 2689:1 4854:1 5706:1 5707:1 5708:1
-1 	|BT| (S (NP (NN Overexpression) (NN PinX1)) (VP (VBD resulted) (SBAR (S (NP (NP (NN G1/S) (NN phase) (NN arrest) (NN cell) (NN growth/proliferation) (NN inhibition)) (, ,) (NP (NN silencing) (NN PinX1))) (VP (VBD led) (NP (NP (NN acceleration) (NN G1/S) (NN transition)) (, ,) (NP (NP (NN cell) (NN growth/proliferation) (NN promotion)) (VP (VBG inhibiting/enhancing) (NP (NN telomerase) (NN activity)) (PP (IN via) (NP (NN p16/cyclin) (NN D1) (NN pathway))))))))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 86:D01.268.556.435 122:C14.280.383 183:G04.299.233.750 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500 215:D12.644.360.262.150.100 1404:G02.111.087.222.880 1536:D08.811.913.696.445.308.300.750.750 1537:G01.595.560.107|ES| 2:1 19:1 94:1 100:1 103:1 383:1 399:1 552:1 594:1 596:1 602:1 668:1 744:1 2228:1 2337:1 2529:1 4430:1 5709:1 5710:1 5711:1 5712:1 5713:1 5714:1
-1 	|BT| (S (NP (NP (NP (NN Overexpression) (NN progastrin)) (, ,) (NP (JJ nonamidated) (ADJP (RB incompletely) (VBN processed)) (NN product) (NN gastrin) (NN gene)) (, ,)) (VP (VBN shown) (VP (VBP induce) (NP (JJ colonic) (NN hyperproliferation))))) (VP (VBP promote) (NP (NP (JJ colorectal) (NN cancer) (NN mouse)) (, ,) (NP (NP (NN mechanism) (NN pathogenesis)) (VP (VBN defined)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413|ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1
-1 	|BT| (S (NP (NN PinX1)) (VP (VBZ suppresses) (NP (NN bladder) (JJ urothelial) (NN carcinoma) (NN cell) (NN proliferation)) (PP (IN via) (NP (NN inhibition) (NN telomerase) (NN activity) (NN p16/cyclin) (NN D1) (NN pathway))))) |ET| |BS|43:F01.145.544 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500 215:D12.644.360.262.150.100 317:C04.557.470.200.430 933:A05.810.890 1536:D08.811.913.696.445.308.300.750.750|ES| 19:1 94:1 103:1 299:1 304:1 383:1 399:1 564:1 596:1 686:1 744:1 1078:1 5709:1 5713:1 5714:1
-1 	|BT| (NP (NP (NN RNA) (NN interference) (JJ knockdown) (NN DRD2) (JJ pancreatic) (NN tumor) (NN cell)) (NP (NP (VBN reduced) (NN growth) (NN xenograft) (NN tumor) (NN mouse)) (, ,) (NP (NN administration) (NN DRD2) (NN inhibitor) (NN haloperidol) (NN mouse) (JJ orthotopic) (NN xenograft) (NN tumor))) (NP (VBD reduced) (JJ final) (NN tumor) (NN size) (NN metastasis))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 113:C04.697.650 156:G05.355.315.203.374.790 362:D12.776.543.750.069.300.400.500 1069:D02.522.352.506 1538:C04.588.274.761|ES| 2:1 7:1 19:1 52:1 94:1 102:1 265:1 380:1 452:1 464:1 467:1 515:1 516:1 806:1 1210:1 2142:1 2575:1 3744:1 3884:1 5283:1
-1 	|BT| (NP (NP (ADVP (RB Similarly)) (, ,) (NP (NP (NN HT-29) (NN colon) (NN cancer) (NN cell)) (, ,) (NP (NN isorhamnetin)) (VP (VP (VBD inhibited) (S (NP (JJ oncogenic) (NN Src) (NN activity) (NN beta-catenin) (JJ nuclear) (NN translocation)) (VP (VBG inducing) (NP (NN expression) (NN csk))))) (, ,) (NP (VBN verified) (NN RNA) (NN interference) (NN knockdown) (NN csk)))))) |ET| |BS|23:D12.776.091.249 122:C14.280.383 156:G05.355.315.203.374.790 279:D27.888.569.100 463:C23.550.210.870 792:A11.251.210.190.475|ES| 2:1 18:1 19:1 60:1 94:1 113:1 115:1 365:1 399:1 464:1 515:1 516:1 726:1 953:1 1256:1 1618:1 1864:1 2782:1 3673:1 3674:1 5715:1 5716:1
-1 	|BT| (S (NP (NNP Simvastatin)) (VP (VP (VBD decreased) (NP (NN Skp2) (NN expression) (JJ transcriptional) (NN level))) (, ,) (VP (VBD resulted) (S (NP (NN p27) (NN accumulation)) (VP (VBG preventing) (NP (JJ proteasomal) (NN degradation))))) (, ,) (NP (NN effect) (VP (VBD mediated) (NP (NP (NP (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NN inhibition)))))) |ET| |BS|43:F01.145.544 209:G02.111.087.847 250:E07.305.812 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900 1281:D05.500.562.500 1293:G03.495|ES| 2:1 10:1 14:1 19:1 75:1 103:1 115:1 202:1 249:1 251:1 437:1 487:1 559:1 594:1 597:1 859:1 860:1 861:1 862:1 1124:1 1785:1 1937:1 2120:1 2961:1 4556:1
-1 	|BT| (NP (NP (ADVP (RB Specifically)) (, ,) (NP (NP (NN coregulation) (NN kinase) (NN p38) (NN ERK)) (, ,) (NP (NN translation) (NN regulator)) (NP (NN 4EBP1)) (, ,) (NP (NP (NN transcription) (NN factor) (NN CREB)) (VP (VBG proliferating) (NP (JJ normal) (NN colon) (NN cell)))) (NP (VBD lost) (NN CRC))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 46:A03.556.124.526.356 145:G02.111.087.675.871 166:D12.776.930 469:D08.811.913.696 809:L01.178.682.920|ES| 2:1 19:1 94:1 113:1 118:1 185:1 235:1 245:1 470:1 473:1 487:1 1666:1 2042:1 2865:1 5047:1 5717:1 5718:1 5719:1 5720:1
-1 	|BT| (S (NP (NN Sulindac)) (VP (VBZ enhances) (NP (NP (JJ adenoviral) (NN vector)) (VP (VBG expressing) (NP (NP (NN mda-7)) (: /) (NP (NP (JJ IL-24-mediated) (NN apoptosis)) (NP (JJ human) (NN lung) (NN cancer)))))))) |ET| |BS|39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 123:G05.360.337 251:D02.455.426.559.847.486.875 542:B04.280.030|ES| 18:1 19:1 36:1 89:1 328:1 362:1 810:1 1356:1 2965:1 5721:1 5722:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN administration) (NN SHH) (NN inhibitor)) (VP (MD could) (NP (NP (JJ effective) (NN strategy) (VBP prevent) (JJ colitis-induced) (JJ colorectal) (NN carcinogenesis)) (, ,) (VP (ADVP (RB mainly)) (VBG targeting) (NP (NP (NN IL-6)) (NN signaling))) (, ,) (NP (VBG ablating) (NNS CSCs)) (, ,) (S (VP (VBG suppressing) (NP (NP (JJ oncogenic) (NN inflammation)) (, ,) (S (VP (VBG achieving) (NP (NN chemoquiescence)) (ADVP (RB ultimately))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 53:C06.405.205.265 69:G02.111.087.800 201:D12.644.276.374.465.224 279:D27.888.569.100 525:C23.550.470 556:C11.768.175|ES| 2:1 17:1 19:1 195:1 207:1 380:1 616:1 733:1 793:1 796:1 908:1 953:1 1114:1 1537:1 1538:1 1639:1 1966:1 2250:1 2575:1 3064:1 3148:1 5488:1 5664:1 5723:1 5724:1 5725:1 5726:1 5727:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)) (, ,) (S (VP (VBG finding) (NP (JJ demonstrative) (NN existence) (JJ novel) (NN pathway) (NN simvastatin)))))) (VP (VBZ induces) (NP (NP (NN G0/G1) (NN arrest)) (VP (VBG upregulating) (NP (NP (NN p21) (NN p27) (VBG activating) (NNP AMPK)) (VP (VBG inhibiting) (NP (NN STAT3-Skp2) (NN axis)))) (, ,) (ADVP (RB respectively)))))) |ET| |BS|82:D12.644.360.024.342.300 122:C14.280.383 259:D12.776.395.240.150.500 507:D12.776.157.743 579:A02.835.232.834.151.383 754:D02.455.426.559.847.638.400.900|ES| 2:1 19:1 214:1 371:1 383:1 602:1 880:1 891:1 927:1 1124:1 1135:1 1537:1 1538:1 1958:1 2089:1 2679:1 3140:1 4692:1 5666:1 5728:1 5729:1 5730:1
-1 	|BT| (NP (NP (NP (DT The) (NN colon) (JJ epithelial) (NN cell) (NN line)) (NP (NP (NN NCM460) (NN colon) (NN cancer) (NN cell) (NN line) (NN HT-29) (NN Caco-2)) (VP (VBN exposed) (NP (NN P) (NN anaerobius) (NN control) (NNS bacteria))))) (: ;) (NP (NN cell) (VBN analyzed) (NP (NN immunoblot)) (, ,) (NP (NN proliferation)) (, ,) (NP (NP (JJ bacterial) (NN attachment) (NN analysis)) (VBN compared) (NN gene) (NN expression) (VBG profiling) (NN study)))) |ET| |BS|41:A11 46:A03.556.124.526.356 94:A11.251.210 718:E05.588.570 792:A11.251.210.190.475 802:E05.478.566.320 1286:E05.393.332 1539:B03|ES| 2:1 9:1 18:1 19:1 50:1 94:1 113:1 115:1 127:1 131:1 217:1 264:1 289:1 299:1 311:1 661:1 691:1 1168:1 2148:1 2782:1 2830:1 3102:1 3355:1 5731:1 5732:1 5733:1 5734:1 5735:1
-1 	|BT| (S (NP (DT The) (JJ limonoid-treated) (NN xenograft)) (VP (VP (VBD exhibited) (NP (NP (JJ significant) (NN downregulation) (NN expression) (NN protein)) (VP (VBN involved) (NP (NP (NP (NN tumor) (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (NN c-IAP-1)) (, ,) (NP (NN survivin)) (, ,) (NP (NN Mcl-1))) (-RRB- -RRB-))) (, ,) (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN c-Myc) (NN cyclin) (NN D1)) (-RRB- -RRB-))) (, ,) (NP (NN invasion) (-LRB- -LRB-) (NN MMP-9) (, ,) (NN ICAM-1))))) (-RRB- -RRB-)) (, ,) (NP (NP (NN metastasis) (-LRB- -LRB-) (NN CXCR4) (-RRB- -RRB-)) (, ,) (NP (NP (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-)))))) |ET| |BS|7:D12.776 8:C04 52:E02 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 108:G04.299.316 113:C04.697.650 175:J01.897.280.500.269 215:D12.644.360.262.150.100 586:D08.811.277.656.300.480.205.360 1204:D12.776.543.750.100.160.500.400 1325:D12.776.395.550.200.450|ES| 2:1 4:1 7:1 10:1 14:1 19:1 94:1 115:1 135:1 158:1 265:1 274:1 299:1 595:1 609:1 620:1 691:1 743:1 744:1 774:1 806:1 824:1 2066:1 2158:1 2229:1 2502:1 4220:1 4732:1 4814:1 5312:1 5736:1 5737:1
-1 	|BT| (S (PP (DT These) (S (VP (VBG finding) (S (VP (VBP demonstrate) (NP (NN miR-137) (JJ crucial) (NN regulator) (NN cancer) (NN response) (NN doxorubicin) (NN treatment))))))) (, ,) (VP (VBP identify) (S (NP (NN miR-137) (ADJP (RB highly) (JJ promising)) (NN target)) (VP (VB reduce) (NP (JJ CAR-driven) (NN doxorubicin) (NN resistance)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 66:F01.658.293 136:D02.455.426.559.847.562.050.200.175 139:J01.937.500.100|ES| 2:1 18:1 19:1 160:1 235:1 420:1 494:1 502:1 546:1 599:1 626:1 792:1 832:1 927:1 1094:1 1517:1 2361:1 3690:1 5738:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (S (VP (VBG signaling) (NP (NN cascade) (, ,) (JJ positive) (ADJP (NN feedback) (NN loop) (JJ cooperative)) (NN interplay) (NN transcription) (JJ factors-induced) (NN expression) (NN IGFBP1) (NN gene)))) (VP (VBP contribute) (NP (JJ overall) (NN response) (NN emodin)))) |ET| |BS|69:G02.111.087.800 83:L01.143.283.425 155:G05.355.310 166:D12.776.930 696:V02.270.500 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400|ES| 2:1 9:1 19:1 115:1 195:1 233:1 247:1 248:1 450:1 487:1 494:1 1691:1 2510:1 5274:1 5613:1 5739:1 5740:1 5741:1 5742:1
-1 	|BT| (S (S (VP (TO To) (VP (VB confirm) (S (VP (VBG sensitizing) (NP (NN effect) (NN NAC1) (NN inhibition) (NN cytotoxicity) (NN cisplatin))))))) (VP (VBD attributed) (NP (NN suppression) (NN autophagy)) (, ,) (NP (NP (VBN assessed) (NN effect) (NN autophagy) (NN inhibitor) (NN 3-methyladenosine) (NN chloroquine)) (, ,) (NP (NP (NP (JJ small) (VBG interfering) (NNS RNAs)) (PRN (-LRB- -LRB-) (NP (NNS siRNAs)) (-RRB- -RRB-))) (VP (VBG targeting) (NP (NN beclin) (CD 1) (NN Atg5) (NN cytotoxicity) (NN cisplatin))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 117:D13.150.650.700 390:G04.299.139.399 498:D01.210.375 946:D27.888.569.213 961:D03.438.810.050.180|ES| 2:1 10:1 14:1 19:1 75:1 98:1 103:1 380:1 616:1 750:1 828:1 1317:1 1761:1 2137:1 2453:1 3019:1 3044:1 3317:1 3378:1 3531:1 3823:1 5743:1 5744:1 5745:1 5746:1 5747:1 5748:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (JJ similar) (NN result) (JJ cellular) (NN model)) (JJ hepatocellular) (NN colon) (NN cancer)) (, ,) (S (VP (VBG indicating) (S (NP (JJ doxorubicin-sensitizing) (NN effect) (NN miR-137) (NN tumor)) (ADJP (JJ type-specific))))))) |ET| |BS|8:C04 41:A11 136:D02.455.426.559.847.562.050.200.175|ES| 2:1 7:1 18:1 19:1 72:1 75:1 101:1 113:1 261:1 303:1 332:1 420:1 843:1 2236:1 3074:1 5749:1 5750:1
